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ABSTRACT
The bone marrow contains a multipotent stromal cell, commonly referred to as a
mesenchymal stem cell (MSC). There has been recent interest in the clinical use of MSCs for
cell-based therapy because: (1) bone marrow aspiration is a routine method used in medicine
thereby allowing for easy accessibility to human MSCs; (2) MSCs are easily isolated and can
expand to clinical scales in a relatively short period of time; (3) MSCs can be biopreserved
without loss of potency and stored for point-of-care delivery; and (4) human trials of MSCs thus
far have shown no adverse reactions to allogeneic versus autologous MSC transplants
suggesting that therapy can cross histocompatibility barriers.
This thesis describes the development of new modalities and indications for MSC-based
treatments by leveraging the endogenous functions of these cells for therapeutic purposes.
First, it is known that marrow stromal cells support hematopoiesis by secreting bioactive
molecules that aid in the growth, differentiation, function and migration of hematopoietic cells
within the marrow cavity. We show that these same secreted molecules derived from MSCs ex
vivo can be formulated as an intravenous drug. In a D-galactosamine model of acute liver
failure, a bolus injection of a concentrated form of MSC conditioned medium (MSC-CM) led to a
significant survival benefit with a one week study endpoint. We employed in vitro and in vivo
assays to demonstrate the effect of MSC-CM on leukocytes and resident liver cells. Traditional
biochemical approaches were performed to identify active fractions within MSC-CM that were
responsible for its therapeutic efficacy. As a corollary to an injectable drug, we developed MSC-
based extracorporeal devices to serve as a dynamic source of MSC-CM in a dialysis-like setting.
Liver injured rats supported by extracorporeal bioreactors seeded with MSCs had significant
improvements in liver serologies and survival in the short-term, whereas a composite device
containing both MSCs and hepatocytes was shown to have a long-term survival benefit after 30
days.
The second natural function of MSCs that was exploited for therapy concerns recent
evidence that stromal cells can present antigens in lymphoid organs. We discovered that MSCs
can express peripheral tissue antigens similar to other specialized antigen presenting cells in
the thymus and lymph nodes - a process known to induce tolerance to self-reactive T cells in
vivo. We show that MSC transplantation can be an effective treatment of intestinal
autoimmunity in a chemically-induced model of colitis and a mouse model deficient in regulatory
T cells. In addition, we demonstrate that MSC grafts increase the endogenous population of
suppressor cells in vivo, which can potentially amplify and sustain the immunosuppression of
the original transplant.
The proposed work is significant, as development of such therapies for acute liver failure
and inflammatory bowel disease would potentially treat an estimated 100,000+ newly diagnosed
patients or ones who are refractory or contraindicated to standard-of-care medical/surgical
procedures. These studies may empower the future use of MSCs in other organ failure
syndromes and autoimmune conditions. Finally, exploration of the therapeutic functions of
MSCs is expected to enhance our understanding of the mechanisms involved in cell therapy
and give further insight to the natural functions of MSCs during health and disease.
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CHAPTER I
MESENCHYMAL STEM CELL IMMUNOTHERAPY
1.1. SIGNIFICANCE
Bone marrow-derived mesenchymal stem cells (MSCs) are an excellent candidate for
cell-based therapy because: (1) bone marrow aspiration is a routine method used in medicine
thereby allowing for easy accessibility to human MSCs; (2) MSCs are easily isolated and can
expand to clinical scales in a relatively short period of time1' 2; (3) MSCs can be biopreserved
without loss of potency and stored for point-of-care delivery3' 4; and (4) human trials of MSCs
thus far have shown no adverse reactions to allogeneic versus autologous MSC transplants
suggesting that therapy can cross histocompatibility barrierss5 7. To date, MSC transplantation
has shown encouraging results in clinical therapeutic trials of cardiovascular8'9, neurological0'o11
and immunological diseasel2"13 . In this work, we have developed new immunotherapeutic
strategies for treatment of fulminant hepatic failure (FHF) and inflammatory bowel disease (IBD)
by harnessing the endogenous functions of these cells. The proposed work is significant, as
development of such therapies for FHF and IBD would potentially treat an estimated 100,000+
newly diagnosed patients a year as well as patients who are refractory or contraindicated to
standard-of-care medical or surgical procedures.
The broader impact of the proposed studies is expected to be in multiple areas. First,
the work here could advance the realization of MSCs as a practical therapy in clinical medicine,
especially in organ failure and autoimmune diseases. In addition, this work can aid in the future
development of MSC-based technologies and be extrapolated to other cell-based therapies to
treat relevant diseases. Furthermore, exploration of the therapeutic functions of MSCs is
expected to enhance our understanding of the mechanisms involved in cell therapy of these
potent cells and give further insight to their natural functions during health and disease.
1.2. Origins and Developmental Biology of Mesenchymal Stem Cells
Maureen Owen14 and colleagues, based on the work of Alexander Friendenstien is , proposed
the existence of non-hematopoietic cells in the bone marrow with the ability to give rise to
mesenchymal cells. These cells were isolated from bone marrow mononuclear cells based on
adherence to tissue culture plastic and initially were described as adherent, clonogenic,
nonphagocytic, and fibroblastic in nature, with the ability to give rise to colony forming units-
fibroblastic (CFU-F). Under certain mechanochemical stimuli, it was found that CFU-F could
give rise to connective tissue cells such as osteoblasts, chondrocytes, adipocytes, and
myelosupportive stroma lending credence to a stem cell hypothesis14' 16. These findings were
further popularized by Arnold Caplan in the last two decades 17, who coined the term
mesenchymal stem cells (MSCs) and described the process of mesengenesis. In addition,
they identified the first set of MSC expressed antigens that react with SH2 (CD105) and SH3
(CD73) monoclonal antibodies. Despite lack of a consensus on the relevant cell surface
markers of MSCs from other species, the current expression of a certain immunophenotype of
human MSCs is listed in Table 1.118.
Table 1.1. Immunophenotype of Human MSCs
Positive Negative Inducible
CD13, CD29, CD44, CD49a, CD3, CD4, CD6, CD9, CD10, HLA-DR
b, c, e, f, CD51, CD54, CD58, CD11a, CD14, CD15, CD18,
CD71, CD73, CD90, CD102, CD21, CD25, CD31, CD34,
CD105, CD106, CDw119, CD36, CD38, CD45, CD49d,
CD120a, CD120b, CD123, CD50, CD62E, L, S, CD80,
CD124, CD126, CD127, CD86, CD95, CD117, CD133,
CD140a, CD166, P75, TGF- SSEA-1, ABO
blR, TGF-blIR, HLA-A, B, C,
SSEA-3, SSEA-4, D7, PD-L1
Note: CD, cluster of differentiation; TGF, transforming growth factor; HLA, human leukocyte
antigen; SSEA, stage-specific embryonic antigen; ABO refers to blood group antigens;
The developmental precursor of MSCs has been difficult to identify because MSCs have
no distinguishing features to track in vivo. A number of studies support the concept that the
typical sites of developmental hematopoiesis, including the placenta, aorta-gonad-mesonephros,
and fetal liver, are also populated by embryonic MSCs 19-21. These cells are originally
independent of interactions with hematopoietic stem cells and can be found in the embryonic
circulation at early stages of ontogeny22. Counter-intuitively, a novel embryological source of
MSCs has been identified in the cranial neural crest. Using in situ methods with fluorescent
reporting proteins, one group demonstrated a transient proliferation of Sox-1+ cells originally
from the neuroepithelium that display multipotency and that transitioned through a neural crest
stage to give rise to adult MSCs23. Cells with multilineage differentiation potential and
cytoskeletal elements reminiscent of adult MSCs can be isolated from the first brachial arch
ectomesenchymal cells that give rise to the orofacial connective tissue24-26. These results are
consistent with the promiscuous expression of neural proteins in MSCs in their basal state27'28
1.3. Mesenchymal Stem Cell Localization and Multipotency In Vivo
The physical location, or niche, of a stem cell provides invaluable information of their role
and interactions within the tissue. The MSC niche has been an elusive location and difficult to
observe dynamically primarily because no unique MSC marker has been identified and the
marrow cavity is difficult to probe in vivo. That stated, based on correlations between
immunophenotype and ex vivo CFU-F assays, evidence supports the notion that MSCs exist in
perivascular locations29,'3 . Their stromal counterparts may differentiate and migrate from this
space to reside on the abluminal side of marrow sinusoids and form a three-dimensional
network that invests the capillary bed. Adventitial reticular cells or pericytes that have
processes projecting into the lumen of sinusoids, are likely the in vivo surrogate of CFU-Fs
although clonogenicity has never been proven to date3133. These pericytes share a similar
surface and intracellular protein expression pattern with MSCs implying that the cells are related
ontologically'. This location has been reproduced in artificial systems as well. Ectopic stromal
cells displaying, PDGF-R, NG2, and high expression of CD146 are typically localized in
perisinusoidal regions5. In addition, tissue engineered constructs juxtaposing MSCs and
endothelial cells form long-lasting vascular structures with MSCs naturally displaying pericytic
phenotype and function36. Such localization suggests MSCs may be intimately involved in
angiogenesis, wound healing and interactions with bloodborne entities.
In vivo transplantation of expanded MSCs has illustrated the physiological relevance of
this stem cell. Implantation of MSC grafts under the kidney capsule or in subcutaneous spaces
results in the ectopic formation of bone marrow, including donor-derived bony trabeculae,
myeolsupportive stroma, and adipocytes as well as host-derived hematopoietic cells that
colonize and fully mature within the space'1635 . If MSCs are engrafted in microencapsulated
environments with pore sizes that exclude the immigration of host cells, only connective tissue
cells of donor origin are observed' 4. These results are all specific to MSCs, whereas
experiments performed with fibroblasts or differentiated connective tissue cells fail to
recapitulate the same histological image.
Though the bone marrow has been established as the primary source of MSCs, due to
the invasive nature of bone marrow aspiration, efforts are underway to identify other abundant
and reliable sources of MSCs for clinical purposes. The isolation of MSCs from peripheral
sources such as umbilical cord blood (UCB)37'38, placental tissue19-21, and adipose tissue 39 has
been reported with cells displaying similar immunophenotypes and multipotency, though other
contradictory studies report the absence of MSCs in these peripheral locations40,41.
Furthermore, it is unclear if there is a definitive relationship between these cells from various
sources and it is important to be wary of interpretations of CFU-F analysis of MSCs from sites
other than the bone marrow given that many adherent and clonogenic fibroblastoid cells exist in
non-hematopoietic tissues.
1.4. The Interaction Between the Bone Marrow Stroma and Hematopoiesis
MSCs exist within the bone marrow as a precursor to connective tissue components that act
primarily as supportive elements to hematopoiesis. An understanding of the endogenous
functions of MSCs and their precursors within the marrow can provide insight into mechanisms
involved when these cells are used in a therapeutic context. The initial appreciation for the
important interaction between stromal cells and hematopoietic cells was obtained from the
analysis of two different spontaneous mutations in mouse colonies that led to the same anemic
phenotype. Analysis of these mutant mice revealed that a stromal cell ligand known as stem
cell factor (SCF) and its associated receptor, c-kit, found on hematopoietic stem cells (HSCs)
was essential for the maintenance of HSCs. Other cell-cell interactions between MSC progeny,
such as osteoblasts and HSCs has also proved essential for HSC self-renewal42 43. Moreover,
stromal elements secrete a number of insoluble and soluble species within the marrow space
that promote the growth and differentiation of hematopoietic cell lineages44-47 .
Experimentally, MSCs can act as a surrogate feeder layer and promote the self-renewal
and differentiation of HSCs in long-term colony initiating-culture (LTC-IC) and CFU assays48
Two types of culture techniques utilizing stromal cell layers and defined chemical supplements
allow for the establishment of lymphoid and myeloid cells in vitro. The Whitlock-Witte method
cultures bone marrow cells on a confluent layer of irradiated stromal cells with a low-serum
containing medium without corticosteroids 49,50. It is a lymphoid culture system, which supports
the growth of B-lymphocytes and with some modifications in culture parameters can also allow
selective proliferation and differentiation of all developmental stages of pre-B-cells and B-
lymphocytes. A myelopoietic culture system, known as Dexter bone marrow cultures, maintains
myeloid progenitor cells in vitro. Dexter-type culture systems differ from Whitlock-Witte cultures
by making use of high concentrations of serum and hydrocortisone and lower incubation
temperatures51'52. Collectively, the marrow stroma can direct the differentiation of lymphoid and
myeloid cells in vitro and it is likely that the mechanisms underlying this directed differentiation
will be of relevance to the immune response to MSCs in vivo.
The soluble milieu that is maintained by MSCs may also be protective in the context of
immune cell development within the bone marrow. Recent evidence suggests that the bone
marrow can be considered a bona fide secondary lymphoid organ that contains perisinusoidal B
cell niches to partake in microbial immunity within the cavity53. Interestingly, these
perisinusoidal B cells are restricted in their ability to respond to antigen and can only perform T-
independent immune reactions that may be indicative of the bone marrow being a T cell
suppressed environment.
1.4. The Role of MSCs During Inflammation
MSCs are traditionally isolated from the bone marrow where these cells functionally support
hematopoiesis by the secretion of cytokines, growth factors and extracellular matrix as well as
by repopulating connective tissue cell types47',5 56. However, cells with MSC characteristics are
reportedly present in virtually every organ5 7, although more rigorous analysis of in vivo self-
renewal and potency was not determined in the study. This raises the possibility that MSCs
constitute a normally quiescent pool of reparative stem cells, ready to be activated as a source
of trophic factors and support in the event of injury. Mobilized and subsequently recruited MSCs
may also play a role, as supported by observations that stressful events (e.g. hypoxia) result in
the mobilization of MSCs into the systemic circulation58. This hypothesis is supported by the
observation that mesenchymal stem cell-like cells commonly referred to as pericytes are located
almost exclusively in the perivascular space of most blood-vessels, which enhance the
likelihood of their mobilization potential. In addition, molecules locally upregulated in the event of
injury facilitate the recruitment of circulating MSCs59-61 (Table 1.2.). However, the physiological
role of endogenous MSCs in tissue repair remains elusive due to a lack of unique MSC markers
and knockout models.
It is likely that true stem cells do not circulate peripherally, but rather produce lineage-
restricted cell types that home to tissues as a mechanism of non-parenchymal cell
replenishment during injury. Fibrocytes are circulating bone marrow-derived cells (-0.1-0.5% of
nonerythrocytic cells in peripheral blood) that are phenotypically a mixture of monocytes and
fibroblasts expressing type I collagen and the surface markers CD1 1b, CD13+, CD34+, and
CD45RO+ 62. In sex-mismatched bone marrow chimeras, these cells were found to be the
progeny of a radioresistant precursor from the bone marrow 63. During injury, fibrocytes were
rapidly and specifically found in the areas of inflammation63 , fibrosis , and cancer5 ~8 where
they are thought to mature into tissue-resident myofibroblasts69. They express chemotactic
receptors such as CCR3, CCR5, CCR7, and CXCR4 and are absent of CCR4, CCR6, and
CXCR3". Interestingly, fibrocytes express surface molecules such as MHC class II, CD80 and
CD86 and were shown to present pulsed antigens to naive T cells in an efficient manner when
compared to monocytes and dendritic cells, although this was not verified in vivo70.
Table 1.2. Molecular Interactions Facilitating Migration
and Engraftment of MSCs to Sites of Tissue Injury
Receptor/Enzyme Tissue Ligand/Substrate Reference
c-met HGF 71,72
CXCR4 SDF-1 71,73-76
CX3CR1 Fractalkine 74
MMP2 Collagen 71,73
MMP9 Collagen 71
CD44 Hyaluronic Acid 59,77
PDGF-R PDGF-AB, BB 72,75,78
EGF-R EGF 72
FGF-R2 FGF2 72,79
IGF-R IGF-1 72,75,80
RANTES-R RANTES 75
MCP-1 R MCP-1 81,82
CCR2/3/4 CXCL8 75,81
Note: HGF, hepatocyte growth factor, SDF-1, stromal cell-derived factor-i; MMP, matrix
metalloproteinase; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; FGF,
fibroblast growth factor; IGF, insulin-like growth factor; MCP-1, monocyte chemoattractant
protein-1
1.5. The Interaction Between MSCs and the Innate and Adaptive Immune System In Vitro
MSCs have been demonstrated to modulate the immune system. MSCs were first noted to be
immunopriveleged after it was observed that hMSCs could engraft without immunosuppression
in a xenogenic, adult host 83. The immunosuppressive ability was first exploited clinically in the
treatment of an 8-year old boy with severe, acute graft-versus host disease (GVHD), that was
refractory to steroid immunosuppression84, who was successfully treated by MSC
transplantation. In recent years, this immunosuppression has been found to be an active
process and the mechanisms underlying MSC immunomodulation operate at different levels of
the innate and adaptive immune system. We discuss in vitro coculture experiments to exemplify
the effects of MSCs on individual populations of immune cells. A schematic is shown in Figure
1.1.
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Figure 1.1. In Vitro Interaction of MSCs and immune cells. Schematic of MSC interactions
with distinct subsets of immune cells as adapted from Rasmusson I, Exp Cell Res (2): 198,
2006. Inhibitory effects are immune cell functions are shown by hatched arrows and stimulatory
effects shown by arrowheads. The upper right bar chart shows a representative dose response
of immune cell inhibition as a function of MSC number. The lower right bar chart shows an
example of results comparing the effect of MSC cell contact versus diffusible factors in immune
cell inhibition. NK, B, and T refer to NK, B, and T cells, respectively. DC1: mature monocytic
dendritic cells; DC2: mature plasmacytoid dendritic cells.
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The majority of in vitro studies have shown that MSCs can directly inhibit CD3+, CD4+ T
cell proliferation and secretion of IL-2 and IFN-y induced by mixed lymphocyte reactions (MLR),
mitogens and TCR or costimulatory receptor engagement. T cells in the presence of MSCs
appear to be anergized by the lack of a 'second danger signal' by MSCs, which do not express
the costimulatory molecules CD80, CD86 and CD40 ' , however this has yet to be definitively
proven. Several investigations have also shown a direct suppressive effect of MSCs on
cytotoxic CD8+ T cells. MSCs prevented cytolysis of target cells by alloantigen-specific CD8+ T
cells when present during the priming of cytotoxic cells86. Some investigators attribute the
inhibition of cytotoxicity by MSCs to an intrinsic "veto" function or the generation of suppressor
CD8+ cells after coculture87 , although there exist conflicting data. Nonetheless, other reports
have also observed generation of CD4+ CD25+ T cells, a cell surface marker expression
pattern of both newly activated CD4+ lymphocytes and regulatory T cells (Tregs)88'89. Analysis of
Foxp3, a transcription factor required for the development and function of Tregs, was not
performed in these studies to rigorously quantify the true Treg population.
Suppression, in most studies, was reproduced in the absence of cell-cell contact and in
a dose-dependent manner, indicating the role of soluble factors. Furthermore, these inhibitory
molecules can exert their effects across species barriers as evidenced by suppression of MLRs
in xenogeneic cultures"' 91 . It remains highly debated as to which soluble mediators are
involved in T cell suppression, although many candidates have shown promise in neutralization
studies. MSC-conditioned supernatants had no anti-proliferative effect on T cells, yet did
suppress the stimulation of B cells92. This suggests that MSCs can dynamically react to their
immunological environment, in the context of T cells, while also secreting immunomodulatory
molecules in their quiescent, undifferentiated state, in the context of B cell development. Also,
there is an approximate 1-2 order of magnitude difference between the number of MSCs
needed to suppress T cell activity compared to B cell activity93' 94. In contrast, other reports have
shown that MSCs can stimulate antibody secretion and induce polyclonal differentiation and
expansion of healthy human B cells 95,96, consistent with the supportive role of stromal cells in B
lymphopoiesis. In addition, these same supportive mechanisms may advance the progression
of B cell-mediated disease such as multiple myeloma and systemic lupus erythematosus
questioning the use of MSCs in such disease contexts95'97 . Although the principal source of
MSC immunosuppression appears to be secreted molecules, cell-cell interactions via the
programmed death (PD) receptor-1 and its ligands PD-L1 and PD-L2 were shown to be
necessary for inhibition of mouse splenocytes by MSCs 92 . Yet, no single mechanism has yet to
sufficiently explain their potent and stable inhibition of an adaptive immune response.
MSCs also have an indirect effect on T cell function via antigen presenting cells (APCs).
Dendritic cells (DCs) are the major link between innate and adaptive immunity due to their ability
to present antigens with high efficiency to lymphocytes. In coculture with MSCs, monocytes
failed to differentiate into DCs when cultured in lineage-specifying growth conditions98'99 . In
addition, MSCs inhibited the maturation of DCs to present appropriate antigens and
costimulation to T cells through CDla, CD40, CD80, CD86, and HLA-DR 98,100. After coculture
with MSCs, DCs were ineffective in their ability to activate lymphocytes in DC-CD4+ MLRs99.
This interaction was found to be y-secretase dependent, indicating the role of the Notch
pathway in MSC-DC interactions101 . Ultimately, MSCs may drive, or "license", DCs to a
suppressor phenotype which can further attenuate T cell-mediated immunity.
1.6. The Paracrine Theory of MSC Therapy in Regenerative Medicine
There has been a recent paradigm shift in what is considered to be the therapeutic
promise of MSCs in diseases of vital organs. The term MSC was originally tailored for the
regenerative capacity of this cell type through its ability to differentiate into mesodermal cell
types including adipocytes, chondrocytes, osteocytes and stromal cells. When cultured MSCs
were also observed to adopt characteristics of cardiomyocytes'02, hepatocytes 103,104 and
several other cell types'0 5' 106, many investigators put this presumed widespread regenerative
potential to the test in injury models of vital organs. Despite a lack of evidence for replaced
organ function through differentiation of transplanted MSCs into functional cells, a clear
therapeutic effect was consistently reported in models ranging from myocardial infarction to
stroke'8"0 7 10 9. Common findings in these therapeutic trials were: (1) inhibition of inflammatory
responses; (2) reduction in apoptosis; (3) prevention of fibrosis (4); stimulation of endogenous
regenerative programs; and (5) neovascularization. Studies in the past years have shown that
paracrine cytokines, growth factors and other secreted signaling molecules are responsible for
these trophic effects. To broaden the scope of the paracrine effect of MSCs on specific cellular
mechanisms, an integrated view of MSC therapy compiled from data from disease models of
the heart, liver, lung, kidney and brain, is presented with emphasis on the role of specific
mediators (see Figure 1.2).
1.6.1. Apoptosis
During disease, protection of injured cell mass by inhibition of programmed cell death can
potentially preserve organ function. Several studies have shown that MSCs have the ability to
inhibit apoptosis of various types of host cells through paracrine mechanisms. A group of
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Figure 1.2. Effects of MSC-Derived Factors on Pathogical Processes in Tissue Injury. For
each growth factor, cytokine, chemokine or other mediators a summary of the observed effects
and the model in which this was investigated is provided. VEGF, vascular endothelial growth
factor; bFGF, basic fibroblast growth factor; IGF-1, insulin-like growth factor-i; HGF, hepatocyte
growth factor; BMP-2, bone morphogenetic protein-i; MCP-1, monocyte chemoattractant
protein-i; IL, interleukin; SDF-1, stromal cell-derived factor-i; Sfrp-2, secreted frizzled protein-2;
BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; IL-1RA, interleukin-1
receptor antagonist; HLA, human leukocyte antigen; TGF-P, transforming growth factor-1; PG-
E2, prostaglandin-E2; MMP, matrix metalloproteinase; TNF-a, tumor necrosis factor-a; CNTF,
ciliary neurotrophic factor.
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researchers led by Dzau used a set of elegant experiments to demonstrate that the
cardioprotective effect of MSC transplantation in a rat myocardial infarction model was largely
ascribed to the anti-apoptotic effects of MSC molecules'1 o. Local administration of MSCs into
the infarcted rat myocardium resulted in a dose-dependant normalization of cardiac function11 .
Genetic engineering of MSCs to overexpress a pro-survival gene, Akt-1, prevented massive
death of transplanted cells and resulted in dramatically improved results'". These studies
showed a remarkable improvement of cardiac function in a relatively short amount of time after
graft administration, suggesting a role for soluble cues rather than replacement of
cardiomyocytes by infused MSCs. In further experiments using conditioned medium from
cultured MSCs, paracrine factors secreted by MSCs were shown to be responsible for the
therapeutic effects 112' 113. Conditioned medium directly inhibited apoptosis of cardiomyocytes
cultured under hypoxic conditions. Moreover, injection of the conditioned medium into infarcted
rat hearts reduced the number of apoptotic cardiomyocytes, reducing infarct size and preserving
heart function. Silencing studies using RNA-interference identified secreted frizzled related
protein 2 (Sfrp-2) as a key anti-apoptotic mediator'14
Investigations by other researchers and in other organ systems have demonstrated that
several other mediators secreted by MSCs play a role in inhibition of programmed cell death.
Koc et al. observed enhanced anti-apoptotic effects of MSCs modified to overexpress stromal
derived factor-1 (SDF-1), identifying the SDF-1 - CX chemokine receptor-4 (CXCR4) axis as an
important mechanism of myocardial preservation via downregulation of pro-apoptotic Bax
protein"" 116. Others demonstrated that MSC-derived insulin-like growth factor-1 (IGF-1) and
vascular endothelial growth factor (VEGF) have cardiomyocyte apoptosis-inhibiting effects using
in vitro studies' 17 . IGF-1 was also shown to have important pro-survival effects in cultured
proximal tubular epithelial kidney cells, crucial in the development of acute kidney failure 18 .
Anti-apoptotic effects due to paracrine MSC factors have also been observed in injury
models of the liver, kidney and brain. Increased levels of the pro-survival neurotrophins brain-
derived neurotrophic factor (BDNF) and nerve growth factor (NGF) were observed in rats
subjected to stroke and treated with MSC infusions, suggesting a role for these molecules in
reducing cell death in the ischemic brain" 9. In a rat model of toxin-induced fulminant hepatic
failure, we demonstrated that MSC therapy using cells isolated from human bone marrow
samples significantly reduced mortality and was correlated with a reduction in the number of
apoptotic hepatocytes (see Chapters 2 and 3)120121 . In this study, several different modes of
MSC therapy were assessed, including: (1) transplantation of whole cells; (2) infusion of cell
lysates; (3) infusion of MSC-derived conditioned medium (MSC-CM); and (4) a MSC-based
extracorporeal device. Animal survival was found to be a function of MSC-CM dose, but above
a certain threshold the conditioned medium became ineffective. These results suggest important
pharmacodynamic characteristics of MSC-CM or the presence of molecules that are harmful at
high concentrations (e.g. tumor necrosis factor (TNF)-(o) 122. A separate cohort of animals was
treated using an MSC-based extracorporeal device that allowed for MSCs to dynamically
supplement the animal's plasma continuously during a 10-hour treatment. The strongest effect
on hepatocellular damage and survival was observed in the animals treated with this MSC-
based bioreactors (see Chapters 6 and 7). A third group of animals was unsuccessfully treated
with systemically delivered MSCs, although immunorejection or increased pulmonary lodging of
large, xenogeneic cells may have been responsible for the lack of effect.
1.6.2. Immune Response
MSCs have potent inhibitory effects on immune cells. Secreted molecules inhibit lymphocyte
proliferation, B-cell differentiation and the formation of natural killer cells, dendritic cells and
cytotoxic T-lymphocytes 89,93,99'123 . Human leukocyte antigen (HLA) class I molecules, interleukin
(IL)-10, transforming growth factor (TGF)-3 and prostaglandin (PG)-E2 have been proposed as
responsible mediators, but contradictory reports exist. The potency of MSC immunosuppression
is illustrated by the successful treatment of severe steroid-resistant acute graft-versus host
disease (GVHD) after bone marrow transplantation84. Several patients have now been
successfully treated with systemic MSC infusions, resulting in a significant survival-benefit in a
randomized controlled trial13 .
Infiltrating immune cells are essential in the response to tissue injury, but resolution of
the inflammation is critical to prevent chronic damage and control harmful immune cell-mediated
cytotoxicityl24',125 . Dampening effects on immune cells have been described in several models of
vital organ injury. In a rat model of fulminant hepatic failure, we show in Chapter 2 that the
number of infiltrating leukocytes was dramatically reduced after systemic administration of
concentrated conditioned medium from MSC culturesl21 . Fractionation of the conditioned
medium resulted in preservation of the therapeutic effects only for the heparin-binding fraction,
suggesting an important role for known heparin ligands such as growth factors and chemotactic
cytokines (see Chapter 5). Several groups have described a similar inhibition of accumulating
immune cells in different models of lung injuryl26,127 . Mei and co-workers observed enhanced
anti-inflammatory effects of genetically engineered MSCs to overexpress angiopoietin-1,
suggesting a role for this molecule in the immunomodulatory effects of MSCs.
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Besides the cellular immune response, the cytokine response is an important component
of the inflammatory response to tissue injury. Control of this response is critical for resolution of
the inflammatory infiltrate and cytotoxic effects of pro-inflammatory cytokines as described for
TNF-(a and IL-1128. MSC therapy induces local and systemic downregulation of proinflammatory
cytokines but also upregulation of anti-inflammatory cytokines including IL-10 in models of lung
injury, kidney and liver failure (see Chapter 2)129-132. MSC-secreted interleukin-1 receptor
antagonist (IL-1 RA) is an important factor in the inhibition of pro-inflammatory cytokine
production1".
1.6.3. Fibrosis
Unresolved inflammation leads to fibrosis and scar formation. The deposition of large amounts
of extracellular matrix inhibits organ function and regeneration. MSCs have the potential to
inhibit scar formation and extracellular matrix accumulation in disease models of myocardial
infarction, liver fibrosis, lung fibrosis and stroke. Several groups have demonstrated that
administration of MSCs therapeutically inhibits fibrosis formation in rodent models of toxin-
induced chronic liver injury 34,135, triggering the start of a randomized controlled clinical trial
evaluating the effect of intraportally infused MSCs on patients with decompensated liver
cirrhosis 136.
Transplanted MSCs were shown to express high levels of matrix metalloproteinase
(MMP)-9, which directly degrades extracellular matrix'37 . However, indirect immunomodulatory
effects on resident cell types likely play a role in the anti-fibrotic effects of MSCs. Using in vitro
studies described in Chapter 4, we observed dynamic interactions between MSCs and activated
stellate cells, the principal mediator of matrix deposition in liver fibrosis. We identified IL-10 and
TNF-a as key molecules inhibiting matrix deposition by stellate cells, while MSC-derived HGF
induced apoptosis in these cells'22. Such alterations in the secretome of MSCs in response to
stress-signals138 is likely to have implications for the techniques required to obtain MSC-
conditioned medium preparations with an optimal therapeutic effect.
MSC therapy also inhibits matrix deposition and scar formation in models of heart
infarction, lung fibrosis and stroke. Paracrine mechanisms were identified in a study effectively
using a monolayer of fat-derived MSCs to prevent detrimental myocardial remodelling after
infarction, which is associated with improved compliance and elasticity of the infarct zone,39'
In a rat model of brain ischemia, the reduction in scar volume was accompanied by a decreased
number of macrophages in the scar wall, again suggesting an indirect mechanism through
immunomodulation of scar-promoting cell types .41
1.6.4. Regeneration
Enhanced regeneration through stimulation of endogenous repair programs, either through
activation of a local adult stem cell pool or via enhanced replication of differentiated cell types,
has been identified as another mode of MSC therapy. Investigators implanting human MSCs
into the hippocampus of severe combined immunodeficient (SCID)-mice demonstrated
enhanced proliferation and differentiation of endogenous neural stem cells and suggested a
direct effect of cytokines produced by the MSCs including NGF and ciliary neurotrophic factor
(CNTF), both neurotrophins known to enhance neurogenesis59'119142. In coculture studies
soluble factors were shown to be responsible for increased oligodendrogenesis from neural
stem cells, but a screen for candidate molecules could not identify a specific mediator' 43.
Enhanced proliferation of endogenous non-stem cell types has been demonstrated in
experimental liver and kidney injury131 '44'45. In Chapter 3, we demonstrated that secreted
factors were sufficient to enhance liver regeneration in a model of acute liver failure in which
animals were treated with the MSC-conditioned medium 120. Animal studies of cisplatin-induced
acute kidney failure identified IGF-1 as a crucial MSC-derived mitogenic stimulus for proximal
tubular epithelial kidney cells resulting in improved organ function' 18.
1.6.5. Angiogenesis
Liver regeneration' 46, recovery from ischemic heart disease' 47, stroke' 48 and many other forms
of healing149,150 are associated with the formation of new blood vessels. Although MSCs have
the capacity to differentiate into endothelial cells51 , this phenomenon is not sufficient for the
formation of fully functional blood vessels, which requires many well coordinated steps.
However, MSC have the capacity to provide trophic support for the entire process of
angiogenesis and collateral formation. Using conditioned medium from cultured MSCs, Kinnaird
and colleagues provided evidence that secreted factors are sufficient to improve new vessel
formation and improve outcome in a rodent model of limb ischemia, demonstrating independent
roles for both VEGF and bFGF 152. Others have confirmed the importance of these two
molecules, but in vitro evidence suggests that IGF-1, hepatocyte growth factor (HGF), bone
morphogenetic protein-2, monocyte chemoattractant protein (MCP)-1 and interleukins 6, 8 and
11 are also involved'17"5 3 54. MSC therapy results in a significantly increased capillary density in
models of myocardial infarction and dilated cardiomyopathy"6'51s5"156
1.7. Clinical Trials of MSC Transplantation
Physicians often do not know the exact mechanism of action of a particular therapeutic, yet this
has not deterred drug usage. At this point in time, the same may be said for MSC-based cell
therapies. MSCs have a number of attributes that make them a favorable candidate for the next
generation of cellular medicines, in that they are: (1) readily isolated and expandable to meet
clinical demands; (2) genetically stable in culture for a number of passages; and (3) are easily
stored and transported for bedside use. Thus far, MSCs have been tested in a number of
clinical scenarios and been shown to have minimal side effects, likely due to their low
immunogenicity. We provide a brief review of the major clinical trials (see Table 1.3.) in
progress within the field of MSC therapy with an emphasis on further understanding MSC
biology. In addition, we acknowledge commercialized MSC-based products from Osiris
Therapeutics, Inc. (http://www.osiristx.com/) to exemplify the development of MSC-based
therapy within the biotechnology sector.
1.7.1 Orthopedic Reconstructive Grafts based on MSCs
The initial indications for MSCs were in the field of regenerative medicine for treatment of
orthopedic pathologies based on the mesodermal lineage commitment of these stem cells. The
first studies were seen in bone tissue engineering, whereby MSCs were seeded into
biocompatible scaffolds for insertion into bone defects157. These pre-clinical test have
culminated in a Food and Drug Administration (FDA) approved product known as Osteocel® by
Osiris Therapeutics, Inc. The use of MSCs for bone repair has been extended to genetic
diseases of skeletal dysplasia. Osteogenesis imperfecta is an autosomal dominant disorder
that results in deficiency of type I collagen, which is a critical component of the bone
extracellular matrix (ECM) 158. Infusion of allogeneic MSCs in childrenl 59 161 and in one patient in
utero162, showed accelerated growth velocities in all subjects compared to untreated patient
cohorts, however low engraftment was noted in all trials. Larger clinical trials are ongoing to
determine the efficacy of MSC therapy as a first-line treatment for this orphan disease. These
studies were further evaluated in mice models of osteogenesis imperfecta and revealed
interesting dynamics of the MSC grafts in vivo. First, engraftment of osteoprogenitor cells was
found to be saturated suggesting that higher doses of cells would be an ineffective strategy to
improve engraftment1 63 . Secondly, temporal tracking of enhanced green fluorescent (eGFP)
expressing MSCs showed that transplanted cells showed limited proliferation self-renewal
capacity after engraftment, yet they could be serially passaged and repopulate another host'4.
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Table 1.3. Examples of Clinical Trials within the Public Sector using Human MSCs
Indication Patient Trial Design Cell Mass and Measured Parameters Study Conclusions of Ref.
Enrollment Delivery and Follow-up Time CTx Group vs. Control
(Ntotal; Ncontrol, Ncell) after CTx
MI
GVHD
MLD
01
ALS
BMTx
Recovery
48-60 x109 MSCs into
coronary artery lesion
1,5, or 10 x10 6
MSCs/kg iv
2-10 xl 06 MSCs/kg iv
5.7-7.5 x10 8 bone
marrow cells/kg i.v.
MSCs suspended in
CSF infused into T7-T9
exposed spinal cord
1.5-3.9x1 06 CD34+
cells/kg and 2.2x106
MSCs/kg
Echocardiography
(monthly)
PET (3, 6 months)
EKG (3 months)
Hematopoietic Recovery
(daily)
Acute GVHD
Nerve conduction velocity
Mental/Physical Exams
Growth analysis
(6 months)
MRI (3, 6 months),
Neuromuscular exam (3
months)
Neutrophil and platelet
counts (daily),
CFU (42 days), Mortality(100 days)
(1) Decreased akinetic,
dyskinetic, hypokinetic
segments
(2) Increased wall
movement at infract
(3) LVEF higher
(1) Prompt hematopoietic
engraftment in most
patients
(2) 23/46 patients did not
undergo acute GVHD with
11 showing longer relapse
time
(1) No toxicity
(2) Improved nerve
conduction velocity
(3) No clinical change in
overall mental or physical
status
Increased growth rates that
slowed over time
(1) No adverse reactions
(2) No structural MRI
changes
(3) Mild increase in muscle
strength of a lower limb
muscle group
(1) Prompt hematopoietic
engraftment of 8 days
(2) 70% CFU recovery
(3) One patient death after
100 days
24
(69; 35, 34)
(56; 10, 46)
(5; 1,4)
(7; 2, 5)
(7; 5, 2)
(23; 15, 8)
CTx 10 days after
PCI
Open-label,
multicenter trial of
hematological
cancers patients
treated with CTx 4
days prior to
haploidentical BMTx
Patients with
successful matched
bone marrow
transplants
Diagnosed severe
type III 01 with
similar growth rates
Diagnosed ALS with
severe lower limb
and mild upper limb
impairment
Local advanced or
metastatic breast
cancer with high-
dose chemotherapy
and PBPC Tx given
Ctx at 1 or 24 hours
later
Note: CTx, cell transplant; MI, myocardial infarction; PCI, percutaneous coronary intervention; MSC, mesenchymal stem cell; PET, positron
emission tomography; EKG, electrocardiogram; LVEF, left ventricular ejection fraction; GVHD, graft-versus-host-disease; BMTx, bone marrow
transplant; MLD, metachromatic leukodystrophy; 01, osteogenesis imperfecta; ALS, amyotrophic lateral sclerosis; CSF, cerebrospinal fluid;
MRI, magnetic resonance imaging; PBPC, peripheral blood progenitor cells; CFU, colony forming unit
1.7.2. MSC Therapy for Cardiovascular Diseases
Cardiovascular dysfunction remains atop the list of major diseases that affect patients today. In
particular, myocardial infarction is still the number one killer. Death of cardiac tissue leads to
contractile dysfunction and tissue remodeling that is often ineffective because of ongoing
ischemia of the heart. Many investigators have examined the efficacy of intracoronary infusion
of bone marrow cells or purified MSCs in the peri-infarction period. In general, bone marrow
aspiration was performed after stabilization of the patients and cells were delivered by catheter-
based methods to the lesion of interest. The initial excitement in using CD34+ bone marrow cell
transplantation as a therapy for myocardial infarction'• was found to not have a survival benefit
nor clinically ameliorate signs of disease after long term follow-up in a large cohort, multi-center
trial 169' 170 . An initial trial transplanting culture amplified MSCs showed improvements in cardiac
parameters after short-term follow-up8, although no long-term data exists. In Phase I clinical
trials, ProvacelTM by Osiris Therapeutics, Inc. was found to be safe for use and enrollment of
heart attack patients for larger cohort testing has begun.
1.7.3. Hematological and Immunological Use of MSCs
Indeed the natural target tissue of MSC therapy may be the hematopoietic system.
Historically, autologous MSCs were used in the setting of allogeneic bone marrow
transplantation to enhance engraftment and limit co-morbidities, such as GVHD. Initial efficacy
data by Lazarus et al. demonstrated no toxicity or adverse reactions to transplants, which was
further elaborated by this group in a larger trial12'167 (Table 1.3). These studies were further
extrapolated to patients undergoing severe acute GVHD and being treated with haploidentical
MSCs leading to a clinical remission in a large fraction of patients relative to the standard of
care 3'84. A female patient diagnosed with myelogenous leukemia given an allogeneic HSC and
MSC transplant from her haploidentical father showed rapid engraftment with a trilineage
hematological response and no signs of acute or chronic GVHD. Interestingly, several months
after treatment, chimera studies of the patient's bone marrow revealed that all MSCs were of
recipient origin suggesting that the donor MSCs did not engraft in the marrow. Moreover, a
patient with severe idiopathic aplastic anemia treated with MSCs led to a partial resolution of
tissue hemorrhage and edema, while repopulating adipocytes and stromal cells' 71. However, no
functional recovery of the hematopoietic system was found with MSC transplants alone. MSCs
from human marrow are being tested in a variety of immunological diseases in patients by Osiris
Therapeutics, Inc. with ongoing testing in steroid refractory/acute GVHD and Crohn's disease' 72
entering phase III clinical trials for their product ProchymalM .
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1.8. Potential Side-Effects of MSC Therapy
After the treatment of 9 patients suffering from GVHD with MSC infusions, 3 developed viral
infections 173. Although these patients were at increased risk for developing opportunistic
infections through the nature of their disease, concerns were raised that immunosuppression by
the MSCs had caused a reduction of immunosurveillance to pathogens. These findings are
supported by in vitro observations that lymphocyte proliferation by herpes viruses is suppressed
by MSCs 173. Another potential serious side-effect is cancer. Theoretically, MSCs could be
tumorigenic through direct transformation, direct trophic effects on the tumor, metabolizing of
chemotherapeutic agents, and/or suppression of the anti-tumor immune response. All these
phenomena have been reported in the literature. MSCs have the potential to transform into
sarcoma when Wnt signalling is suppressed 174. Animal studies by Djouad and colleagues have
revealed enhanced tumor growth after MSC transplantation when tumor cells were
implanted90' 175 . It is unclear whether MSCs facilitated the tumor growth via immunomodulatory
or trophic effects. Karnoub et al demonstrated that MSCs within tumor stroma promote breast
cancer metastasis via cancer cell-induced de novo secretion of the chemokine CCL5 in MSCs 176.
Mesenchymal cells were shown to regulate the response of acute lymphoblastic leukemia to
asparaginase chemotherapy, by metabolizing the drug via their high expression of asparaginase
synthetase'77 ,178 . In addition, bone marrow stromal cells, highly enriched for MSCs, promote
survival of B- and plasma-cell malignancies by inducing hedgehog signaling1 ". Moreover,
MSCs used for the treatment of GVHD limited the graft-versus-leukemia effect of allogeneic
bone marrow transplantation leading to a higher rate of relapse compared to control
groups 18 '181 . Although potent anti-tumor effects of MSCs have been observed, patients with
increased risk may not be suitable candidates for MSC therapy and a potential effect on
spontaneous tumor formation should be taken into account when assessing trials until more
conclusive experimental data become available.
1.9. Thesis Objectives
This thesis describes the development of new modalities and indications for MSC-based
therapy in the treatment of immune-mediated disease. In addition, we discover a new cellular
phenomena displayed by these cells that may explain their immunomodulatory phenotype. Two
theories of the endogenous functions of bone marrow stromal cells are leveraged for therapeutic
purposes: (1) stromal cells support hematopoiesis by secreting ECM, cytokines, and growth
factors; and (2) stromal cells can present antigens in lymphoid organs. Based on the first theory,
we ask if MSC secreted molecules can be formulated as an intravenous drug or delivered to the
subject by seeding MSCs within extracorporeal devices. Based on the second theory we ask if
MSC-based antigen presentation can be used to induce tolerance in autoimmune disease.
Hence, this thesis is subdivided into three sections: (a) a new class of immunotherapeutics
derived from MSC molecules (Chapters 2-5); (b) the incorporation of MSCs within biomedical
devices (Chapters 6-7); and (c) MSC transplants as a treatment for autoimmune disease
(Chapters 8-10).
In Chapter 2 we describe the first use of MSC-derived molecules for the treatment of an
inflammatory condition in vivo. Using a rat model of fulminant hepatic failure, we reduce to
practice the method of preparing and delivery MSC molecules intravenously. The treatment
was found to have a significant survival benefit and to affect peripheral and tissue-infiltrating
leukocytes.
In Chapter 3 we demonstrate a direct effect of MSC molecules on parenchymal liver
cells. Treatment of liver failure with MSC molecules led to an increase in the mitotic index of
hepatocytes, while decreasing their cell death in vivo. We developed in vitro assays and
verified that MSC molecules could directly affect these same processes on primary hepatocytes
in culture under appropriate stimuli.
In Chapter 4 we present in vitro studies of the paracrine modulation of resident liver cells
known to promote chronic liver disease. During inflammation, hepatic stellate cells become
activated, undergo phenotypic changes and ultimately create scar tissue that encases
hepatocytes leading to impaired liver function. Coculture of MSCs with stellate cells resulted in
a decrease in collagen secretion and cell growth parameters suggesting that MSC molecules
may be effective in fibrotic diseases of the liver.
In Chapter 5 we conclude the first section with a description of the composition of MSC
secretions with initial insight into therapeutic fractions using size and affinity separation
techniques. We show that MSCs secrete a large number of growth factors and chemotactic
cytokines that correlate with the therapeutic efficacy seen with the unfractionated form.
In Chapter 6 we begin the second section with proof-of-principle studies incorporating
MSCs into extracorporeal bioreactors for the treatment of liver failure. We observed a marked
benefit in short-term survival and a decrease in serum markers of liver injury. Moreover, we
show that MSCs alter their secretome in response to serum from liver injured rats compared to
healthy subjects suggesting that MSCs may dynamically respond to disease while seeded in the
device.
In Chapter 7 we develop a coculture device incorporating both hepatocytes and MSCs to
provide both hepatic and immunological support for animals undergoing acute liver failure.
MSCs were first shown to stabilize the hepatocyte phenotype in vitro in a dose-dependent
manner. Survival studies of a coculture extracorporeal reactor indicated a significant long-term
benefit seen after the MSC/hepatocyte coculture treatment compared to appropriate coculture
control devices which had optimal hepatic function but no immunological support.
In Chapter 8 we turn our attention in this last experimental section to MSC grafts for the
treatment of chronic disorders, specifically autoimmune disease. MSCs were found to
specifically improve histological parameters in the intestine after screening multiple diseased
tissues in a mouse model of multi-organ autoimmunity. In addition, engrafted cells were found
in gut associated and ancillary lymphoid tissue rather than in the intestinal parenchyma, and
effected local T cell populations in situ.
In Chapter 9 we further explore the therapeutic potential and mechanism of action of
MSC transplantation in a more specific model of intestinal autoimmunity. Treatment with MSCs
led to the prevention and amelioration of chemically-induced colitis. Histopathological analysis
verified changes in the gut and tissue-associated lymph nodes consistent with our previous
findings in the multi-organ autoimmunity model. Furthermore, we show that MSC grafts lead to
a local increase in the number of suppressor cells within lymph nodes suggesting an
amplification of immunosuppression by endogenous mechanisms
Finally in Chapter 10, we discover that MSCs naturally present peripheral tissue self-
antigens. This mechanism of antigen presentation has been described in other lymphoid
organs and is herein shown to take place in the bone marrow stroma. This finding will have
important implications in identifying the endogenous role of such antigen presentation within the
bone marrow as well as harnessing this ability for tolerance inductive strategies for disease.
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Section II
A Natural Poly-Drug Based on Mesenchymal Stem Cell-Derived Molecules
OVERVIEW
The bone marrow is a site of an extraordinary number of cellular events that take place
during the development of blood cells. The correct chemical environment must be locally
maintained and orchestrated in order for such diverse processes to take place in a compartment.
Mesenchymal stem cells and their stromal progeny are a major source of various chemical
species that fortify the bone marrow cavity. In this section, we have concentrated these
chemical species derived from MSCs and have tested and demonstrated their efficacy in a
disease context, specifically liver diseases. In Chapter 2, we describe the proof-of-principle
study, whereby treatment with MSC-derived molecules reversed fulminant hepatic failure in rats.
A comprehensive pathological response is reported with a focus on the immune system as an
initial target of MSC molecules. In Chapter 3, we extend the cellular targets of MSC molecules
to include the parenchymal cells of the liver. Treatment with MSC molecules directly inhibited
cell death and promoted proliferation of hepatocytes in vivo and in culture. MSC molecules
were also found to effect non-parenchymal liver cells that are implicated in chronic disease. In
Chapter 4, we show that short-term coculture of MSCs with activated stellate cells, the principal
scar-forming cell during liver fibrosis, led to a reduction in collagen synthesis and viability of the
stellate cells in a contact-independent fashion. Finally, in Chapter 5 we conclude with a
molecular description of MSC molecules using traditional and new biochemical methods.
CHAPTER II
MESENCHYMAL STEM CELL-DERIVED MOLECULES REVERSE ACUTE LIVER FAILURE
2.1 INTRODUCTION
The immune response to acute liver injury begins locally with activated Kupffer cells,
which phagocytose cellular debris leading to the expression of death ligands and release of pro-
inflammatory molecules such as tumor necrosis factor (TNF)-a, interleukin (IL)-1 and IL-6 at
the wound site 182. Depletion or functional blockade of Kupffer cells in vivo can ameliorate many
animal models of liver injury 183. These cytokines result in activation of liver sinusoidal
endothelial cells (LSECs) to coordinate the recruitment of circulating immune cells. LSECs
constitutively express cellular adhesion molecules such as CD54 and CD106 leading to the
margination of leukocytes, which further intravasate into the tissue due to chemokine gradients
184. Neutrophils are a major cellular component of innate immunity that causes tissue
destruction during acute liver inflammation as evidenced by studies that have shown a
protective effect by depleting circulating neutrophils prior to 1/R injury 18. After extravasating
into the interstitium, neutrophils can potentiate hepatocyte damage by peroxidation of cellular
membranes via liberation of free radicals and proteases 186. The adaptive immune system also
plays an integral role in the progression of acute liver injury and has been correlated to events
within the sinusoidal space. Platelets found in the luminal space, most likely due to
intravascular fibrinogen deposition at denuded endothelium 87, play a pivotal role in T cell
infiltration. Recent studies have shown that platelets actively contribute to liver pathogenesis by
mediating the interaction of T lymphocytes and the endothelium in an anti-coagulant
independent manner 188,189 TH1 and cytotoxic T lymphocytes (depending on the type of injury)
at the endothelial border are presented with class I and II major histocompatibility complex
(MHC) antigens as well as costimulatory ligands CD80 and CD86 by LSECs 190. These
lymphocytes create a feedback loop to further enhance a secondary leukocyte migration as
shown by the loss of granulocyte accumulation in injured livers in CD40 -/- mice or by the use of
an immunoglobulin-linked negative costimulatory ligand CTLA-4 189,191. Furthermore, these T
cells coordinate the progression of the granulocytic immune reaction and can also have direct
hepatocytolytic activity. In summary, the response to acute liver injury involves local activation
of non-parenchymal cells that then direct the influx of lymphocytes and granulocytes causing
hepatocyte death secondary to the initial insult. These processes are summarized in Figure 2.1.
Within the bone marrow space, multipotent stromal cells, also referred to as
mesenchymal stem cells (MSCs), are known to be the precursor cell for stromal tissues that
Figure 2.1. The Temporal Cellular Response to Liver Injury In Vivo. A primary insult causes
diffuse hepatocyte necrosis. Resident Kupffer cells phagocytose cell debris leading to cell
activation and release of proinflammatory cytokines. Liver sinusoidal endothelial cells (LSECs)
are stimulated to recruit circulating immune cells by secreting chemokines and displaying
homing receptors on their cell surface. Neutrophils extravaste into the interstitium and release
potent reactive oxygen species causing further tissue damage. This secondary tissue damage
can be further coordinated circulating T cells that interact with platelets and the endothelium and
causing a new wave of leukocyte infiltrates.
support hematopoiesis' 92. The immunomodulatory function of these cells was first reported
after it was observed that MSCs could evade immunosurveillance after cell transplantation83.
This ability of MSCs to alter an immune response has been exploited for therapeutic purposes
as demonstrated by the case of a patient suffering from steroid-refractory graft-versus-host
disease who was successfully treated by the infusion of haploidentical MSCs8. In vitro studies
have subsequently shown that MSCs actively inhibit the function of several immune cells
through secreted cytokines, growth factors and enzymatic action, although controversy exists on
the identity of the responsible mediators89' 98'100' 19 4. The fortification of the soluble
microenvironment by MSCs can also affect non-hematopoietic cells as well. A study using
MSCs for cellular cardiomyoplasty after an ischemic event revealed that MSC-derived soluble
molecules inhibited hypoxia-induced apoptosis of cardiomyocytes during the acute phase of
injury resolution"12 ,113. Taken together, these studies indicate that MSCs can independently
affect immune and tissue cells by paracrine means. On this basis, we hypothesized that the
paracrine function of MSCs may be of therapeutic value when used in the setting of acute organ
failure, specifically liver failure, wherein parenchymal cell loss is integrated with a local and
systemic inflammatory response.
In this chapter we describe the first experimental evidence of the medicinal use of MSC-
derived molecules in the treatment of an inflammatory condition, namely acute liver injury and
organ failure. In proof-of-principle studies we report that the administration of MSC-derived
molecules via an intravenous bolus of conditioned medium (MSC-CM) can provide a significant
survival benefit in rats undergoing fulminant hepatic failure (FHF). We then characterize the
animal response to therapy using pathological, serological, and radiological assays.
2.2 MATERIALS AND METHODS
Materials were purchased from Sigma-Aldrich, St. Louis, MO unless otherwise stated.
2.2.1. Cell Culture
Human MSCs were isolated from commercially available bone marrow aspirates (Clonetics-
Poietics, Walkersville, MD) and grown as previously reported. Cells were used for experiments
during passages 3-7. NIH 3T3-J2 fibroblasts were a kind gift from Dr. Howard Green and
cultured according to donor's protocols.
2.2.2. Preparation and delivery of cells, cell lysates and conditioned medium
Cellular lysates were prepared by sonication (VWR Scientific, West Chester, PA). The dose of
sonicated cells administered was 2x106 cells per subject, which represented the same cell mass
used for cell transplant experiments. Conditioned medium was prepared by collecting serum-
free medium (supplemented with penicillin/streptomycin and 0.05% bovine serum albumin) after
24 hour culture of different cell masses. The majority of experiments were performed with the
optimal cell mass of 2x106 cells. The medium was then concentrated, approximately 25 fold,
using ultrafiltration units (Amicon Ultra-PL 3, Millipore, Bedford, MA, USA) with a 3 kDa
molecular weight cut-off. A total volume of 500 ýI, containing cells, cellular lysates, vehicle
(PBS) only or 900 il of conditioned medium was infused in the penile vein 24 hours after
induction of FHF using the same anaesthesia protocol described for the cannulation procedure.
2.2.3. Liver Injury/Failure Induction
The induction of FHF is previously reported195 . All animals were cared for in accordance with the
guidelines set forth by the Committee on Laboratory Resources, National Institutes of Health.
All experimental procedures performed were approved by Subcommittee on Research Animal
Care and Laboratory Animal Resources of Massachusetts General Hospital.Briefly, male
Sprague-Dawley rats weighing between 280 and 370 grams were subjected to a lethal regimen
of D-galactosamine (Gal-N) induction. At t = 0 and 12 hours, 1.2 g/kg Gal-N freshly dissolved
in physiological saline and adjusted to pH 7.3 with 1 N NaOH was injected i.p., followed by a
second equal injection 12 hours later. In certain instances, we chose a dose of 0.6 g/kg Gal-N
per injection to induce FHF with an intermediate level of mortality based on our previous studies
so as to ensure that a subgroup of vehicle treated animals would survive long enough to be
analyzed for comparison.
2.2.4. Treatment Arms and Animal Monitoring
At t = 24 hr. post-FHF induction rats were anaesthetized using i.p. injections of ketamine and
xylazine at 110 and 0.4 mg/kg, respectively. Subsequently, animals were treated with penile
vein injections of cells, lysates, or conditioned medium derived from MSCs and compared to
either saline or a mock-cell control. With respect to MSC-CM, 0.9 ml of MSC-CM or 0.9% NaCI
solution was infused. Animal survival was monitored every 12 hours. We used 4 animals per
group for tissue collection after sacrifice at 36 hours after treatment and 10 animals per group
for survival analysis. In a separate group of animals (N=4 per group), blood samples were
collected at 12, 36, 60, 108 and 156 hours after treatment by tail snip for analysis of liver
enzyme release levels.
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2.2.5. Quantification of Aminotransferase Release
Plasma or whole blood was harvested by tail vein puncture and analyzed for liver injury
biomarkers. Serum samples were stored at -800 until analysis. Measurement of alanine and
aspartate aminotransferase (ALT and AST, respectively) levels were carried out using Thermo
Electron Infinity ALT and AST Reagent (Louisville, CO) according to the manufacturer directions.
2.2.6. Cytokine Levels
Quantification of serum levels of rat interleukin (IL)-113, tumor necrosis factor-a (TNF-a), IL-6, IL-
2, IL-1 receptor antagonist (IL-1ra) and IL-10 was determined using enzyme-linked
immunosorbant assay (ELISA) per manufacturer's instructions (R&D Systems, Minneapolis,
MN).
2.2.7. Liver Histology
Formalin-fixed, paraffin-embedded liver samples were sectioned at 4 lm thickness and stained
with hematoxylin & eosin (H&E). Histological assessment was performed by a blinded observer,
who scored the liver sections using the following criteria: normal histology "0"; minor
hepatocellular death and inflammation "1"; widely distributed patchy necrosis and inflammation
"2"; complete disruption with panlobular necrosis and inflammation "3"; mortality "4".
2.2.8. Adoptive transfer of radiolabeled leukocytes. Leukocytes were isolated from whole
rat blood by NH4CI erythrocyte lysis. Cells were pelleted, washed once with PBS and
resuspended in 0.9% saline containing the In"' oxine isotope (GE Healthcare Biosciences
Corp., Piscataway, NJ). Cells were labeled at 92% efficiency with high viability. Approximately
15x106 cells were infused into the penile vein of Gal-N injured (0.6 g/kg) directly after treatment
with vehicle or MSC-CM. SPECT images were captured using a M.CAM gamma camera setup
(Siemens Medical Systems, Malvern, PA) at 0, 3 and 24 hours after leukocyte infusion.
2.2.9. Protein array analysis of MSC-CM.
Supernatants were prepared by collecting serum-free medium after 24 hour culture of
approximately 2x106 MSCs. These were analyzed for a panel of specified proteins using an
antibody array (RayBio Human Cytokine Antibody Array C Series 2000, RayBiotech Inc.,
Norcross, GA) as specified by the vendor.
2.2.10. Digital Cell Quantification
Quantification of cell numbers in stained liver sections was performed in 10 random 40x images
per animal using the public software ImageJ (http://rsb.info.nih.gov/ij/). Positive cells were
quantified using appropriate criteria for a specific threshold of staining intensity as well as
corresponding sizes of the nuclei. Nuclei of area greater than 700 pixel2 were analyzed to
specifically identify hepatocytes from resident non-parenchymal and infiltrating inflammatory
cells' 96. Infiltrating inflammatory cells were counted by similar thresholding of H&E sections and
analysis of nuclei with area less than 700 pixel2 and were qualitatively verified as CD45+ cells by
immunofluorescence.
2.2.11. Statistical Analysis
Data are expressed as the mean ± standard error of the mean. Statistical significance was
determined by a two-tailed Student's t-test and, specifically a Log Rank test for survival analysis.
A P-value of < 0.05 was used for statistical significance. Statistical image analysis was
performed after determining that the data could be fit with a normal distribution. A two-tailed
Student's t-test was employed after the exclusion of outliers that were less or greater than 2
standard deviations away from the median.
2.3. RESULTS
2.3.1. MSC-Derived Components Reverse FHF
We first assessed various MSC treatment modalities such as cell transplantation, delivery of
cellular lysates or conditioned medium to assess the most efficacious therapy. Sprague-Dawley
rats were intraperitoneally administered a total of two injections of 1.2 g/kg of a hepatotoxin, D-
galactosamine (Gal-N), each separated by 12 hours' 97 . With this regimen of liver failure
induction, we have previously shown that death occurs 36-72 hours after injection of the first
dose and is associated with significant hepatocellular necrosis concomitant with leukocyte
infiltration and an increase of inflammatory cytokines in liver tissue. Animals were treated 24
hours after FHF induction with intravenous injections of whole cells or cell lysates. No significant
benefit was seen after the intravenous infusion of 2x106 human MSCs 24 hours post-induction,
which is most likely due to poor engraftment, entrapment in the alveolar capillary bed and/or
immune rejection of the cells (Figure 2.2A). In contrast, treatment with cellular lysates, derived
from the same cell mass used for transplantation, showed an increased survival trend compared
to vehicle (P=0.47) and fibroblast lysate (P=0.36) controls. We then determined if the efficacy
observed with lysates could be reproduced by using the secreted molecules from MSCs. A
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Figure 2.2. MSC-Derived Molecules Reverse Fulminant Hepatic Failure. Sprague-Dawley
rats were administered lethal intraperitoneal injections of a hepatotoxin. Animals were treated
with i.v. injections of MSCs, MSC lysates, or concentrated MSC-CM. Controls received saline or
NIH 3T3-J2 fibroblast components. (A) Kaplan-Meier survival analysis of Gal-N administered
rats treated with cell transplants and lysates. (B) Kaplan-Meier survival analysis of Gal-N
administered rats treated with concentrated MSC-CM. (C) Dose response of animal survival 72
hours after liver failure induction as a function of MSC mass (N=8 per each dose). Results are
cumulative data of two independent experiments using different donors of MSCs. P-value
determined by Log Rank Test. FHF, fulminant hepatic failure; MSC, mesenchymal stem cell;
MSC-CM, mesenchymal stem cell-conditioned medium; Gal-N, D-galactosamine.
A
longitudinal study using MSC-CM from the same cell mass (i.e., 2x10 6 human MSCs) revealed a
distinct survival benefit compared to vehicle (P=0.032) and fibroblast (P=-0.026) concentrated
medium (Figure 2.2B). In addition, we monitored 72 hour survival of FHF-induced rats as a
function of MSC mass from which medium was conditioned (Figure 2.2C). Interestingly, the
effect of MSC concentrate was abrogated at higher cell masses indicating a therapeutic window
of effectiveness. Moreover, the observation that xenogeneic MSC lysates and supernatants
decreased animal mortality suggests that these factors can cross species barriers.
2.3.2. MSC-CM Therapy Inhibits Liver Enzyme Release and Improves Liver Injury Survival
When massive hepatocyte death overwhelms the regenerative capacity of the liver during FHF,
death ensues. Liver enzyme levels measured in the peripheral blood provide a good estimate
of ongoing liver damage. Two of four vehicle-treated animals died between 12 and 36 hours
following treatment. In the surviving animals, the peak in liver damage was measured at 36
hours after the systemic treatment, both in the control and the MSC-CM treated group.
However, the maximum ALT and AST levels were reduced by 67% (P=-0.012) and 65%
(P-0.009) respectively in the MSC-CM treated animals (Figure 2.3A-B). No significant
differences were observed at any of the other timepoints. In the rats treated for survival
analysis using a 0.6 g/kg Gal-N induction regiment, a significant survival benefit was observed
for the MSC-CM treated animals (Figure 2.3C). Only one animal died during the observation
period in the MSC-CM group, versus 50% of the control rats (P=0.046). Figure 2.3D describes
a significant survival benefit for MSC-CM treated animals when compared to either conditioned
medium derived from normal human dermal fibroblast cultures (P=-0.031) or vehicle treatment
(P=0.040). These results suggest that the therapeutic effect is not specific to secretions of
human proteins from any mesenchymal cell type but is MSC-specific. Overall, these results
show that MSC-CM protects the liver from excessive damage and reduces mortality associated
with this model of Gal-N induced FHF.
2.3.3. MSC-CM Treatment Downregulates Systemic Inflammation
Massive liver injury results in a local and systemic inflammatory response that can ultimately
lead to multi-organ failure and death. Analysis of serum cytokine levels (Figure 2.4) revealed a
non-significant decrease for IL-13 (P=-0.054), but significantly lower levels of TNF-c (64%;
P-0.0002) and IL-6 (54%; P--0.0002) following MSC-CM treatment. These pro-inflammatory
cytokines are known to be upregulated during liver injury. Levels of IL-2 did not change (P--0.43).
In contrast, the concentration of soluble IL-1 ra was 87% lower in MSC-CM treated animals
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Figure 2.3. Infusion of MSC-CM Prevents Liver Injury and is a Cell-Specific Therapy. Liver
injury was induced in Sprague-Dawley rats using Gal-N (0.6 g/kg twice i.p.). Animals were
treated with systemic infusions of concentrated MSC-CM or with vehicle 24 hours after the
induction of FHF. (A) ALT and (B) AST enzyme release levels in peripheral blood samples
collected at 12, 36, 60, 108 and 156 hours after the systemic treatment. (C) Kaplan-Meier
survival analysis of Gal-N treated rats. * P=0.046 (Log Rank Test). (D) Kaplan-Meier survival
analysis of Gal-N treated (1.2 g/kg) rats after systemic treatment with MSC-CM, concentrated
medium derived from normal human dermal fibroblast cultures or vehicle. * P<0.05 (Log Rank
Test). MSC-CM, mesenchymal stem cell-conditioned medium; FHF, fulminant hepatic failure.
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(P--0.0002). Levels of the anti-inflammatory cytokine IL-10 were increased 4-fold in MSC-CM
treated animals (P-0.032). Taken together, these data demonstrate that the infusion of
molecules secreted by MSCs alters the systemic cytokine profile associated with FHF to a more
anti-inflammatory state.
2.3.4. MSC-CM Therapy Improves Gross and Microscopic Liver Histopathology and
Reduces Leukocyte Infiltration
Gal-N induced FHF is accompanied by characteristic changes in the gross appearance of the
liver consisting of increased pallor and a soft and shrunken consistency'98 . One of four control
animals died before animals were sacrificed. Necropsy was not performed on this animal, but
based on our prior experience with this model we expect that gross pathology of the liver was
abnormal. Two of the three remaining control livers were pale, soft, and shrunken (Figure 2.5A).
The liver of one vehicle treated rat appeared normal. In contrast, none of the four MSC-CM
treated livers demonstrated gross pathological changes (Figure 2.5B). Microscopic evaluation
of liver tissue from vehicle treated rats revealed profound hepatocellular death with cytoplasmic
vacuolization, severe distortion of tissue architecture, bile duct duplication and panlobular
mononuclear CD45+ leukocyte infiltration (Figure 2.5C-D,G). In contrast, livers of MSC-CM
treated animals demonstrated minor periportal immune cell infiltration (Figure 2.5E) with edema
and fibrin deposition, characteristic of tissue repair (Figure 2.5F,H).
Semi-quantitative histological examination of liver tissue confirmed significant
differences between the groups (Figure 2.51). The average score in the MSC-CM group was 1.5
+ 0.6 and 3.0 ± 0.8 for vehicle treated animals (P-0.024). A 58% decrease in the number of
infiltrating CD45+ immune cells was observed after MSC-CM infusion (33 ± 9.3 compared to 84
± 37 in controls; P--0.004; Figure 2.5J). These results demonstrate that MSC-CM therapy
inhibits the development of histopathological changes and immune cell infiltration in the liver in
Gal-N induced FHF.
2.3.5. MSC-CM Treatment Alters Peripheral Blood Leukocyte Counts and Liver Infiltrates
At the same time point of liver tissue analysis, we harvested peripheral blood and did a
complete blood cell count and differential. To our surprise, we observed a significant
leukocytosis associated with MSC-CM that was primarily lymphocytic in nature (Figure 2.6A).
We observed a significant increase in peripheral leukocytes from 8 ± K/ul to 13 ± K/ul after
MSC-CM treatment (P--0.001). The differential cell count was remarkable for an approximate
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Figure 2.5. Histopathological Analysis of Liver Tissue After MSC-CM Treatment. FHF rats
were sacrificed 36 hours after systemic vehicle or MSC-CM treatment. Livers were inspected
and samples were subjected to histological analysis after hematoxylin & oesin staining. Gross
appearance of representative liver lobes after (A) control or (B) MSC-CM treatment.
Microscopic high-power field of liver tissue after (C-D) vehicle or (E-F) MSC-CM infusion.
Verification of CD45+ infiltrates by immunofluorescence staining of (G) vehicle or (H) MSC-CM
treatment. Bar = 200 pm. (I) Scores determined by semi-quantitative histological exam. (J)
Quantification of infiltrating immune cells. Data shown are mean ± standard error of the mean
of 10 random high power fields per animal. * P=0.024, ** P=0.004. MSC-CM, mesenchymal
stem cell-conditioned medium; FHF, fulminant hepatic failure; FOV, field of view.
L..e
_J
I
i
M DAn
three-fold increase in lymphocytes after MSC-CM treatment (vehicle, 3.5 ± K/ul; MSC-CM 9.2 ±
K/ul; P-0.001), along with marginal changes in granulocytes (neutrophil: vehicle, 4 ± K/ul; MSC-
CM, 2.5 ± K/ul; P-0.05; monocyte: vehicle, 1 ± K/ul, MSC-CM, 0.5 ± K/ul; P=0.03). The origin of
these leukocytes may be due to increased mobilization and/or production of blood cells by
MSC-CM. We hypothesized that one potential explanation for the lack of panlobular leukocyte
infiltration may be that MSC-CM treatment may affect immune cell viability and/or divert immune
cell migration away from an inflamed, target organ. To test this theory, we adoptively transferred
radiolabeled leukocytes, directly after MSC-CM or vehicle treatment, into Gal-N (0.6 g/kg)
injured rats and monitored leukocyte viability and trafficking using single photon emission
computed tomography (SPECT) over time (Figure 2.6B). Qualitatively, more leukocytes were
seen migrating to the liver in vehicle treated animals over time (Figure 2.6C). In contrast, there
was a distinct decrease in signal intensity in the liver of MSC-CM treated animals over time
(Figure 2.6D). These results suggest that there was a selective pressure upon leukocytes to
either die or emigrate from the liver due to MSC-CM, unlike control conditions where leukocytes
eventually migrated to the injured organ. These data support our hypothesis that altered
leukocyte viability and migration may be a potential target of MSC-CM therapy.
2.4. DISCUSSION
Our findings demonstrate that MSC-derived molecules can protect against hepatocyte death
and increase survival in Gal-N induced FHF. Specifically, we have shown that an intravenous
bolus of MSC-CM during active disease can reverse organ failure. The efficacy of MSC-CM
was found to be a function of the cell mass from which media were conditioned suggesting
important pharmacological aspects of this treatment. Local downregulation of pro-inflammatory
cytokines and upregulation of anti-inflammatory cytokines, such as IL-10, after MSC
transplantation has been described in models of lung and kidney injury' 32' 133,154 . Our results
demonstrate that these alterations occur on a systemic level. Mortality from FHF is partly
attributed to the uncontrolled systemic inflammatory response that manifests into multi-organ
failure'". Downregulation of this response may contribute to improved survival of FHF after
MSC-CM treatment.
Histological evaluation of liver tissue after MSC-CM treatment provided initial insight into
the cellular targets of therapy. A striking reduction in mononuclear leukocytes was seen post-
treatment, suggesting that MSC-CM may inhibit the ability of immune cells to invade and/or
function within the injured tissue. Using SPECT imaging of adoptively transferred leukocytes,
we provide evidence showing altered immune cell migration after MSC-CM treatment supporting
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Figure 2.6. Alteration in Peripheral and Tissue Leukocytes in Response to MSC-CM
Therapy. Gal-N induced rats were treated with MSC-CM or vehicle and peripheral blood was
acquired 36 hours later. (A) Absolute and differential peripheral blood leukocyte count (N=4 per
group). (B) Experimental design of adoptive transfer study. Gal-N injured rats were treated with
vehicle or MSC-CM followed by infusion of Inl'l-labeled leukocytes. SPECT images were
acquired at t = 0, 3, and 24 hr. (left to right) for MSC-CM (C) and vehicle (D) treated rats,
respectively.
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our hypothesis that MSC-CM modulated the immune response to organ injury. Interestingly, it
appears that MSC-CM did not divert leukocyte trafficking from the injured site initially, but rather
induced selective death or emigration of homed leukocytes from the organ. In addition, we
observed a reduction in hepatocyte apoptosis and inhibition of bile duct duplication after MSC-
CM treatment. We further investigate in Chapter 3 if these are direct or indirect effects of MSC-
CM in order to evaluate which processes are the primary targets of MSC-CM and which are
merely secondary effects.
Systematic proteomic analysis combined with fractionation studies of MSC-CM is
necessary to identify key therapeutic components, but also potentially harmful components. In
chapter 5, we further explore the molecular signature of MSC-CM using different proteomic
methods to provide insight into the chemical composition of MSC-CM. Such investigations will
ideally lead to the development of a balanced cocktail of trophic compounds with an optimized
therapeutic effect in FHF.
The vast majority of reports describe cell transplantation as the primary mode of MSC
therapy, although Dzau and colleagues have described a therapeutic effect of locally
administered MSC-CM in a rat model of myocardial infarction112 . Compared to MSC-CM, cell
transplantation has the potential advantage of regeneration via stem cell differentiation and
sustained release of active molecules by long-term engrafted cells. Although differentiation of
MSCs into cells with an hepatocyte-like phenotype has been described1", differentiation into
fully functional hepatocytes is at most a rare phenomenon. Moreover, engraftment levels of
MSCs are often insignificant 200 and long-term actions may be deleterious in acute organ injury.
The liver is not suitable for local injections and portal vein injection to circumvent pulmonary
lodging and embolus-formation by transplanted cells is invasive and often lethal in rodents. For
these reasons, systemic infusion of MSC-CM represents an effective alternative of delivering
the therapeutic effects of MSCs in acute and potentially chronic settings without the
aforementioned problems.
In conclusion, we describe the first use of the secretory functions of MSCs to derive a
new class of immunotherapeutics. The present study shows that systemic MSC-CM therapy
ultimately improves survival in rats undergoing Gal-N induced FHF, creating a new potential
avenue for the treatment of this devastating disorder. These data describe local and systemic
changes in inflammation after treatment with MSC-CM. In the next chapter, we focus our efforts
to define the response of hepatocytes to MSC secreted factors.
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CHAPTER III
DIRECT MODULATION OF HEPATOCELLULAR DEATH AND REGENERATION IN VIVO
AND IN VITRO BY MESENCHYMAL STEM CELL-DERIVED MOLECULES
3.1 INTRODUCTION
Fulminant hepatic failure (FHF) affects approximately 2,500 people in the US annually
with mortality rates exceeding 30% even in highly specialized centers'99 . Orthotopic liver
transplantation is the current gold standard of care, but its use is limited due to organ donor
shortage, financial considerations and the requirement for lifelong immunosuppression2 01.
Strategies aimed at restoring liver functions using acellular and hepatocyte-based technologies
have shown promising results in animal models and human testing of small patient cohorts, but
efficacy has yet to be demonstrated in controlled clinical trials202'203. FHF is typically associated
with massive hepatocellular necrosis with a compensatory regeneration of the organ that fails to
meet the cellular losses204. Therefore, effective treatment strategies aimed at protecting the
dying liver cell mass and stimulating regeneration could offer major benefits in the treatment of
FHF.
Bone marrow-derived mesenchymal stem cells (MSCs) are known to naturally support
hematopoiesis by secreting a number of trophic molecules, including soluble extracellular matrix
glycoproteins, cytokines, and growth factors56'205. Recent studies in models of myocardial
infarction, acute kidney failure and stroke have shown that MSC therapy has the potential to
inhibit cell death and stimulate endogenous regeneration programs 112'132 '140,206. We
demonstrated in Chapter 2 that systemic administration of MSC-derived molecules by a bolus
injection of conditioned medium (herein referred to as MSC-CM), significantly improved short-
term survival in a D-galactosamine (Gal-N) induced rat model of FHF121. We observed
alteration in immune cell function following MSC-CM therapy, however the effect of MSC-CM on
resident liver cells was not fully explored.
In this chapter, we investigated whether systemic infusion of MSC-CM leads to a
hepatoprotective response in the acutely injured liver, specifically by inhibiting cell death and
stimulating reparative programs. In a sub-lethal regimen of Gal-N induction, we demonstrate a
reduction in apoptotic hepatocytes and an increase in the number of proliferating hepatocytes in
vivo. Using in vitro assays, we show that secretions from MSCs have a direct inhibitory effect
on hepatocyte death and a stimulatory effect on their proliferation.
3.2 MATERIALS AND METHODS
Unless otherwise stated, materials were purchased from Sigma-Aldrich (St. Louis, MO).
3.2.1. Animals
Male Sprague-Dawley rats weighing 250-300g were used for the FHF experiments.
Hepatocytes were isolated from 150-200g female Lewis. Animals (Charles River Laboratories,
Boston, MA) were cared for in accordance with the guidelines set forth by the Committee on
Laboratory Resources, National Institutes of Health.
3.2.2. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM)
Human MSCs were kindly provided by the Tulane Center for Gene Therapy. MSCs were
cultured and characterized for surface marker expression and adipocytic and osteogenic
differentiation capacity as described previously122. For the generation of MSC-CM, cells were
allowed to grow to 70-80% confluence (approximately 1x106 MSCs per 175 cm2 flask), washed
thoroughly and cultured in 15 ml serum free Dulbecco's Modified Eagle's Medium supplemented
with penicillin/streptomycin 0.05% bovine serum albumin. Conditioned medium was collected 24
hours later and concentrated 25-fold using ultrafiltration units (Millipore, Bedford, MA) with a
3kD cutoff. The collective medium harvested from two flasks was used for a single rat.
3.2.3. FHF Induction and Treatment
FHF was induced by two injections of Gal-N, delivered i.p. with a 12-hour interval between
injections. We chose a dose of 0.6 g/kg Gal-N per injection to induce FHF with an intermediate
level of mortality based on our previous studies so as to ensure that a subgroup of vehicle
treated animals would survive long enough to be analyzed for comparisonl 21. After 24 hours
post-FHF induction rats were anaesthetized using i.p. injections of ketamine and xylazine at 110
and 0.4 mg/kg, respectively and 0.9 ml of MSC-CM or 0.9% NaCI solution (vehicle control) was
infused into the penile vein. We used 10 animals per group for tissue collection after sacrifice at
36 hours after treatment.
3.2.4. Immunohistochemistry
Four-micron thick sections of formalin fixed tissue were deparaffinized, rehydrated and blocked
in 3% hydrogen peroxide in ethanol for 15 minutes after baking at 600 for 1 hour. For CD45 and
proliferating cell nuclear antigen (PCNA) immunohistochemistry, sections were treated in 10mM
Citrate Buffer at pH 6.0 using a digital pressure cooker, blocked with 1.5% horse serum for 15
minutes and incubated with mouse anti-CD45 (BD, San Jose, CA) or mouse monoclonal anti-
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PCNA (Clone 24, BD, San Jose, CA) at a 1:200 or 1:500 dilution for 1 hour at room temperature,
respectively. Sections for CD45 analysis were washed and incubated with a goat anti-mouse
IgG secondary antibody for 25 minutes at room temperature. Finally, the sections were washed
and mounted with medium containing DAPI (Vector Laboratories, Burlington, CA). With respect
to PCNA analysis, primary antibody was detected using Vectastain Elite ABC kit (Vector
laboratories, Burlington, CA). For Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End
Labeling (TUNEL) staining, we used the ApopTag Peroxidase In Situ Apoptosis Detection Kit
(Chemicon International, Temecula, CA) according to the vendor's instructions. The sections
were developed using 3,3'-diaminobenzidine and counter-stained with hematoxylin.
3.2.5. Digital Cell Quantification
Quantification of cell numbers in stained liver sections was performed in 10 random 40x images
per animal using the public software ImageJ (http://rsb.info.nih.gov/ij/). Positive cells were
quantified using objective criteria for a specific threshold of staining intensity as well as
corresponding sizes of the nuclei. Nuclei of area greater than 700 pixel2 were analyzed to
specifically identify hepatocytes from resident non-parenchymal and infiltrating inflammatory
cells'".
3.2.6. Gene Expression
RNA was extracted from liver tissue homogenates using the Nucleospin RNA purification kit (BD,
Palo Alto, CA) per manufacturer's instructions. Approximately 100 ng-1 [ig of total mRNA was
reverse transcribed to cDNA using the TwoStep reverse transcriptase-polymerase chain
reaction (RT-PCR) Kit (Qiagen, Valencia, CA) and amplified in a Perkin Etus Thermal Cycler
480. Cycling conditions were: 1) 25 oC for 10 minutes; 2) 42 OC for 60 minutes; 3) 94 OC for 10
minutes. cDNA was either analyzed by endpoint or kinetic RT-PCR using the same cycling
conditions for amplification: 1) 94 oC for 10 minutes; 2) 30-40 cycles of 940C for 30 seconds, 55
OC for 30 seconds and 72 OC for 1 minute; 3) 72 OC for 10 minutes. Primers used for
amplification were designed using the public software algorithm Primer3 (Table 3.1).
Quantitative RT-PCR data was analyzed using the 2-Ac' method and displayed as relative fold
changes normalized to vehicle treatment.
3.2.7. Hepatocyte Isolation and Culture Media
Primary hepatocytes were isolated using a two-step collagenase perfusion procedure from
female Lewis rats as previously described20 7 . Viability was greater than 90% as determined by
Table 3.1. Oligonucleotide Sequences of Hepatocyte Regeneration Primers
Gene Primer Sequence 5'-3' Amplicon Size
F: actcccagaaaagcaagcaa
Tumor Necrosis Factor-a R: cgagcaggaatgagaagagg 211
Interleukin-6
Hepatocyte Growth Factor
Heparin Binding-Epidermal
Growth Factor
Epidermal Growth Factor
Stem Cell Factor
Oncostatin M
Amphiregulin
Tissue Inhibitor of Matrix
Metalloproteinase-3
Transforming Growth Factor-a
GAPDH
F: ccggagaggagacttcacag
R: cagaattgccattgcacaac
F: cgagctatcgcggtaaagac
R: tgtagctttcaccgttgcag
F: gcctcctgtaattgctctgc
R: gccaaaaatcctggagcata
F: acaccgaaggtggctatgtc
R: tagagtcagggcaaggcagt
F: caaaactggtggcgaatctt
R: gccacgaggtcatccactat
F: caactgggtgctttcagaca
R: aacccatgaagcgatggtag
F: gtctttgtctccgccgtaag
R: ctgaacttctggagccttcg:
F: tgtacaccccagcctctttc
R: cttctcgccaagacctcaac
F: gcaagttctgcctgttcctc
R: gcactgaaccaacccacttt
F: atgacatcaagaaggtggtg
R: cataccaggaaatgagcttg
trypan blue exclusion. Hepatocyte culture medium consisted of Dulbecco's Modified Eagle's
Medium supplemented with 10% FBS 14 ng/ml glucagon, 0.5 U/ml insulin, 20 ng/ml epidermal
growth factor (EGF), 7.5 Lg/ml hydrocortisone, 200 pg/mI streptomycin and 200 U/ml penicillin.
Culture conditions were hepatocyte medium (control), hepatocyte medium mixed at a 50:1 ratio
with the 25-fold concentrated MSC-CM (2% MSC-CM) and at a 12.5:1 ratio for 8% MSC-CM.
3.2.8. Hepatocyte Apoptosis In Vitro
Hepatocytes were cultured for 7 days in 12-well plates at a density of 1x105 cells/cm 2 in a
collagen gel sandwich configuration in hepatocyte medium as previously described207.
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Actinomycin D was added at a concentration of 0.2 gg/ml for 1 hour, followed by TNF-a (30
ng/ml) with or without MSC-CM at 2% or 8% for 8 hours208. Experiments were performed in
triplicate.
3.2.9. Fluorescence Live-Dead Staining
After induction of apoptosis, hepatocytes were stained using a fluorescent Live-Dead Viability
Assay (Molecular Probes, Eugene, OR) according to the manufacturer's instructions and
imaged on a Zeiss 200 Axiovert microscope. Viable and non-viable cells were quantified in 4
random fields per well using the digital image analysis methods described above. The viable
fraction was defined as the number of viable cells divided by the sum of the viable and non-
viable cells.
3.2.10. Hepatocyte Proliferation In Vitro: Culture System
Hepatocytes were seeded at low density (1.25 x 103 cells/cm2) on a feeder layer of 3T3-J2
fibroblasts (8 x 104 cells/cm 2) that had been growth-arrested by exposure to 12 gg/ml
mitomycin-C for 2.5 hours. Hepatocytes were allowed to proliferate with daily medium changes.
Two separate experiments were performed in duplicate.
3.2.11. Hepatocyte Proliferation In Vitro Assay
Cells were cultured with 10 gM of the DNA synthesis marker bromodeoxyuridine (BrdU). After
48 hours, cultures were fixed in 70% ethanol for 45 min and treated with 4N HCI and 0.2%
TritonX-10. After incubation in blocking buffer for 30 min, cells were incubated for 60 min with
anti-BrdU-Alex594 (Invitrogen, Carlsbad, CA) and rabbit anti-rat albumin at 370C, followed by
FITC conjugated anti-rabbit IgG (ICN Pharmaceuticals, Aurora, OH) at room temperature. BrdU
positive cells in each hepatocyte colony were counted in fluorescence microscopy images.
Albumin content in supernatant samples was determined by ELISA using purified rat albumin
and a peroxidase-conjugated antibody. Urea content was determined with a commercially
available kit (StanBio Laboratory, Boerne, TX) using the manufacturer's instructions.
3.2.12. Statistics
Data are expressed as the mean ± standard error of the mean. Statistical significance was
determined by a two-tailed Student's t-test. A P-value of < 0.05 was used for statistical
significance. Statistical image analysis was performed after determining that the data could be
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fit with a normal distribution. A two-tailed Student's t-test was employed after the exclusion of
outliers that were less or greater than 2 standard deviations away from the median.
3.3. RESULTS
3.3.1. MSC-CM Inhibits Hepatocellular Apoptosis in vivo
To determine whether MSC-CM infusion decreases apoptotic cell death in Gal-N treated rats,
the number of TUNEL-reactive hepatocyte nuclei in liver sections was determined. In sections
from vehicle-treated rats, many large, apoptotic hepatocyte nuclei were observed (Figure 3.1A),
whereas only few were present after MSC-CM treatment (Figure 3.1B). Quantification revealed
a 90% reduction in TUNEL-positive hepatocyte-nuclei (8.3 ± 12 / field of view) when compared
to control animals (81 ± 52/ field of view; P--0.009; Figure 3.1C), confirming that MSC-CM
therapy effectively reduces hepatocellular death in this model of acute liver injury.
3.3.2. MSC-CM Inhibits Hepatocyte Apoptosis in vitro
Inhibition of hepatocellular death by MSC-CM therapy in vivo can either be a direct effect of
trophic molecules preserving liver cells or an indirect effect, for example via alteration of the
immune response to the damaged organ. Therefore, we tested the ability of MSC-CM to
directly inhibit apoptosis induced by actinomycin D and TNF-a treatment of cultured primary
hepatocytes. When the culture medium was supplemented with 2% MSC-CM a 22% increase
in the fraction of viable cells was observed (P--0.005; Figure 3.2). With 8% MSC-CM, no
significant increase in hepatocytes viability was seen (P-0.15). Overall, these experiments
suggest that at low concentrations, MSC-CM has a direct anti-apoptotic effect on hepatocytes.
3.3.3. MSC-CM Enhances Liver Regeneration
Stimulation of endogenous repair programs represents another potential mechanism of an
MSC-induced therapeutic effect. To determine the effect of MSC-CM on liver regeneration, the
number of PCNA positive hepatocytes were quantified and in both the MSC-CM and vehicle-
treated animals. Qualitatively, few PCNA-positive hepatocytes were seen in control livers
(Figure 3.3A). Many were observed in MSC-CM treated animals (Figure 3.3B). We measured a
3-fold increase in the number of proliferating liver cells (15 ± 5.3 in the MSC-CM treated group
compared to 4.5 ± 2.5 / field of view in controls; P--0.04; Figure 3.3C). Evaluation of expression
levels of 10 genes known to be upregulated during liver regeneration revealed visibly stronger
bands in MSC-CM treated samples by endpoint RT-PCR (Figure 3.3D). Quantitative analysis
demonstrated that expression levels of all 10 genes were significantly enhanced after infusion of
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Figure 3.1. Infusion of MSC-CM Decreases Levels of Apoptosis Gal-N Treated Tats. Liver
sections were stained by TUNEL (dark brown nuclei, large for hepatocytes) and counterstained
with hematoxylin (light blue). Representative 40x images from (A) vehicle treated and (B) MSC-
CM treated rats. Bar = 100 pm. (C) Quantification of TUNEL-positive hepatocyte-nuclei by
digital image analysis. Data are reported as mean ± standard error of the mean for 10 random
fields per animal. *P=0.009. MSC-CM, mesenchymal stem cell-conditioned medium; Gal-N, D-
galactosamine; TUNEL, Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling;
FOV, field of view.
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Figure 3.2. MSC-CM Inhibits Hepatocyte Apoptosis at Low Concentrations In Vitro.
Primary rat hepatocytes were cultured in a collagen double gel. Apoptosis was induced using
Actinomycin D and TNF-a. During exposure to TNF-a, hepatocytes were cultured in hepatocyte
medium only or hepatocyte medium supplemented with 2% or 8% of 25x concentrated MSC-CM.
Hepatocytes were stained using a fluorescent Live Dead Assay. Cell death was quantified using
digital image analysis of 4 images per well. Experiments were performed in triplicate. Data are
shown as mean + standard deviation. * P=-0.005. MSC-CM, mesenchymal stem cell-conditioned
medium; TNF, tumor necrosis factor.
MSC-CM (Figure 3.3E). Increases ranged from 4-fold to 27-fold. These results demonstrate
that administration of MSC-derived soluble factors enhances liver regeneration programs during
FHF.
3.3.4. MSC-CM Stimulates Hepatocyte Proliferation in Vitro
Hepatocyte replication, a major component of liver regeneration, is regulated by a complex
interaction of paracrine and endocrine signals involving non-parenchymal liver cells as well
extra-hepatic organs209. To determine whether MSC-derived factors can directly enhance
hepatocyte replication we explored the effect of MSC-CM on the in vitro proliferation of primary
hepatocytes. Proliferation of rat hepatocyte colonies on a feeder layer of growth-inhibited 3T3-
fibroblasts was visualized by double immunofluorescence staining for BrdU and albumin (Figure
3.4A). With 2% MSC-CM supplementation, a 79% increase in BrdU-positive hepatocytes was
observed (93 ± 12 per field of view with MSC-CM vs. 52 ± 14 in control cultures; P--0.001;
Figure 3.4B). When medium was supplemented with 8% MSC-CM, no significant increase was
measured (59 ± 14 BrdU+; P-0.37). In parallel to these findings, the total amount of albumin
secreted and urea synthesized per well was increased in 2% MSC-CM supplemented cultures.
Albumin levels were 29 ± 2.4 Lg/ml/d, compared to 20 ± 1.2 jig/ml/d under control conditions
(P=0.006; Figure 3.4C). No significant difference compared to control was observed in 8%
MSC-CM conditions (23 + 2.2 jpg/ml/d; P=0.14). Urea synthesis (Figure 3.4D) increased from
69 ± 8.1 ILg/ml/d in control cultures to 90 ± 10 gg/ml/d in 2% MSC-CM conditions (P-0.019), but
was not significantly altered in the presence of 8% MSC-CM (53.1 gg/ml/d; P-0.063). Higher
levels were observed for 2% MSC-CM supplementation when compared to 8% MSC-CM for all
three assays indicating a therapeutic window of effectiveness.
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Figure 3.3. Infusion of MSC-CM enhances Liver Regeneration in Gal-N Treated Rats.
Liver samples of Gal-N treated rats were analyzed 36 hours after treatment with MSC-CM or
vehicle. Sections were stained for PCNA (dark brown nuclei, large for hepatocytes).
Representative 40x image from (A) control and (B) MSC-CM treated animals. Bar = 100 pm.
(C) PCNA-reactive hepatocyte-nuclei were quantified by digital image analysis. Data are
reported as mean ± standard error of the mean for 10 random fields per animal. * P=0.04. (D)
Endpoint RT-PCR analysis of 10 genes known to be upregulated during liver regeneration. (E)
Quantification of changes in gene expression by kinetic RT-PCR after MSC-CM treatment.
PCNA, proliferating cell nuclear antigen; MSC-CM, mesenchymal stem cell-conditioned
medium; Gal-N, D-galactosamine; FHF, fulminant hepatic failure; FOV, field of view; OSM,
oncostatin M; AR, -1 amphiregulin; TGF-1, transforming growth factor-p; HGF, hepatocyte
growth factor; TNF, tumor necrosis factor-a; EGF, epidermal growth factor; IL-6, interleukin 6;
SCF, stem cell factor; HB-EGF, heparin-binding epidermal growth factor-like growth factor;
TIMP-3, tissue metalloproteinase 3.
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Figure 3.4. Low Dose of MSC-CM Enhance Proliferation and Functions of Hepatocytes.
Hepatocytes were cultured at low density (1.25 x 103 cells/cm 2) on a feeder layer of growth-
arrested 3T3-J2 fibroblasts. Cells were cultured in hepatocyte medium only or hepatocyte
medium supplemented with 2% or 8% of 25x concentrated MSC-CM. (A) Morphology, albumin
staining, BrdU uptake and merged image of proliferating hepatocytes after 14 days of culture in
2% MSC-CM. Hepatocyte colonies increased in size during culture periods. (B) Quantification
of BrdU-positive hepatocytes by image analysis. (C) Albumin secretion and (D) urea synthesis.
Data shown are mean standard deviation of two separate experiments in duplicate. * P<0.05, **
P<0.01; ns = not significant. MSC-CM, mesenchymal stem cell-conditioned medium; FOV, field
of view.
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3.4. DISCUSSION
Inhibition of cell death is a therapeutic effect of MSC therapy that has been observed in
models of myocardial infarction, acute kidney failure and stroke 112' 1 54,206. In this study, we
provide the first clear evidence that delivery of MSC secretions has the potential to dramatically
reduce cell death in the acutely injured liver. The 90% reduction in the level of hepatocellular
apoptosis that we observed in the livers of rats undergoing FHF was much more dramatic than
the decrease in cell death measured in cultured hepatocytes. It is likely that the inhibition of the
local and systemic immune response after MSC therapy, processes which are known to
enhance levels of hepatocellular death in liver injury210,211, resulted in a further reduction of
hepatocellular death in vivo. In Chapter 2, we showed that MSC-CM altered leukocyte viability
and/or trafficking in the Gal-N induced model of FHF 121. Here, we demonstrate a direct anti-
apoptotic effect on hepatocytes suggesting the effect is not limited to the modulation of the
inflammatory cascade.
Stimulation of endogenous regeneration mechanisms represents an important avenue of
trophic support by MSC therapy, previously described in models of acute kidney failure and
stroke13' 154'212 . Our results demonstrate that MSC therapy can increase the number of
proliferating hepatocytes 3-fold in the regenerating, injured liver and that MSC secreted factors
are sufficient to accomplish this effect. The liver can regenerate via two different pools of
proliferating cells, hepatic stem cells and hepatocytes, themselves. Instances of continuous
regenerative stress after liver injury elicit a response from the hepatic stem cell pool. Hepatic
stem cells, also known as oval cells (OCs), are a bipotential precursor to hepatocytes and
cholangiocytes that are found in the canals of Hering 213. In Chapter 2, we observed significant
bile duct duplication in vehicle-treated rats undergoing FHF suggestive of an expansion in the
OC niche. However, in MSC-CM treated animals we did not observe this phenomenon implying
that the injury was not substantial enough to activate the OC pool. Instead we posit that MSC-
CM signaled directly to hepatocytes to replenish the parenchyma. Hepatocyte replication,
referred to as compensatory hyperplasia, is the result of cell divisions by endogenous liver cells
and is regulated by several overlapping signals 214'215. Existing hepatocytes enter the cell cycle
and undergo one to two rounds of replication without activation of a progenitor cell niche216.
Cytokines produced by the innate immune system are integral to the entry and progression of
hepatocytes through the cell cycle as demonstrated by the dynamics of cytokine expression
profiles post-injury and knockout animal studies 214,215,217-219. In essence, the innate immune
system 'primes' hepatocytes by these acute phase proteins for subsequent growth factor and
mitogen stimulation. In fact, lack of the complement cascade peptides, C3a and C5a, causes a
deficit in liver generation most likely due to a lack of immune cell chemotaxis 220. Specific
growth factors that are involved in hepatocyte proliferation include transforming growth factor
(TGF) -a, hepatocyte growth factor (HGF), heparin-binding EGF-like growth factor (HB-EGF),
amphiregulin 209,221-223 and platelet-derived serotonin 224. In most cases these growth factors are
essential for hepatocytes to proceed through the G1 phase of the cell cycle, although alternate
mechanisms, such as the anti-apoptotic effects of HGF on hepatocytes 223, may also contribute
to the beneficial role of these growth factors in liver regeneration. Although studies
transplanting MSCs in the brain revealed that MSCs can indirectly enhance self-renewal of
neural stem cells'42 , this is the first demonstration of MSCs affecting a self-replicating tissue
cell' " .
The direct stimulatory effect of MSC-CM that we observed on the in vitro proliferation of
hepatocytes was abrogated when high concentrations of MSC-CM were used. This correlates
with observations in previous survival studies in Gal-N induced FHF that supra-therapeutic
concentrations of MSC-CM leads to a loss of the therapeutic effect' 2'. MSC secretions contain
a complex mixture of cytokines, growth factors and chemokines, including small amounts of
TGF-1, a compound with a marked inhibitory effect on hepatocyte-proliferationl 38,225,226. It is
possible that at higher concentrations of MSC-CM the negative effect of TGF-1, for example,
overrules therapeutic effects exerted by trophic components of MSC-CM. Similarly, the effects
of TNF-a, present at low concentrations in MSC-secretions' 22, become more pronounced at
high concentrations of MSC-CM. This may explain why increasing the level of MSC-CM from
2% to 8% has no added anti-apoptotic effect on hepatocytes.
We can only speculate what specific mediators present in MSC-CM are responsible for
the reduction in cell death and stimulation of regeneration. In Chapter 5, we performed protein-
array analysis of MSC-CM and detected 69 of 174 assayed proteins, the majority of which were
growth factors, cytokines and chemokinesl21 . Several of the detected molecules have known
anti-apoptotic and liver regeneration-stimulating effects. Vascular endothelial growth factor, for
example, is known to induce hepatocyte growth factor (HGF) secretion by stellate cells, which in
turn induces expression of hepatocyte-mitogenic TGF-a. HGF, present in MSC-CM, is also
known to inhibit apoptosis in the injured liver. Insulin-like growth factor binding proteins and IL-6
are other examples of MSC-secreted molecules with apoptosis-reducing effects in liver injury210.
Such theories support the notion that at least several molecules are involved. Ultimately, MSC-
CM may serve as a substitute for the molecular cues to prime and induce hepatocyte replication
in vivo and in vitro.
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In conclusion, the present study shows that systemic MSC-CM therapy has profound
inhibitory effects on hepatocellular death and enhancement of liver regeneration programs
during liver injury. Furthermore, we demonstrate direct anti-apoptotic and pro-mitotic effects of
MSC-CM on cultured hepatocytes. This work validates that MSC-CM induces an integrated
response to liver disease by targeting both immune cells (Chapter 2) and parenchymal liver
cells. In the following chapter, we extend our study of the paracrine effect of MSCs on other
resident liver cells, specifically stellate cells, that motivate the use of MSC-CM for chronic liver
disease and fibrosis.
CHAPTER IV
PARACRINE IMMUNOMODULATION OF ACTIVATED HEPATIC STELLATE CELLS BY
MARROW STROMAL CELLS
4.1 INTRODUCTION
Cirrhosis is the 7th leading cause of mortality worldwide, afflicting several hundred million
people 227 , with deaths from complications expected to triple in the next decade" 8. This clinical
syndrome is the endpoint of chronic inflammatory conditions of the liver caused by alcohol
abuse, viral infection and steatosis. Orthotopic liver transplantation is the only curative treatment
to date.
Liver fibrosis, the precursor to cirrhosis, is the result of an imbalance in extracellular
matrix (ECM) synthesis and degradation mediated primarily by activated hepatic stellate cells
(SCs). Following liver injury, SCs undergo a phenotypic switch from a quiescent, vitamin-A
storing cell into a proliferative, a-smooth muscle actin (SMA) positive, myofibroblast-like cell,
which shows an upregulation in collagen synthesis229 . In vivo activation of SCs is divided into a
fibrogenic and hyperplastic response230 that is mediated by many autocrine and paracrine
signals. Spontaneous resolution of liver fibrosis has been reported in different rat models of
chronic liver injury231232. This resolution has been correlated with decreased synthesis of type I
collagen and tissue inhibitor of matrix metalloproteinases (TIMP) 1 and 2 transcripts, with a
concomitant decrease in the number of a-SMA positive SCs232. Yet, it remains unclear whether
the decrease in the number of activated SCs is due to selective apoptosis233' 234 or reversion to a
quiescent state by microenvironmental cues235 237.
A new technique in the treatment of inflammatory conditions involves the infusion of
bone marrow-derived mesenchymal stem cells (MSCs). Recent studies have demonstrated that
MSCs can be of therapeutic benefit in the prevention of fibrotic lesions, such as pulmonary
fibrosis after bleomycin challenge' 27 , and in the protection of cardiac function after a myocardial
infarction112113 . Systemic delivery of MSCs prior to, and during the induction of experimental
liver fibrosis significantly inhibits changes in liver histology and clinical serum
parameters134,135,137 , but the preventative mechanisms have yet to be elucidated.
In this chapter we observe the interaction between MSCs and the primary scar-forming
liver stellate cell. Here, we demonstrate that MSCs indirectly modulate the activity of activated
SCs in vitro via paracrine stimulation with specific cytokines and growth factors.
4.2 MATERIALS AND METHODS
Materials were purchased from Sigma-Aldrich, St. Louis, MO unless otherwise stated.
4.2.1. MSC Isolation and Ex Vivo Expansion
Human MSCs were isolated from commercially available bone marrow aspirates obtained from
a single, male donor of 25 years of age (Clonetics-Poietics, Walkersville, MD) as previously
reported238 . Briefly, whole bone marrow aspirates were plated at a density of 8-10 gl
aspirate/cm2 on 175 cm2 tissue culture flasks and grown to confluence in expansion medium at
37 OC and 5% carbon dioxide. Expansion medium consisted of Dulbecco's modified Eagle's
medium supplemented with 10 % fetal calf serum, 100 U/ml penicillin, 100 gg/ml streptomycin,
0.1 mM non-essential amino acids and 1 ng/ml of basic fibroblast growth factor (Life
Technologies, Rockville, MD). After 4 days of culture, non-adherent hematopoietic cells were
removed by washing with PBS, and monolayers of adherent cells were cultured with medium
changes 2-3 times per week. Cells were passaged using 0.25 % trypsin/0.1 % EDTA,
subcultured at a density of 5x103 cells/cm 2 and used for experiments during passages 4-7.
4.2.2. MSC Characterization
Before use, MSCs were immunophenotyped by flow cytometry (FACS Calibur, Becton
Dickinson, Franklin Lakes, NJ). The surface antigen panel included CD14, CD34, CD44, CD45,
and CD106 (BD Pharmingen, Franklin Lakes, NJ). In addition, the multipotency of MSCs was
assessed in vitro by culturing the cells in osteogenesis, adipogenesis or chondrogenesis
induction medium for 2-3 weeks with medium changes every 3 days. Osteogenic medium
consisted of Iscove's modified Dulbecco's medium (IMDM) supplemented with 0.1 [IM
dexamethasone, 10 mM 3-glycerol phosphate, 0.2 mM ascorbic acid (AsA), 100 U/ml penicillin
and 100 pg/ml streptomycin. Adipogenesis medium consisted of IMDM supplemented with 0.5
mM 3-isobutyl-l-methylxanthine, 1 pM hydrocortisone, 0.1 mM indomethacin, 10 % rabbit
serum, 100 U/mi penicillin and 100 gg/ml streptomycin. For chondrogenesis studies, cells were
transferred into a 15-mL polypropylene tube and centrifuged at 1000 rpm for 5 minutes to form a
pelleted micromass that was then treated with chondrogenic medium. Chondrogenesis medium
consisted of high-glucose DMEM (Chemicon International, Ternecula, CA) supplemented with
0.1 gM dexamethasone, 50 ýpg/mL AsA, 100 pg/mL sodium pyruvate, 40 pg/mL praline, 10
ng/mL TGF-0 1, 50 mg/mL ITS+ premix (Becton Dickinson; 6.25 pg/mL insulin, 6.25 Ig/mL
transferring, 6.25 ng/mL selenius acid, 1.25 mg/mL bovine serum albumin, and 5.35 mg/mL
linoleic acid), 100 U/ml penicillin and100 pg/ml streptomycin.
The phenotype of differentiated cells was evaluated after 2-3 weeks of induction.
Mineral content under osteogenic conditions was determined by the Alizaren red stain. Cells
were fixed with 4% paraformaldehyde for 15 minutes, washed twice with PBS, stained with 1%
silver nitrate under a 100 W light for 60 minutes and washed with deionized water. Lipid
accumulation after adipogenic conditions was determined by oil Red O staining. Cells were
fixed with 4% paraformaldehyde, washed twice with PBS, stained with oil-Red O for 15 minutes
and washed with DI water. Images were captured on a Nikon Eclipse E800 Upright Microscope.
As shown in Figure 4.1A-B, osteogenesis and adipogenesis were induced in their
respective induction mediums. The surface antigen profile of MSCs was CD14-, CD105+,
CD34-, CD45-, CD106+ and CD44+ as determined by flow cytometry (Figure 4.1C-F), which is
consistent with previous reports of undifferentiated MSC surface marker expression 8
4.2.3. SC Isolation and Culture
Primary rat SCs were isolated from 2-3 month-old adult female Lewis rats (Charles River
Laboratories, Wilmington, MA) weighing 180-200 g, by a modified procedure of Seglen as
previously reported in detail for hepatocyte isolation207. Briefly, the supernatant from the
hepatocyte purification steps, containing the non-parenchymal liver cells were obtained and
treated with DNAse I for 15 minutes at 37 OC, centrifuged at 300 g for 20 minutes, and then
resuspended in PBS. This cell suspension was subjected to a density gradient separation by
gently layering the suspension on top of a discontinuous 40%-60% isotonic Percoll gradient.
The layers were then centrifuged at 900 g for 25 minutes. The lowest density layer, enriched in
SCs, was then removed, diluted with PBS and centrifuged at 900 g for 25 minutes. The cells
were resuspended in SC medium and cultured on 175 cm2 tissue culture flasks. SC medium
consisted of Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 U/ml
penicillin and 100 pg/ml streptomycin. SCs were cultured for 10-14 days on tissue culture
plastic, which led to their activation, before use in experiments. The purity and differentiation of
SCs cultures were assessed by performing immunofluorescence for desmin, a myofibroblast
marker, and a-SMA, a marker for myofibroblasts in a more advanced state of differentiation. All
cells stained positively for both desmin and a-SMA after 10 days of culture.
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Figure 4.1. Phenotype and Multipotency of Bone Marrow-Derived MSCs. Passage 4-7 cells
were exposed to adipogenic and osteogenic differentiation conditions for 14 days and assessed
by (A) Oil Red-O and (B) Alizeran Red staining, respectively. Surface antigen profile of MSCs
was (C) CD14- / CD105+, (D) CD34- / CD45-, (E) CD106+, CD44+ as determined by flow
cytometry.
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4.2.4. Coculture Systems
For direct coculture of MSCs and SCs, cells were seeded at a 1:1 ratio in each well of a six-well
plate (Corning Costar, Acton, MA). An indirect coculture system between SCs and MSCs was
assembled using Transwell membranes (24 mm diameter, 0.4 ýLm pore size; Corning Costar,
Acton, MA). Approximately 1.0 x 10s SCs were placed in the lower chamber with either 0-1.0 x
105 MSCs placed on the membrane insert. Cocultures were maintained in SC medium for 4
days.
4.2.5. Cytokine Treatment, Neutralization and Protein Quantification
Human MSCs were treated with IL-6 (2.5 ng/ml; R&D Systems, Minneapolis, MN), IL-1 (5 ng/ml;
R&D Systems, Minneapolis, MN), or tumor necrosis factor-a (TNF-a; 25 ng/ml; R&D Systems,
Minneapolis, MN) supplemented MSC expansion medium for 24 hours. MSCs cultured in
expansion medium served as a negative control. After treatment, cells were harvested and
analyzed for changes in gene expression.
Quantification of human TNF-a, IL-10 and rat IL-6 was determined using an ELISA as
per vendor instructions (Endogen, Rockford, IL). Supernatants were sampled after 48 hours of
coculture and stored at -20 OC until analysis.
Neutralization of specific cytokines was performed during indirect cocultures. For all
neutralization experiments, the ratio of MSCs to SCs was 1:1. Anti-human IL-10 (BioLegend,
San Diego, CA), TNF-a, (BioLegend, San Diego, CA), or HGF and anti-rat IL-6 (Cell Sciences,
Canton, MA) were diluted in SC medium based on the half maximal inhibition concentrations
given by the manufacturer. Fresh medium with neutralizing antibodies was added after 48
hours of coculture.
4.2.6. Total RNA Isolation and RT-PCR
RNA was extracted from 0.1-1.0 x 106 MSCs using the Nucleospin RNA purification kit (BD
Biosciences, Palo Alto, CA) per the manufacturer's instructions. Approximately 1 lag of total
mRNA was reverse transcribed to cDNA using the OneStep RT-PCR Kit (Qiagen, Valencia, CA)
per manufacturer's instructions and amplified in a Perkin Etus Thermal Cycler 480. Cycling
conditions were: 1) 50 OC for 30 minutes; 2) 95 OC for 15 minutes ; 3) 30 cycles at 94 OC for 30
seconds, 55 oC for 30 seconds, and 72 OC for 1 minute; and 4) a final extension step at 72 °C
for 10 minutes. Primers used for amplification were: IL-10 (364 bp)
AAGCCTGACCACGCTTTCTA, GTAGAGCGGGGTTTCACCA; and GAPDH (238 bp)
GAGTCAACGGATTTGGTCGT, TTGATTTTGGAGGGATCTCG.
4.2.7. Proliferation Assay
The proliferative capacity of SCs in culture was evaluated by measuring incorporation of 5-
bromo-2'-deoxyuridine (BrdU). Twenty-four hours prior to analysis, the Transwell insert
containing MSCs was removed and SC cultures were treated with 10 [M BrdU. After the
incubation period, cells were washed with PBS three times, trypsinized and centrifuged at 1200
rpm for 5 minutes. For fixation, the pellet was resuspended in 70 % ethanol for 45 minutes at
room temperature, centrifuged and washed twice with PBS. Cells were incubated with 4 M HCI
for 15 minutes at room temperature, centrifuged, washed twice with PBS and incubated with a
blocking buffer composed of PBS and 10 % FBS for 10 minutes. They were then incubated with
anti-BrdU antibody conjugated to Alexa-Fluor 488 dye for 60 minutes at 37 oC, centrifuged and
washed with PBS. A negative control consisted of cells incubated without the antibody.
Fluorescently labeled cells were analyzed by flow cytometry.
4.2.8. Collagen Synthesis
Collagen synthesis was quantified using an ELISA for procollagen type-I C-peptide (Takara-Bio
Inc., Shiga, Japan). After the coculture period, the Transwell insert containing MSCs was
removed and the medium on the SCs was replaced with fresh medium. Twenty-four hours later,
medium was collected and procollagen type-I C-peptide concentration was measured by ELISA.
4.2.9. Immunofluorescence Microscopy
Immunofluorescent detection was performed after a 15 minute fixation in 4% paraformaldehyde
solution prepared in phosphate buffered saline (PBS), followed by a single wash with PBS. All
steps were performed at room temperature. Cells were permeabilized by incubating with
blocking buffer containing 10% normal horse serum, 0.025% Triton X-100 and 0.5%
dimethylsulfoxide in PBS for 45 minutes. Subsequently, the cells were incubated with mouse
monoclonal anti-a-SMA antibody (GeneTex Inc, San Antonio, TX; 1:100 dilution) or goat
polyclonal anti-desmin antibody (Santa Cruz Biotechnology-clone C18; 1:100 dilution) in
blocking buffer for 60 minutes. After washing three times with blocking buffer, incubation with
rhodamine red-X conjugated goat anti-mouse secondary antibody (1:250 dilution) or FITC-
conjugated donkey anti-goat secondary antibody (1:500 dilution; Jackson ImmunoResearch
Laboratories, West Grove, PA) was performed for 60 minutes, respectively. Three washes were
performed with blocking buffer, incubating with 5 pg/mL of 4',6-diamidino-2-phenylindole (DAPI;
Molecular Probes, Leiden, Netherlands) for 5 minutes during the first wash. Samples without
primary antibody were used as negative controls. Fluorescent and phase-contrast microscopy
were performed on a Zeiss Axiovert 200 M Inverted Microscope.
4.2.10. Apoptosis Assay
Quantification of cell apoptosis/necrosis was determined using the Annexin-V Fluos kit (Roche,
Indianapolis, IN) as per vendor instructions. After coculture, SCs were recovered and stained
with Annexin V for 20 minutes and analyzed using flow cytometry. Serum deprived SCs served
as a positive control for apoptosis. Results were gated based on fluorescent signals greater
than SC autofluorescence.
4.2.11. Statistical Analysis
Results were analyzed using the unpaired Student's t-test provided in the SigmaPlot 2000
software package. Significance values of P<0.05 were considered statistically significant.
Results are given as a mean ± s.e.m.
4.3. RESULTS
4.3.1. MSCs Inhibit Collagen Synthesis in Activated SCs.
The reversal of experimental liver fibrosis in vivo has been highly correlated with a decrease in
tissue collagen content2 9. A similar decrease in tissue collagen has been reported after MSC
infusion into animals with fibrotic livers134' 1 5. We evaluated whether MSCs could influence
collagen production in activated SCs by indirectly coculturing them in a Transwell configuration.
SC secretion of procollagen type-I C-peptide (PIP), a peptide fragment cleaved from precursor
collagen upon extracellular secretion, was measured after four days of indirect coculture as a
function of MSC to SC ratio, with the number of SCs remaining constant. Levels of PIP
secretion by activated SCs (101 ± 11 pg/106 cells/day) were significantly reduced at a MSC:SC
coculture ratio of 1:10 (41 ± 18 pg/106 cells/day; P=0.0491), with a 66% reduction at a 1:1
coculture ratio (34 ± 5 pg/106 cells/day; P=0.004; Figure 4.2A). This reduction in PIP secretion
was not observed in cocultures of SCs with human umbilical vein endothelial cells, suggesting a
MSC-specific effect (Figure 4.2B). These results suggest that soluble factors released by MSCs
inhibit the synthesis of procollagen in activated SCs.
4.3.2. MSCs Induce Apoptosis in Activated SCs
The decrease in hepatic fibrosis observed after transplantation of MSCs is accompanied by a
reduction in the number a-SMA+ (activated stellate) cells observed by immunohistological
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Figure 4.2. PIP secretion from SCs after Indirect Coculture with MSCs. (A) PIP secretion
from SCs decreases as the number of MSCs increases. Data represent the mean of two
experiments performed in triplicate. Error bars are standard deviation. *p<.05, **p<.01
compared to SCs alone (MSC:SC = 0). (B) Inhibition of SC PIP secretion is an MSC-specific
effect. PIP secretion from SCs decreases as a function of MSCs and not human umbilical vein
endothelial cells. Data represent the mean of two experiments performed in triplicate. PIP,
Procollagen type-I C-peptide; SC, stellate cells; MSC, mesenchymal stem cell.
S1oo00
80.
a, 60-60
. 40-
20
0 i1
SC alone SC-MSC SC-MVEC
staining'' 135'137. The mechanism by which the reduction in the number of activated stellate
cells occurs is unclear; there is evidence for decreased proliferative capacity, a reversion to a
quiescent phenotype and for apoptotic cell death229. Therefore, we examined the fate of
activated SCs indirectly cocultured with MSCs by measuring the extent of SC dedifferentiation,
proliferation and death.
The expression of a-SMA was not decreased after coculture, suggesting that SCs did
not revert to a quiescent phenotype in the presence of MSCs (Figure 4.3A-F). We used flow
cytometry to quantify the population of SCs entering the S-phase of the cell cycle, as measured
by BrdU incorporation, after coculture with MSCs. A decline, from 30 ± 9% to 15 ± 4%, in
BrdU+ SCs was observed at a 1:1 coculture ratio (Figure 4.4; P=0.043). Although this result is
statistically significant, in the context of relatively low MSC engraftment in vivo, a 1:1 ratio of
MSCs in close proximity to SCs (estimated to be -15x106 cells/rat liver) may not be a realistic
model for the differences seen in a-SMA+ cells in vivo, notwithstanding the secretion of long-
range soluble factors by MSCs that can act systemically on hepatic SCs.
Microscopic observation of indirect cocultures indicated a decrease in the number of
SCs adhering to the polystyrene plate. To determine if apoptosis accounted for the observed
changes in SC number after coculture, we used Annexin-V-FITC staining and flow cytometry. In
SCs cultured alone, there was a basal level of apoptosis (25%, Figure 4.5A) that was consistent
with previous findings239. However, after coculture with MSCs (1:1) there was an approximate
2.5 fold increase in apoptosis (55%, Figure 4.5B). Coculture with fibroblasts resulted in a level
of apoptosis that was similar to SCs alone (32%, Figure 4.5C), demonstrating that the pro-
apoptotic effect was MSC-specific. Significant SC death also occurred at MSC:SC coculture
ratios of 1:100 or greater (Figure 4.5D), suggesting that small numbers of MSCs can release
potent pro-apoptotic molecules that induce SC death. Taken together, these in vitro results
imply that transplantation of MSCs in vivo may resolve hepatic fibrosis through a mechanism
involving a selective pro-apoptotic effect on activated SCs.
4.3.3. MSCs Secrete IL-10 when Stimulated by Inflammatory Cytokines and Constitutively
secrete TNF-(a.
In an effort to understand the molecular basis of the observed effects of MSCs on SCs, we
evaluated whether MSCs secrete immunomodulatory molecules when exposed to cytokines
known to be involved in liver fibrosis. MSCs were exposed to IL-1, IL-6, or TNF-a, for 24 hours
and IL-10 protein secretion and mRNA levels were determined by ELISA and RT-PCR,
respectively. Exposure to IL-6 (2.5 ng/ml) or TNF-a (25 ng/ml), cytokines which are significantly
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Figure 4.3. SCs do not Revert to a Quiescent Phenotype after Coculture with MSCs.
Immunocytochemistry of a-SMA expression of SCs alone (A) and after coculture with MSCs (B).
Flow cytometry analysis of ca-SMA expression of SCs alone (D) and after coculture with MSCs
(E). Percentages are based on autofluorescence gates (C). SC, stellate cell; MSC,
mesenchymal stem cell; SMA, smooth muscle actin.
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Figure 4.4. BrdU incorporation in SCs as a Function of MSC:SC Ratio. Proliferation of
activated SCs is inhibited by indirect coculture with MSCs. Data represent the mean of two
experiments performed in triplicate. Error bars are standard deviation. *p<.05 compared to
SCs alone (MSC:SC = 0). BrdU, bromodeoxyuridine; SC, stellate cell; MSC, mesenchymal stem
cell.
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elevated in liver injury models, led to the upregulation of both IL-10 mRNA (Figure 4.6A) and
protein secretion into the culture medium (Figure 4.6B).
In line with the observation that both TNF-a and IL-6 induce the expression of IL-10 by
MSCs, we sought to determine if these cytokines were present at appreciable levels in a direct
coculture system of SCs and MSCs. ELISA measurements with species-specific antibodies
indicated that both cytokines were present in the coculture (Figure 4.7A), and that they were of
distinct origins; IL-6 was secreted by activated SCs (65 ± 1 pg/106 cells/day), while TNF-oa was
secreted by MSCs (23 ± 1 pg/10 6 cells/day). Indirect coculture of the two cell types led to
mRNA expression of IL-10 (Figure 4.7B). To determine whether activated SCs could induce
MSCs to secrete IL-10, MSCs and SCs were directly cocultured at a 1:1 ratio. Direct coculture
of MSCs and SCs led to an increase in IL-10 secretion (54 pg/106 cells/day; Figure 4.7C), a
level similar to that observed when MSCs were treated with IL-6 and TNF-a. We next
investigated whether activated SCs could induce IL-10 secretion by differing ratios of MSCs in a
paracrine manner, using the Transwell configuration. At a ratio of MSC:SC of 1:10 or greater,
IL-10 mRNA levels were increased in MSCs and the rate of IL-10 protein secretion increased to
32 ± 7 pg/106 cells/day (P<0.01; Figure 4.7D).
Since both IL-6 and TNF-a were detected in MSC-SC cocultures, neutralization by
monoclonal antibodies was performed to determine the role of each cytokine on IL-10 release
by MSCs. A significant decrease in IL-10 release (48 ± 4 to 18 ± 1 pg/106 cells/day; P<0.01)
was observed when the indirect cocultures were treated with 1250 ng/ml of anti-lL-6 neutralizing
antibody (Figure 4.7E). No significant difference was observed after treatment with anti-TNF-ca
neutralizing antibody (data not shown). Taken together, these data imply that activated SCs
secrete IL-6, which induces MSCs to secrete IL-10.
4.3.4. Paracrine Stimulation with IL-10 and TNF-a from MSCs Synergistically Inhibits
Collagen Synthesis and Proliferation in SCs.
Autocrine IL-10 stimulation in SCs has been shown in vitro to modulate the expression of
collagen type I and favor a more quiescent state236' 237. However, expression of IL-10 is
suppressed upon activation in vivo and is thought to indicate a transition to a more advanced
stage of fibrosis. TNF-a( has also been observed to be an anti-proliferative/fibrogenic stimulus
for activated SCs 240. Thus, we sought to determine if the previously observed suppression of
collagen synthesis and proliferation in activated SCs, after indirect coculture with MSCs, was
mediated by MSC-derived IL-10 and TNF-a.
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Figure 4.6. IL-10 mRNA and Protein Secretion of Cytokine-Treated MSCs. MSCs were
treated with expansion medium containing IL-1 (5 ng/ml), IL-6 (2.5 ng/ml), or TNF-ca (25 ng/ml)
for 24 hours. IL-10 mRNA levels were determined by RT-PCR analysis and protein secretion by
ELISA on cell culture medium. GAPDH served as an internal control for RT-PCR analysis. One
representative RT-PCR result is shown. ELISA results are the mean of two experiments
performed in triplicate. Error bars are standard deviation. **p<.01 compared to unstimulated
MSCs.
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Figure 4.7. Dynamic Cytokine Signaling Between MSCs and SCs. (A) Cytokine secretion in
monoculture and direct coculture of SCs and MSCs (1:1 ratio). IL-6 and TNF-a concentrations
were measured by ELISA with species-specific antibodies after 2 days of culture. (B) IL-10
mRNA levels and (C) protein secretion in direct and indirect coculture with activated SCs.
Detection of IL-10 mRNA transcripts by RT-PCR in MSCs after 4 days of 1:1 indirect coculture
with activated SCs. GAPDH served as an internal control. ELISA measurement of IL-10
secretion after 2 days of monoculture or 1:1 direct coculture of MSCs and SCs. (D) IL-10
secretion as a function of MSC number. **p<.01 compared to SCs alone (MSC:SC = 0). (E)
Inhibition of IL-IO secretion by MSCs in direct (1:1) coculture with activated SCs after treatment
with anti-IL-6 neutralizing antibody. IL-10 secretion from MSCs is induced by IL-6 release from
activated SCs. **p<.01 compared to no antibody. Results are the mean of two experiments
performed in triplicate. Error bars are standard deviation.
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Levels of PIP secretion by activated SCs were measured after four days of indirect
coculture with MSCs in the presence of neutralizing antibodies to IL-10, TNF-a, or both. Partial
normalization of PIP secretion was observed after neutralization of IL-10 or TNF-a at antibody
concentrations of 1000 ng/ml (Figure 4.8A) and 500 ug/ml (Figure 4.8B) or greater, respectively.
Neutralization of both IL-10 and TNF-a in coculture led to a synergistic rise in PIP levels from 79
+ 9 pg/106 cells/day to 215 ± 20 pg/106 cells/day (P=0.002) at maximal antibody concentrations
(Figure 4.8C).
We also evaluated the effects of MSC-derived TNF-a and IL-10 on the proliferation of
activated SCs. Neutralizing the effects of IL-10 in a 1:1 coculture led to a marginal rise in the
number of BrdU-positive cells, from 12% to 15% at the maximum antibody concentration (Figure
4.9A; P<.035). Neutralization of TNF-a resulted in a more significant effect on proliferation with
an increase in BrdU-positive cells from 13% to 33% (Figure 4.9B; P=-0.0197). Neutralization of
both cytokines led to the most significant increase proliferation population (13% to 44%)
suggesting synergy between the two signaling pathways (Figure 4.9C; P=-0.009).
4.3.5. MSC-Derived Hepatocyte Growth Factor Induces Apoptosis in Activated SCs.
Given the observation that a relatively small number of MSCs could cause SC apoptosis, we
analyzed the indirect coculture supernatants for potent pro-apoptotic signals. ELISAs for nerve
growth factor (NGF) and MMP-9, proteins previously reported to induce apoptosis in SCs were
negative. In contrast, we detected a considerable amount of hepatocyte growth factor (HGF) in
mono- and cocultures that was produced at approximately equivalent levels by both SCs and
MSCs (Figure 4.10A). A decrease in apoptosis was observed as a function of neutralizing
antibody to HGF (Figure 4.10B). This decrease in apoptosis did not occur when the cultures
were incubated with a control antibody with no HGF specificity (data not shown). These data
support a role for MSC-derived HGF in accelerating the rate of SC apoptosis.
4.4. DISCUSSION
The beneficial effect of MSCs in liver injury models is often attributed to the differentiation of
MSCs into a hepatic lineage241. However, a recent study using MSCs as a post-myocardial
infarction cardioprotective treatment suggests that paracrine factors produced by MSCs may
contribute to their therapeutic benefit' 12' 113 . We sought to evaluate this paracrine hypothesis in
the context of previous studies of liver fibrosis. Prior studies have shown that transplantation of
a CD45- population of bone marrow cells prevented histopathological changes during chronic
exposure to hepatotoxins 134 ,135 ,137 . These observations were correlated with a co-localization of
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Figure 4.8. PIP Secretion in Indirect Cocultures with Cytokine Neutralization. PIP
secretion after treatment with various concentrations of (A) IL-10 neutralizing antibody and (B)
TNF-a neutralizing antibody. (C) PIP secretion after treatment with various concentrations of
TNF-c neutralizing antibody and fixed (1500 ng/ml) IL-10 neutralizing antibody. Inhibition of PIP
secretion by SCs is mediated by MSC-derived IL-10 and TNF-a. Data represent the mean of
two experiments performed in triplicate. Error bars are standard deviation. *p<.05, **p<.01
compared to no IL-10 or TNF-a neutralizing antibodies, respectively.
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Figure 4.9. Decreased SC Proliferation in Response to MSC Secreted Cytokines. (A)
BrdU+ SCs after varying the concentration of neutralizing IL-10 antibody in the presence of
MSCs. The ratio of MSCs:SCs was fixed at 1:1. (B) BrdU+ SCs after varying the concentration
of neutralizing TNF-a antibody in the presence of MSCs. The ratio of MSCs:SCs was fixed at
1:1. (C) BrdU+ SCs after varying the concentration of neutralizing TNF-a antibody in the
presence of MSCs and anti-IL-10. The ratio of MSCs:SCs was fixed at 1:1 and the
concentration of anti-IL-10 was fixed at 1500 ng/ml. Data represent the mean of two
experiments done in triplicate. Error bars are standard deviation. *p<.05, **p<.01 compared to
no IL-10 or TNF-a, respectively.
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FIGURE 4.10. MSC-Derived HGF-Mediated Apoptosis of SCs. (A) HGF secretion after 2
days of monoculture or 1:1 direct coculture of SCs and MSCs. (B) Flow cytometry of SCs after
indirect coculture with MSCs. Results are the mean of two experiments performed in triplicate.
transplanted cells and SCs, a reduction in the number of ca-SMA+ cells, decreased tissue
collagen content, and increased gelatinase gene expression. These in vivo findings provided a
rationale for the therapeutic benefit of MSCs, although evidence supporting this mechanism in
vitro does not exist. Thus, we investigated the effects of paracrine factors secreted by MSCs on
activated SCs, the primary extracellular matrix-producing cell type in the liver.
We observed that MSCs inhibit the proliferative and fibrogenic function of activated SCs
in a paracrine manner and as a function of MSC number. This inhibition was caused by MSC-
derived IL-10 and TNF-a, which acted synergistically. The secretion of IL-10 by MSCs was
found to be a dynamic response to IL-6 secretion by activated SCs. Secretion of IL-10 by MSCs
in response to TNF-a was observed after exogenous stimulation, but not during mono- or
coculture. This result is presumably due to the high levels of stimulation used in vitro (25 ng/ml)
compared to the low levels measured in coculture (-2.5 ng/ml) indicating a potential threshold
concentration of TNF-a necessary for IL-10 expression. In addition, both IL-6 and TNF-a have
been shown to increase nuclear factor (NF)-KB signaling in other cell types242, suggesting that
this transcription factor may play a role in MSC cytokine expression during inflammation.
Furthermore, MSCs induced apoptosis in activated SCs that is, in part, mediated by HGF. The
effects of MSC-derived HGF and IL-10 may be supplementary to the autocrine signaling of
these proteins in SCs. These results support the hypothesis that the therapeutic effect of MSCs
may be due to paracrine factors that modulate the proliferation, viability, and function of resident
SCs.
Our studies demonstrate that MSCs act through multiple mechanisms to coordinate a
dynamic, integrated response to fibrosis. It is also likely that similar immunoprotective
mechanisms may influence the phenotype of resident hepatocytes, Kupffer cells, sinusoidal
endothelial cells, and immune cells that infiltrate the liver during inflammation, which some of
these multi-cellular effects were examined in Chapters 2 and 3.
Several prior studies have documented the presence of host bone marrow-derived cells
in the liver and mobilization of stem cell progenitors during liver fibrosis. Endogenous bone
marrow-derived, CD45- cells have been observed in human livers during fibrosis243, although
their role in disease progression was not determined. A recent study by Russo et al.
demonstrated that bone marrow-derived MSCs actively contributed to the myofibroblast
population of the liver during the progression of fibrosis. We hypothesize that MSCs may be
mobilized in response to injury for the benefit of the organ, but their therapeutic gains may be
subdued after chronic insults. Our investigation documents an acute, one-way response of
MSCs to activated SCs, however studies of long-term coculture of MSCs and SCs focused on
the reciprocal reaction in the phenotype of MSCs may add to a more global assessment of a
potential in vivo outcome.
In addition, when hematopoietic stem cell mobilization agents, such as granulocyte
colony-stimulating factor, were administered to acute and chronic liver-injured mice a rapid
recovery was observed and was notable for infused Y-chromosome positive bone marrow cells
in the female mouse livers and increased hepatocyte proliferation244. Although the investigators
attributed the results to a CD45+ population, these results should be interpreted with caution,
since dual staining for CD45 and Y-chromosome was not performed. Other studies have shown
that MSCs are mobilized in patients receiving granulocyte colony-stimulating factor, although
conflicting data exist in the literature245' 246. Nonetheless, it is possible that results using stem
cell mobilization agents may reflect a MSC-mediated effect. Investigations of MSC mobilization
may prove invaluable, not only as a means to concentrate these cells into the peripheral
circulation for isolation and transplantation, but also to determine the endogenous response of
CD45- bone marrow-derived cells and their role in the prevention, progression, or possibly the
combination of these processes during pathogenesis.
In conclusion, immunomodulation of SCs by MSC soluble factors provides the first
mechanistic evidence that MSCs can exert a protective role through paracrine signaling to liver
SCs. These findings may be relevant to the beneficial effects of transplanted MSCs in various
models of acute and chronic liver injury as well as to motivate the potential use of MSC
molecules as a therapeutic for liver fibrosis. In the next chapter, we conclude this section with a
description of MSC secreted factors.
CHAPTER V
A MOLECULAR PORTRAIT OF STEM CELL-DERIVED FACTORS
5.1 INTRODUCTION
Mesenchymal stem cells (MSCs) are known to be the precursor to stromal cells that support
hematopoiesis by fortifying the chemical environment of the bone marrow 47,5-56 . Investigators
have recently begun comprehensive expression analysis of these cells to identify the gene
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and proteomic 250' 251 landscape in health and disease. In addition, we and others have shown
that MSC secrete factors that can have therapeutic benefits in experimental models of
myocardial infarction, kidney disease, acute liver failure, and stroke"2," 13 1 6,119,1 21"32' 154
In this chapter, we begin with a comparison of the secretory function of MSCs compared
to typical mesenchymal cells with respect to the amount of protein produced by the cells. We
then provide a molecular description of MSC-CM using rational and shotgun proteomic
approaches, separate and identify therapeutically active fractions of MSC-CM, and introduce a
novel method to study the biodistribution of cell-derived proteins. Finally, we end with a detailed
discussion of the current knowledge on trophic mechanisms of MSC therapy.
5.2. MATERIALS AND METHODS
5.2.1. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM)
Human MSCs were kindly provided by the Tulane Center for Gene Therapy. MSCs were
cultured and characterized for surface marker expression and adipocytic and osteogenic
differentiation capacity as we described previously 122. For the generation of MSC-CM, cells
were allowed to grow to 70-80% confluence (approximately 1x106 MSCs per 175 cm2 flask),
washed thoroughly and cultured in 15 ml serum free Dulbecco's Modified Eagle's Medium
supplemented with 0.05% bovine serum albumin. Conditioned medium was collected 24 hours
later and concentrated 25-fold using ultrafiltration units (Millipore, Bedford, MA) with a 3kD cutoff.
For fractionation experiments, concentrated medium was passed over a heparin-agarose
column and the flow-through and eluted fractions were collected and reconcentrated using the
same ultrafiltration system. Human dermal fibroblasts were cultured according to vendor's
protocols and conditioned in the same manner as MSCs.
5.2.2. Protein Array Analysis of MSC-CM
Supernatants were prepared by collecting serum-free medium after 24 hour culture of
approximately 2x106 MSCs. These were analyzed for a panel of specified proteins using an
antibody array RayBio Human Cytokine Antibody Array C Series 2000, RayBiotech Inc.,
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Norcross, GA) as specified by the vendor. Internal positive and negative controls are spotted on
the array for relative comparison of spot intensity. Densiometric analysis using a commercially
available software package (ProteinOne, BD) is presented with respect to internal controls.
5.2.3. Gel-Permeation Chromatography Analysis
MSC-CM and Fibroblast-CM was prepared as previously described and protein content was
measured using a conventional Bradford Assay. Concentrated media (500 iL) was applied to a
bed (26 mm X 70 cm) of Bio-Gel P-100 Gel, Medium (Biorad) and eluted with phosphate saline
buffer (1 mL/minute flow) in a AKTA System (Amersham Pharmacia Biotech, GE Healthcare).
Column calibration was obtained using a mix of the following protein standards at a
concentration of 0.2-1.0 mg/mL: ACTH (4290 Da), a-lactoalbumin, (14,400 Da), ovalbumin
(43,000 Da) and phosphorylase (94,000 Da). Blue Dextran 2000 at 0.2 mg/mL was used alone
as final standard.
5.2.4. Liver Injury Induction
Male Sprague-Dawley rats weighing 250-300g were used for biodistribution experiments and
were cared for in accordance with the guidelines set forth by the Committee on Laboratory
Resources, National Institutes of Health. All experimental procedures performed were approved
by Subcommittee on Research Animal Care and Laboratory Animal Resources of
Massachusetts General Hospital. Liver injury was induced by two injections of D-galactosamine
(Gal-N), delivered i.p. with a 12-hour interval between injections at a dose of 0.6 g/kg Gal-N per
injection. After 24 hours, animals were anaesthetized using i.p. injections of ketamine and
xylazine at 110 and 0.4 mg/kg, respectively and infused with: (a) fractionates from separation
studies, or (b) radiolabeled conditioned medium or a phantom control for biodistribution studies.
5.2.5. Radiotracer Assay for Cell-Derived Molecules
To generate a radiolabeled, cell-derived concentrate, we incubated cells with a radioactive,
essential amino acid. Prior to concentration, fibroblasts or MSCs were cultured in serum-free
methionine-deficient medium supplemented with 3S-methionine, which was incorporated into
newly formed secreted proteins. The conditioned medium was collected and concentrated to
the appropriate dose and infused in the penile vein of rats 24 hours after treatment with GalIN.
Animals were sacrificed at 1, 8, and 24 hours after infusion of radiolabeled concentrates and all
tissues were assessed for levels of radioactivity by scintillation counts and normalized to tissue
weight. We used 4 animals per group for tissue collection after sacrifice at each time point after
treatment.
5.2.6. Statistical Analysis
Data are expressed as the mean ± standard error of the mean. A two-tailed Student's t-test was
employed after the exclusion of outliers that were less or greater than 2 standard deviations
away from the median.
5.3. RESULTS
5.3.1. Radiotracer Method for In Vivo Distribution of Cell-Derived Molecules
The biodistribution of a drug is an important component of its characteristic profile. In order to
study the trafficking of cell-derived biomolecules, we developed a new radiotracer method by
employing traditional protein labeling techniques (Figure 5.1A). Prior to concentration, cells
were cultured in serum-free methionine-deficient medium supplemented with 3S-methionine,
which was incorporated into newly formed secreted proteins. The conditioned medium was
collected, concentrated to the appropriate dose, and infused in the penile vein of rats 24 hours
after initial treatment with Gal-N. Animals were sacrificed at 1, 8, and 24 hours after infusion of
radiolabeled concentrates and tissues were assessed for levels of radioactivity by scintillation
counts and normalized to tissue weight. Both MSC-CM and Fibroblast-CM had a broad
distribution with no distinct foci of localization during FHF (Figure 5.1B). These data indicate
that there was no preferential activity in these cellular secretions that would explain differences
in efficacy.
5.3.3. MSC-CM is Composed of Many Chemokines and Growth Factors that Correlate with
Therapeutic Activity
In an effort to understand the molecular mediators of the observed efficacy of MSC therapy, we
examined MSC-CM using a high-density protein array. MSC-CM contained 69 of the 174
proteins assayed (Figure 5.2A), which included a broad spectrum of molecules involved in
immunomodulation and liver regeneration. Cluster analysis revealed that a large fraction of
MSC-CM was composed of chemokines (30%) and growth factors (37%) (Figure 5.2B), many of
which were expressed at very high relative levels. We decided to fractionate MSC-CM based on
functionality using affinity-based methods rather than other arbitrary molecular criteria such as
size or hydrophobicity. MSC-CM was passed over an affinity column impregnated with heparin
sulfate, a known ligand for all chemokines and many growth factors and separated into bound
and unbound fractions. Each fraction was infused into FHF-induced rats with overall survival as
the study endpoint. We observed that the therapeutic activity of MSC-CM was restricted to the
heparin bound fraction, providing a strong correlation between chemokines and growth factors
and the survival benefit after MSC-CM infusion in FHF-induced rats shown in Chapter 2 (Figure
5.2C).
5.3.4. Size-Based Analysis Reveals Large Amounts of >50kDa Proteins of MSC-CM
Compared to Fibroblast-CM
We also used traditional biochemical separation approaches to analyze MSC-CM. We
employed gel-phase chromatography to determine differences in protein size fractions of MSC-
CM compared to Fibroblast-CM prior to separation techniques. Qualitatively, the
chromatographs from the two cell types differed primarily in the >50kDa fraction with a large
intensity peak observed with MSC-CM that was absent in Fibroblast-CM (Figure 5.4A). When
MSC-CM was fractionated into <10kDa, 3-50kDa, and >50kDa eluents using ultrafiltration
membranes with specified molecular weight cut-offs, no statistically significant differences were
observed between the fractions (Figure 5.4B). However, based on our prior understanding of
Kaplan-Meier analysis the step-wise reduction in survival seen only with >50kDa fraction
suggests that there was certain bioactivity of this fraction that failed to be efficacious in the
short-term.
5.4. DISCUSSION
MSCs can be considered to be professional secretory cells. Moreover, the composition of these
secretions is quite assorted. To put this statement in context, using the same proteomic array, a
previous group identified 36, 32, and 28 molecules from human umbilical vein endothelial cells,
cholangiocytes, and hepatic stellate cells, respectively, as compared to 69 detected in MSC-
CM252. These data suggest that MSCs may have unique intracellular machinery to handle the
metabolic stress involved in protein expression and secretion.
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Figure 5.1. Biodistribution of Radiotraced Cell-Derived Molecules. (A) Depiction of the
experimental method used to analyze the biodistribution of cell-derived molecules in vivo.
Methionine-deficient serum free medium supplemented with S35-methionine was incubated with
cells for 24 hours, harvested, concentrated, and infused into rats undergoing liver failure.
Tissues were harvested at different time points and analyzed for radioactivity content by
scintillation counting. The biodistribution of MSC-CM (B) and Fibroblast-CM (C) is plotted as a
function of weight adjusted S35 counts relative to time and the tissue of study.
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Our studies indicate that a large fraction of the proteins secreted by MSCs are chemokines and
growth factors. The heparin-bound fraction of MSC-CM, enriched for chemokines and growth
factors, correlated with the therapeutic activity of unfractionated MSC-CM. In addition, MSCs
were found to secrete >50kDa molecules more so than other mesenchymal cell types. Since
many chemokines fall below 10kDa in molecular weight and many growth factors are >50kDa,
these data suggest that growth factors may be the primary active ingredient. However, there
were quantifiable differences in survival observed between unfractionated and size-fractionated
forms of MSC-CM indicating a potential combinatorial effect of molecules within the secreted
concentrates. Biodistribution analysis of unfractionated MSC-CM showed no specific
accumulation in certain tissues compared to Fibroblast-CM. These data rule out any "tropic"
efficacy of MSC-CM and have developed a new assay to study the fate of cell-derived
biomolecules in vivo.
MSCs secrete an array of trophic mediators with therapeutic potential in diseases of
several vital organs through modulation of cell death, inflammation, fibrosis, regeneration and
angiogenesis. Experimental success has been obtained using several different modes of MSC
therapy: cell transplantation, incorporation of MSCs into biocompatible devices and delivery of
only the MSC-secreted molecules. However, important questions regarding the optimal delivery
method of MSC therapy remain. Transplanted MSCs have the potential benefit of homing to
the site of injury and continued delivery of the trophic signals. However, long-term engraftment
levels are low 253 and invasive methods for local delivery of the cells is often necessary to
circumvent pulmonary lodging2' .On the other hand, delivery of only MSC-derived products (e.g.
conditioned medium) has the potential of becoming an off-the-shelf therapy. Intravenous
injections of MSC-CM are easy to titrate, have short-term effects that quickly fade by natural
metabolism or degradation of molecules inside the body, and can be sufficient for treatment of
acute insults. MSC-based bioreactor treatment (discussed in Chapters 6-7) offers a treatment
option with continued delivery of MSC-products that are secreted dynamically in response to
circulating cues from the sick subject, which can significantly alter the secretome of MSCs.
Thorough head-to-head comparisons of treatment methods will be necessary to determine
which treatment strategy has the greatest potential in specific disease state.
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Figure 5.2. Heparin Affinity-Based Separation of MSC-CM. Serum-free MSC-CM was
analyzed using an antibody array for 174 specified proteins. (A) Densiometry of spotted
antibody array results. Data are presented as spot intensity relative to the negative control and
normalized to positive control. (B) Pie chart showing cluster analysis of MSC secreted proteins
based on reported function. MSC-CM was fractionated over a heparin-agarose column into
heparin bound and unbound fractions. (C) Kaplan-Meier survival analysis of Gal-N administered
rats treated with the (+) heparin MSC-CM and (2) heparin MSC-CM. Time points of interventions
are stated above survival plots. Results for (C) are cumulative data of two independent
experiments using different batches of MSC-CM (N = 8 per each group). P-value determined by
Log Rank Test
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Figure 5.3. Size-Based Fractionation of MSC-CM. (A) Gel-permeation chromatogram of
MSC-CM and Fibroblast-CM. Shown is intensity versus elution time of serum-free concentrated
medium. (B) Kaplan-Meier analysis of size-based fractions of MSC-CM.
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SECTION III
MESENCHYMAL STEM CELL-LADEN EXTRACORPOREAL DEVICES
OVERVIEW
In the setting of acute organ failure, methods are needed to supplement the loss of
tissue function to prevent systemic complications while promoting an appropriate tissue repair
program. In the case of liver failure, the loss of hepatic mass leads to potentially fatal sequelae
of multi-organ dysfunction syndrome, hypoglycemia, increased clotting time, and an increase in
plasma nitrogen wastes that can cause encephalopathy. Thus, the primary goal of most cell-
based therapies for liver disease has been to stabilize liver function by exogenous means in
order to serve as a bridge to transplantation. The most promising of hepatocyte-based
therapies for acute liver failure are extracorporeal bioreactors, however efficacy has yet to be
shown with current technologies. In Chapter 6, we show that a MSC-based extracorporeal
device is sufficient to provide short-term survival benefit without the need for hepatocytes. In
Chapter 7, we develop a cocultured bioreactor composed of primary hepatocytes and MSCs
and document a long-term survival benefit that can be considered as an experimental liver
assist device with an indication as a destination therapy.
CHAPTER VI
MSC-BASED EXTRACORPOREAL BIOREACTOR SUPPORT FOR ACUTE SETTINGS
6.1 INTRODUCTION
End-stage liver disease accounts for over 30,000 deaths annually in the United States.
Liver failure can lead to neurological and systemic effects such as hepatic encephalopathy,
renal failure, and sepsis that result in a high mortality of approximately 28% in the United
States255. Currently, patients are managed by treating the underlying condition, which may
allow a window of time for compensation and reversal of organ failure. However, when
significant fibrosis and loss of tissue mass has occurred, the deterioration of the patient is
inevitable and there are no medications that exist to address this issue. Orthotopic liver
transplantation is the only treatment that has shown survival benefit in liver failure, yet its use is
limited by the severe shortage of organ donors256.
Alternatives to liver transplantation have been studied with limited success.
Nonbiological systems based on dialysis, hemoperfusion or ion exchange resins were first
explored. These approaches were found to be ineffective because they did not support the
metabolic functions of the liver, possibly depleted serum factors that would be beneficial to
tissue regeneration, and had adverse effects on hematopoietic cell counts2 . The next
generation of experimental therapies incorporated hepatocytes, the parenchymal cells of the
liver as a means of hepatic support. These therapies can be broadly grouped as tissue
engineered constructs for transplantation or extracorporeal bioreactors (EBs). Tissue
engineered constructs generally seed living cells within an artificial or natural polymer scaffold
and may embed specific soluble factors to enhance viability and function of the graft257. These
methods have associated problems with transport, adequate cell mass, and tissue rejection that
have deterred long-term efficacy of these bioartificial grafts. EBs consisting of functioning viable
heptocytes could provide temporary support for patients with liver failure and save lives of
patients awaiting orthotopic liver transplantation. The central feature of these devices is a
hollow-fiber unit that allows for whole blood or plasma constituents to diffuse to hepatocytes
and/or other cells seeded within the device.
In the past few years, there have been several clinical studies testing the efficacy of EBs
in treating liver failure. Although these studies have provided some promising results, the
current generation of EBs has not demonstrated sufficient efficacy and reliability for routine
use258. While several technical difficulties remain to be addressed with respect to the design of
these devices, clearly a major hurdle is the procurement of a sufficient number of cells that are
required to achieve a therapeutic effect. Human hepatocytes appear to be the "natural" choice
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for a clinical EB; however, they are scarce due to a competing demand of livers for orthotopic
liver transplantation.
We have previously shown that immunomodulation via interleukin-1 receptor antagonism
in the form of: (a) the recombinant protein, (b) adenoviral vector gene therapy, or (c) transfected
hepatocytes seeded in an extracorporeal device, can provide a survival benefit in an animal
model of FHF'95 . However, due to concerns associated with gene transfer in vivo or ex vivo
and the expense of recombinant protein production, we sought to identify a natural human
"cellular equivalent" of immunomodulation that could be incorporated into bioartificial liver assist
devices. In this chapter, we describe the development and use of a mesenchymal stem cell
(MSC)-based EB to circumvent the cell source problem and modulate the injury to a failing
organ in trans.
6.2 MATERIALS AND METHODS
6.2.1. Cell Culture
Human MSCs were isolated from commercially available bone marrow aspirates (Clonetics-
Poietics, Walkersville, MD) and grown and characterized as previously reported' 22. Cells were
used for experiments during passages 3-7. NIH 3T3-J2 fibroblasts were a kind gift from Dr.
Howard Green and cultured according to donor's protocols.
6.2.2. Liver Failure Induction and Extracorporeal Bioreactor Support
All experimental procedures performed were approved by Subcommittee on Research Animal
Care and Laboratory Animal Resources of Massachusetts General Hospital. The induction of
fulminant hepatic failure and extracorporeal device operation is previously reported259 . Briefly,
male Sprague-Dawley rats weighing between 280 and 370 grams were anaesthetized using
intraperitoneal injections of ketamine and xylazine at 110 and 0.4 mg/kg, respectively. The left
carotid artery and right jugular vein were cannulated and the animal was placed in a metabolic
cage. Twenty-four hours later, 1.2 g/kg Gal-N freshly dissolved in physiological saline and
adjusted to pH 7.3 with 1 N NaOH was injected i.p., followed by a second equal injection 12
hours later. Twenty-four hours after the first injection of Gal-N, the arterial and venous lines
were connected to an extracorporeal circuit. Plasma was separated using a plasma separator
(MicroKros, pore size 0.2 micron). Plasma was perfused through the polycarbonate, flat-plate
bioreactor and subsequently reunited with the cellular components of the blood and returned to
the animal. The extracorporeal bioreactor was operated for 10 hours. Animals that died during
reactor operation and failed to receive adequate treatment (MSC-EB, N= 3 and Fibroblast-EB,
N= 2) were censored from analysis. Animal survival was monitored every 12 hours. Plasma or
whole blood was analyzed for liver injury biomarkers using a microfluidic metabolic assay
(Picollo, Abaxis, Union City, CA).
6.2.3. Protein Array of MSC-CM After Stimulation with Inflammatory Serum
Serum from wild-type and FHF-induced rats (48 hours post-induction) was harvested by
cannulation of the aorta and insaguination of the animal. MSCs were stimulated for 10 hours
with serum to simulate a bioreactor exposure and subsequently washed and cultured in fresh
serum-free medium. Conditioned medium was prepared by collecting serum-free medium after
24 hour culture of approximately 2x106 MSCs. MSC-CM was analyzed for a panel of specified
proteins using an antibody array (RayBio Human Cytokine Antibody Array C Series 2000,
RayBiotech Inc., Norcross, GA) as specified by the vendor.
6.3 RESULTS
6.3.1. Combined Metabolic and Secretory function in MSC-EB Support Provides
Hepatoprotection and Survival Benefit
Based on our results in Chapter 2, we developed a MSC-EB to combine the effectiveness of
intracellular and secreted molecules of MSCs in a single device (Figure 6.1). Animals were
treated 24 hours after FHF induction with a human MSC-EB connected to the systemic
circulation of the animal. Bioreactors seeded with fibroblasts (fibroblast-EB) and acellular
(acellular-EB) bioreactors served as controls. After 10 hours of extracorporeal perfusion,
animals were taken off assist support and monitored for survival. Plasma was obtained at the
start of, and 24 hours after, bioreactor treatment and analyzed for hepatocyte enzyme release.
Liver serologies, including aspartate aminotransferase (P-0.02) and alanine aminotransferase
(P-0.001) were improved in animals treated with the MSC-EB (Figure 6.2A). These data
demonstrate a hepatoprotective effect of device therapy as shown by the reduction in
biochemical markers of hepatocyte death. More importantly, 71% of animals treated with the
MSC-EB survived at a 7 day study endpoint, compared to 14% in both acellular (P=0.037) and
fibroblast controls (P=0.05; Figure 6.2B).
6.3.2. Change in MSC Secretome after Stimulation with Liver Failure Serum
Since MSCs were seeded within the bioreactor and constantly exposed to the plasma of liver
injured rats during the support period, we questioned whether the cells would alter their
secretory profile in response to the inflammatory signals found in the sera. To this end, we
performed proteomic analysis of MSC conditioned medium (MSC-CM) after stimulation with
medium supplemented with serum from wild-type (WT) or liver injured (LI) rats. MSCs were
incubated with wild-type or inflamed serum for 10 hours (to simulate their serum exposure in the
EB), before subsequent conditioning in serum-free medium for 24 hours. LI serum stimulation
led to a decrease in the total secreted protein of MSCs compared to WT serum stimulation (451
+ 47 pgg/10 6cells/day versus 362 ± 64 gg/10 6cells/day; P=-0.014; Figure 6.3A). MSC-CM was
then analyzed using a high-density antibody array in response to its initial preconditioning
stimuli. The total number of species detected by the array was not different between serum
stimulation groups (WT=51 species; LI=50 species), but 19 species were uniquely detected
after WT stimulation compared to 8 species with LI stimulation (Figure 6.3B). In addition, 10
species had significant fold changes after WT stimulation versus 20 species with significant fold
changes after LI stimulation. The specific chemical composition of MSC-CM was found to be
dependent on pre-conditioning. After WT stimulation, MSCs secreted a mixture of growth
factors (32%), chemokines (31%), carrier proteins (11%), extracellular matrix-modifying
molecules (11%), cytokines (5%), cytokine antagonists (5%), and other substituents (5%; Figure
6.3C). On the contrary, MSCs stimulated with LI serum prior to conditioning secreted a mixture
of cytokines (37%), chemokines (37%), growth factors (13%), and carrier proteins (13%), with
no significant secretion of extracellular matrix-modifying molecules, cytokine antagonists, or
other substituents (Figure 6.3D). The chemical species are shown in Figure 6.3C-D.
6.4. DISCUSSION
Acute organ failure is a life-threatening clinical syndrome that requires immediate medical
and/or surgical support. The crowning example of extracorporeal support is kidney dialysis, in
which an acellular device filters the blood of patients. However, the liver performs several
synthetic and metabolic functions that necessitate the need for a cellular component within
analogous, extracorporeal support devices. Human hepatocytes are clearly the natural choice
for the cellular component of such a device, but it is unclear if this technology can be adopted
because of cell source limitation. Furthermore, hepatic support may not be the only immediate
consideration during FHF as it is clear that an associated immune response may contribute to
local and systemic pathogenesis. In an effort to address the cell source and immune response
shortfalls of current EBs, we incorporated MSCs into existing devices and successfully
supported rats undergoing FHF.
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Figure 6.1. Description of ELAD Circuit Design. Two days before ELAD treatment, the
carotid artery and jugular vein are nnulated. One day prior to treatment, two i.p. injections of D-
galactosamine at a dosage of 1.2 g/kg are administered. Twenty four hours after the first
injection, animals are treated for 10 hours with ELAD. Whole blood is separated by a
plasmapheresis unit. The plasma is flowed through a flat-plate bioreactor containing cells. The
cell-conditioned plasma stream is then reconnected with the outlet stream of the
plasmapheresis unit and returns to the host circulation via the jugular vein. Animals are
monitored every 12 hours for survival. Blood is sampled at different time points from catheter
ports.
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Figure 6.2. MSC-EB Support Reduces Liver Injury Biomarkers and Increases Survival.
Animals were treated with an MSC-EB, using a 3T3 fibroblast-based bioreactor (fibroblast-EB)
and an acellular bioreactor (acellular-EB) as controls. (A) Serum biomarkers of liver injury,
aspartate aminotransferase and alanine aminotransferase preceding and 24 hours after
treatment with a MSC-EB (n = 5) or an acellular-EB (n = 3). Due to mortality, n = 1 in the
acellular group after treatment. (B) Kaplan-Meier survival analysis of Gal-N administered rats
treated with EBs. Time points of interventions are stated above survival plots. Each result for (B)
was an independent experiment using different batches of MSCs. P-value determined by
student's t-test analysis for panel (A). P-value determined by Log Rank Test for panel (B).
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Treatment with a MSC-EB, which combined both the secretory and metabolic functions of MSCs
in a single device, provided the greatest benefit in short-term survival. These results are
significant because we have identified a non-hepatic source of human cells with minimal
metabolic demands that can be expanded to clinical scale for liver assist devices. Although,
investigators have showed that MSCs can transdifferentiate into hepatocytes given a proper
inductive cues we assume that MSCs did not provide hepatocyte-like functions within the device
given the short exposure (10 hr.) of undifferentiated MSCs to the circulation of the animal. The
success of the MSC-EB most likely revolves around the immunomodulatory and regenerative
effects of the molecules secreted by MSCs as demonstrated in previous chapters. However,
the added benefit of a MSC-EB compared to an intravenous bolus of MSC-CM may be due to:
(1) metabolism of serum factors; (2) pharmacokinetic differences between a single treatment of
MSC-CM and a 10 hr. support period with a MSC-EB; or (3) secretion of a new panel of
molecules with increased efficacy as a dynamic response of MSCs to inflamed serum from liver
injured rats.
With respect to the dynamic serum stimulation, we showed that pre-incubation of MSCs
in medium supplemented with LI serum alters the composition of MSC-CM. Irrespective of the
exact chemical species, the major global difference between WT and LI serum stimulation in
MSC-CM composition was an increase in cytokines from 5% to 37% and a decrease in growth
factors from 32% to 13%, respectively. Previous reports have shown that MSCs stimulated with
non-specific inflammatory cytokines such as TNF-a and IFNy cause changes in MSC
function260, although we cannot determine if these were the major inducers of the change in
MSC-CM. Furthermore, we do not know if this global change in MSC-CM was directly related to
the increased efficacy of a MSC-EB. Nonetheless, these data support the notion that MSCs
are reactive to their chemical environment and change their secretory patterns accordingly. The
clear stimulus-dependent composition of MSC-CM may also give insight into future derivation of
stem cell extracts for targeted therapeutic goals.
In conclusion, we demonstrate the first incorporation of MSCs within biomedical
devices for immunological support. In the next chapter, we determine the long-term in vivo
efficacy of cellular coculture devices using MSCs and parenchymal liver cells to provide both
hepatic and immunological support for subjects undergoing FHF.
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CHAPTER VII
COMPOSITE CELLULAR EXTRACORPOREAL DEVICES
FOR LONG-TERM SURVIVAL BENEFIT
7.1 INTRODUCTION
Acute liver failure (ALF) affects approximately 2000 individuals annually in the United States,
with mortality rates reportedly as high as 80% without successful liver transplantation.
According to the U.S. Acute Liver Failure Study Group (1998-2007), of the 44% of patients who
were listed for transplantation, only 25% of the overall group received a graft and 10% died on
the waiting list261. Because the donor shortage is still limiting, investigators have looked for
alternative approaches to provide temporary support for patients as a "bridge" to transplantation
or recovery of the failing organ as a destination therapy.
Cell-based technologies to support or artificially restore organ function represent one of
the most promising avenues in the treatment of FHF. These different approaches can be
broadly classified as cell transplantation strategies, tissue engineered grafts, and cell-laden
extracorporeal devices. Hepatocyte transplantation has been used in clinical trials for the
treatment of various liver diseases in more than 25 patients and has been associated with
partial improvements, but no significant correction of disease22 . Tissue engineered grafts have
yet to be tested clinically, and it is unclear if the complex organ structure and function can be
recapitulated in an artificial graft. Furthermore, the first two approaches involve implantation of
grafts and will encounter major immunological barriers for clinical success, assuming an
allogeneic or xenogeneic cell source. Extracorporeal devices, by nature, are not implantable
and circumvent the problem of immune rejection. However, efficacious devices have yet to be
realized. Liver assist devices (LADs) are either non-cell based detoxification units or cell-based
devices to provide metabolic support as well as detoxification. Acellular devices include open
circuit systems such as one-pass albumin dialysis and plasma exchange units263 and closed
circuit systems such as the Prometheus albumin dialysis unit26 and the molecular absorbents
recirculation system265. Limitations of these approaches include inadequate removal rates, non-
selective losses in open circuit devices and equilibrium constraints on total removal versus
effective plasma transit time within the closed circuit devices266'267. To date, five cell-based
devices have been clinically tested and appear safe20 2,268-273, but none have shown a survival
benefit in ALF274.
A number of basic, yet critical design criteria can guide the development of the
technology and should be considered, such as: (1) a readily available cell source (in clinical
studies, cell masses vary from 100-500 g/device); (2) the structure, function, and viability of the
parenchymal cells seeded in the device under fluid flow (in clinical studies, flow rates vary from
20-200 mUmin); (3) the pathogenesis of the target tissue; as well as (4) the storage and
transport of the product all within the context of clinical practicality and feasibility. The expected
cell type used in a bioartifical liver device is clearly a human hepatocyte to support the systemic
dysfunction that occurs after liver failure. However, a supportive cell type cocultured with
hepatocytes in the device can aid in meeting these design criteria in a secondary manner.
Ideally, a supportive cell can: (1) reduce the hepatic and/or overall cell mass needed in a device
by optimizing hepatocyte function ex vivo; (2) provide a therapeutic benefit by parenchymal cell-
independent mechanisms thereby leading to synergism; and (3) enhance the preservability of
parenchymal cells during storage and transport.
In this chapter, we demonstrate that the choice of this supportive cell is essential for the
long-term efficacy of a LAD. We've previously observed a short-term survival benefit to rats
undergoing acute liver failure (ALF) after treatment with a mesenchymal stem cell (MSC)-laden
extracorporeal bioreactor (see Chapter 6). In the present study, we first determined if human
MSCs could support hepatocyte functions in vitro with an emphasis on understanding optimal
cellular conditions for future LAD treatments. Finally, we coculture hepatocytes with human
MSCs in LADs and compared the long-term efficacy of this treatment with a coculture scheme
known to provide high-level hepatocyte function.
7.2. MATERIALS AND METHODS
7.2.1. Animals
Female Lewis rats weighing 180-200g and male Sprague-Dawley rats weighing 280-370g
(Charles River Labratories, Boston, MA) were used for hepatocyte isolation and fulminant liver
failure model, respectively. The animals were cared for in accordance with the guidelines set
forth by the Committee on Laboratory Resources, National Institutes of Health. All experimental
procedures performed were approved by Subcommittee on Research Animal Care and
Laboratory Animal Resources of Massachusetts General Hospital. All animals were acclimated
to the animal research laboratory for 7 days before initiating the experiments, and all had free
access to food and water, both before and after the operation.
7.2.2. Hepatocyte Isolation
Hepatocytes were isolated using a two-step collagenase perfusion procedure as previously
described207. Typically, 150-250x106 hepatocytes were isolated from a single liver, with viability
greater than 90%, as measured by Trypan blue exclusion. Nonparenchymal cells were less than
1%, as judged by their size and morphology during cell counting. Hepatocyte culture medium
consisted of Dulbecco's Modified Eagle's Medium supplemented with 10% FBS 14 ng/ml
glucagon, 0.5 U/ml insulin, 20 ng/ml epidermal growth factor (EGF), 7.5 gg/ml hydrocortisone,
200 pg/ml streptomycin and 200 U/ml penicillin.
7.2.3. MSC and Fibroblast Culture
Human MSCs were kindly provided by the Tulane Center for Gene Therapy. MSCs were
cultured and characterized for surface marker expression and adipocytic and osteogenic
differentiation capacity as previously reported22. Cells were used for experiments during
passages 3-7. NIH 3T3-J2 fibroblasts were a kind gift from Dr. Howard Green and cultured
according to donor's protocol.
7.2.4. In Vitro Cocultures
A fixed number of primary hepatocytes (7.5x10 5 cells) were seeded in each well of a 6 well
tissue culture dish that had been pre-treated with a type I collagen coating. Mesenchymal cells
were seeded at various ratios simultaneously. All cultures were incubated with hepatocyte
culture medium and subjected to daily medium changes. Media samples were collected at each
time point and stored at -20 degrees C for subsequent analysis of albumin and urea content.
7.2.5. Albumin Enzyme-Linked Immunoabsorbent Assay (ELISA)
Albumin concentrations were determined by a competitive ELISA using a polyclonal antibody to
rat albumin (Organon Teknika Corporation, West Chester, PA) as described previously207. 0-
Phenylenediamine and hydrogen peroxide solution were purchased from Sigma.
Chromatographically purified rat albumin was obtained from ICN Biomedicals, Aurora, OH. The
absorbance was measured in a Versamax microplate reader (Molecular Devices, Sunnyvale,
CA).
7.2.6. Urea Assay
Urea concentration was measured by the specific reaction of diacetyle monoxime with urea
using the commercially available Urea Nitrogen Assay Kit (Stanbio Laboratory, Boerne, TX) in
accordance with the manufacturer's instructions. The absorbance was measured in a Versamax
microplate reader (Molecular Devices).
7.2.7. Immunocytofluorescence and Microscopy
Immunocytofluorescent detection was performed on cocultures after 15 minutes fixation in 4%
paraformaldehyde solution prepared in PBS. All steps were performed at room temperature.
After washing, cells were incubated with a blocking and cell permeabilization buffer containing
10% normal horse serum and 0.025% Triton X 100 in PBS for 45 minutes. Subsequently, the
cells were incubated with a goat polyclonal anti human albumin at 5 pg/ml (ICN Biomedicals)
primary antibody for 60 minutes. After washing three times with PBS, incubation with FITC-
conjugated donkey anti-goat antibody (Jackson ImmunoResearch Laboratories, West Grove,
PA), was performed in a 1:200 dilution for 60 minutes, followed by 3 PBS washes and 3
blocking buffer washes. Fluorescent and phase-contrast microscopy was performed with a
Zeiss Axiovert 200 M Inverted Microscope.
7.2.8. Incorporation of Cells into the LAD
The construction, maintenance, and operation of the flat-plate LADs used in these studies has
been described previously259. Five experimental groups were established for use in cell-based
LAD perfusion studies: (1) Hepatocytes alone (Hep-LAD, N=6); (2) Fibroblasts alone (Fb-LAD,
N=8); (3) MSCs alone (MSC-LAD, N=7); (4) Fibroblast-Hepatocytes coculture (Fb+Hep-LAD,
n=10); (5) MSCs-Hepatocytes coculture (MSC+Hep-LAD, n=9). Animals that died during device
operation and failed to receive adequate treatment (Hep-LAD, N=2; Fb-LAD, N=2; MSC-LAD,
N=3; Fib+Hep-LAD, N=1; and MSC+Hep-LAD, n=1) were censored from analysis. In all of the
groups, the glass surface of the lower plate of the LAD was pre-coated with 0.125 mg/mL rat-tail
collagen solution. Both Hep-LADs and Fb-LADs contained 15x10 6 cells each seeded 7 days
before perfusion. The MSC-LADs contained 1.5 x106 cells seeded 4 days before perfusion. In
the coculture group, Fib+Hep-LAD contained hepatocytes (7.5x106, seeded 7 days before
perfusion) with fibroblasts (15x106, seeded 1 day after hepatocytes) or MSCs (1.5x106, seeded
1 day after hepatocytes).
7.2.9. Liver Failure Induction and Support by LAD
The induction of ALF and LAD operation is previously reported'9 7. Briefly, animals were
anaesthetized using intraperitoneal injections of ketamine and xylazine at 110 and 0.4 mg/kg,
respectively. The left carotid artery and right jugular vein were cannulated and the animal was
placed in a metabolic cage. Twenty-four hours later, 1.2 g/kg Gal-N freshly dissolved in
physiological saline and adjusted to pH 7.3 with 1 N NaOH was injected i.p., followed by a
second equal injection 12 hours later. Twenty-four hours after the first injection of Gal-N, the
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arterial and venous lines were connected to an extracorporeal circuit. Plasma was separated
using a plasma separator (MicroKros, pore size 0.2 micron). Plasma was perfused though the
polycarbonate, flat-plate LAD and subsequently reunited with the cellular components of the
blood and returned to the animal. The LAD was operated for 10 hours. Animal survival was
monitored every 12 hours.
7.2.10. Blood Sampling
Blood was drawn at 24 hours after the initial Gal-N injection via the carotid artery and serum
from all animals was stored at -80 degrees until analytical study. Plasma or whole blood was
analyzed for liver injury biomarkers using a microfluidic metabolic assay (Picollo, Abaxis, Union
City, Ca).
7.2.11. Statistical Analysis. The Kaplan-Meier survival analysis and Log Rank test were used
for statistical analysis of mortality and performed with the StatView software package (Abacus
Concepts, Berkeley, California, USA).
7.3. RESULTS
7.3.1. Hepatocyte Morphology is Retained when Cocultured with MSCs without
Transdifferentiation of MSCs
We performed in vitro coculture experiments to determine if human MSCs can provide non-
parenchymal support to hepatocytes. Hepatocytes and mesenchymal cells were simultaneously
seeded on a collagen coated surface at a 5:1 ratio and cultured in hepatocyte medium for 12
days with daily maintenance. After 12 days of coculture hepatocytes showed a typical cuboidal
morphology with distinct polarity when cocultured with either fibroblasts (Figure 7.1A) or hMSCs
(Figure 7.1B). The cultures naturally assembled into homotypic clusters of hepatocytes
surrounded by heterotypic interactions with mesenchymal cells. Since some reports state that
MSCs can transdifferentiate into hepatocyte-like cells'03.104, we attempted to verify if this
phenomenon was occurring in this system. To determine if hMSCs were differentiating to
hepatocyte-like cells, we co-cultured rat hepatocytes and hMSCs and stained for human
albumin. After 7 days of coculture, no human albumin positive MSCs were identified
demonstrating that hMSCs are not significantly differentiated to hepatocytes (data not shown) in
this coculture.
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Figure 7.1. Hepatocyte Morphology During Coculture With MSCs. Phase contrast
micrographs of hepatocytes seeded with 3T3-J2 fibroblasts (A) or MSCs (B) and cultured for 7
days in C+H medium.
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7.3.2. MSCs Stabilize Hepatocellular Metabolic Function in a Similar Fashion to
Fibroblasts
Hepatocytes in monoculture are known to exhibit poor metabolic function when seeded on
collagen coated surfaces207. When cocultured with mesenchymal cells hepatocyte function
becomes stabilized, however it was unknown if MSCs could exhibit similar non-parenchymal
support. We fixed the total hepatocyte number for at 7.5x105 cells for in vitro coculture studies
to analyze the effect of non-parenchymal support on experimental outcomes. In addition, we
varied the hepatocyte:non-parenchymal cell ratios to determine if hepatocyte function was
dependent on the number of non-parenchymal cells. When cocultured with 3T3-J2 fibroblasts in
heterotypic contact, hepatocyte function as measured by albumin secretion becomes stabilized
in long-term culture, which is consistent with prior reports275. Albumin secretion at the end of the
culture period at a 1:5 ratio of fibroblasts:hepatocytes was 191±12 pg/d/dish. Similarly,
cocultures with human MSCs and hepatocytes at a 1:5 ratio led to an albumin secretion rate of
125±10 pg/d/dish. In both cases, albumin secretion was found to be a function of mesenchymal
cell number; however, at a ratio of 1:50, MSCs failed to support long-term function (Figure 7.2A-
B). Urea synthesis was used as another indicator of hepatocyte metabolism and showed similar
trends between both groups (Figure 7.2C,D). Urea synthesis of hepatocytes at day 10 of the
culture period was 81±13 pg/d/dish when cocultured with MSCs and 98±19 gig/d/dish when
cocultured with fibroblasts. Overall, these in vitro studies demonstrated no major differences
between MSCs and fibroblasts with respect to their support of hepatocyte function that would
negate the future use of MSCs as a substitute for fibroblasts in hepatocyte-based therapies.
7.3.3. MSC-Hepatocyte Composite Device Improves Liver Serologies and Demonstrates
Long-Term Survival Benefit
We developed flat-plate LADs that were seeded with different cellular compositions to observe
the effect of non-parenchymal support in the efficacy of the overall LAD treatment. The number
of hepatocytes seeded in the device was fixed at 15x106 cells to provide minimal hepatic
support. Our in vitro studies showed a direct correlation between hepatic function and the
number of non-parenchymal cells, therefore we seeded the maximal number of mesenchymal
cells that led to confluent bioreactor cultures. This resulted in a 1:5 ratio of MSCs:hepatocytes
and a 2:1 ratio of 3T3-J2 fibroblasts:hepatocytes, both ratios of which we've previously shown to
sufficiently stabilize hepatic function in vitro. Cells were seeded and cultured in the device for 7
days to stabilize viability and function of hepatocytes prior to therapeutic operation.
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After 10 hours of extracorporeal perfusion, animals were taken off assist support and monitored
for serological measures of liver function and overall survival. Plasma was obtained prior to,
and at 10 hours after LAD treatment and analyzed for hepatocyte enzyme release. Liver
serologies were improved in animal groups after treatment with MSC-LADs, MSC+Hep-LADs,
and Fb+Hep-LADs (Figure 7.3A). Using MSC+Hep-LAD support as an example, alanine
aminotransferase (ALT) was reduced from 1019±193 U/I to 292±176 U/I and aspartate
aminotransferase (AST) was reduced from 1824±567 U/I to 759±393 U/I. These data suggest
that either composite device could reduce the amount of hepatocyte death. MSC-LADs,
MSC+Hep-LADs and Fb+Hep-LADs had distinct survival benefits at a short-term endpoint of 7
days compared to devices seeded only with hepatocytes (MSC+Hep-LAD: 77%, MSC-LAD:
71%, Fb+Hep-LAD: 50%, Hep: 0% ; Figure 7.3B; P<0.05). However, significant differences in
long-term survival were observed between the composite devices. At a 30 day endpoint, 66%
animals treated with MSC+Hep-LADs were alive while only 20% of animals treated with
Fb+Hep-LADs survived in the long-term (P=-0.048). No statistical difference was seen between
the MSC-LAD and the composite LADs.
7.4. DISCUSSION
Biomedical devices that incorporate primary cells for therapeutic use often require non-
parenchymal cells to support tissue-specific functions ex vivo. In this study, we have
determined that the choice of the non-parenchymal cell type can be critical in the long-term
efficacy of the device. These results may solely rely on the intrinsic differences between MSCs
and other mesenchymal cells with respect to their trophic secretions 12 11 6 '121 '133,' 154. In Chapter 6,
we previously reported that an extracorporeal bioreactor seeded with human MSCs could
provide a short-term survival benefit to rats undergoing FHF when compared to an acellular or
fibroblast-laden device' 21. Furthermore, we have shown the molecules secreted by MSCs are
bioactive and can modulate the immune and hepatocellular response to liver failure (see
Chapters 2 and 3)120,121 . However, these results were solely due to immunological support
provided by MSCs and were assessed with a short-term study endpoint. In this study, we
assessed whether the combination of hepatic and immunological support would yield greater
long-term efficacy of existing LAD prototypes.
Coculture of hepatocytes with nonparenchymal cells has been shown to preserve typical
hepatocyte morphology and a variety of synthetic, metabolic and detoxification functions of the
liver275'276 . Prior studies indicated that the murine embryonic fibroblast cell line, NIH 3T3-J2, is
superior to other nonparenchymal cells in its ability to induce liver specific functions in isolated
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rat hepatocytes277. We first verified if MSCs can stabilize hepatocyte phenotype and function
when compared to the gold-standard of a 3T3 fibroblast-hepatocyte coculture. Hepatocytes
showed typical cuboidal morphology with epithelial cell polarity when cocultured with either
fibroblasts or MSCs. In addition, hepatocyte function as measured by albumin secretion and
urea synthesis became stabilized in long-term culture with MSC as well as fibroblasts in a
mesenchymal cell dose-dependent manner. These results are consistent with other reports
describing an efficacy of hepatocytes cocultured with bone marrow derived stem cells278,
although we demonstrated this phenomenon with human MSCs. These in vitro results
suggested that MSCs and fibroblasts may utilize similar mechanisms that may be generalized to
other mesenchymal cells to stabilize hepatocellular function, and many investigations are
underway277.
Since some reports describe the differentiation of MSCs to hepatocyte-like cells' 4, we
tested whether such transdifferentiation events were occurring in our coculture system. We
demonstrated that MSCs do not significantly differentiate to hepatocytes after a 7 day coculture
period. However, we can no rule out that MSCs have not differentiated into other cell types or
underwent possible functional changes in their phenotype during coculture. One challenge in
monitoring the fate of MSCs in coculture is that there are no relevant secreted biomarkers that
truly correlate to the functional state of these cells in vitro.
Given that MSCs could stabilize hepatocellular function in vitro and independently
secrete molecules that are therapeutic in FHF, we next determined if MSCs could be a
substitute for fibroblasts in the development of a coculture LAD. We first defined the cellular
components and their relative ratios based on known competing constraints, specifically: (1)
meeting minimal hepatic support needs; (2) maximizing the surface area of the device available
for cell seeding; and (3) minimizing the dead volume of the device. Previous analyses had
suggested a minimal hepatocyte mass necessary for artificial liver support to be approximately
10% of hepatocytes in whole liver. According to the literature, the total number of hepatocytes
in the liver of rat weighing 300g is around 5x10 8 cells 279. Based on these parameters 50x10 6
hepatocytes would be a target hepatic mass. We used 15x10 hepatocytes in order to allow
enough surface area for attachment of mesenchymal cells. We added the maximal number of
mesenchymal cells that would result in a confluent bioreactor. Since human MSCs are
significantly larger in cell size, approximately 2.5x106 MSCs were seeded compared to 30x106
3T3-J2 fibroblasts.
Post-LAD treatment, both composite devices showed reduction of liver injury biomarkers
compared with those from control groups. These data demonstrate a hepatoprotective effect of
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device therapy. In the short term, both coculture LADs were effective in the treatment of FHF.
However, the MSC+Hep-LAD provided a significant long-term survival benefit compared to
Fb+Hep-LAD. An improved survival trend was observed between the MSC-LAD and the
MSC+Hep-LAD, which can be attributed to the addition of hepatic support. The total cell
number seeded on MSC+Hep-LAD was smaller, which suggests that MSCs can minimize the
overall cell number and more importantly can potentially reduce the number of hepatocyes for
future LADs. Based on these data, we speculate that the MSC+Hep-LAD integrated two
therapeutic modalities within a single device to provide a long-term survival benefit: (1)
hepatocellular metabolism, synthesis, and secretion; and (2) MSC bioactive molecules that have
been shown to enhance hepatocyte regeneration, inhibit hepatocyte apoptosis, and modulate
the immune system.
In conclusion, these findings demonstrate the importance of non-parenchymal cells in
the cellular composition of LADs. In particular, MSCs can not only stabilizing primary cell
functions in biomedical devices, but also secrete anti-inflammatory molecules that directly
modulate systemic and tissue injury. Furthermore, the incorporation of MSCs may reduce the
total number of primary cells required for clinical application thereby expanding the number of
patients that can be treated. This in vivo evidence supports the notion of MSC+Hep-LADs as a
potential destination therapy for FHF.
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SECTION IV
MESENCHYMAL STEM CELL GRAFTS FOR TREATMENT OF AUTOIMMUNE DISEASE
OVERVIEW
Inflammatory bowel disease (IBD) has a prevalence of 1.2 million people in the U.S. alone
representing a significant burden to healthcare costs and patient morbidity/mortality28m. IBD is a
group of chronic, relapsing, and remitting intestinal inflammatory conditions, which is classified
into two major forms, ulcerative colitis (UC) and Crohn's disease (CD). Pathological hallmarks
of disease distinguish UC from CD281. UC typically involves the colorectal tissue only, with
restricted inflammation in mucosal lesions. On the other hand, CD has pan-gastrointestinal
involvement and is characterized by transmural inflammation and granulomas. Growing
evidence has demonstrated that changes in epithelial barrier function, as well as impairments in
innate and adaptive immunity increase susceptibility to the disease282. Current medical
standards of care do not specifically target self-reactive lymphocytes and therefore have
deleterious side effects281.
One exciting new avenue for autoimmunity treatment is cell-based tolerogenic therapy,
whereby the infusion of specific cell types can delete or "re-educate" lymphocytes to self283. The
central question remains: which cell type? In the following chapters we tested the efficacy of
MSCs in models of autoimmune disease and discovered that MSCs are specialized antigen
presenting cells. Chapter 8 describes the use of MSCs in a multi-organ model of autoimmunity,
where we uncovered a tissue- and bcell-specific effect in the bowel. In Chapter 9, we explored
this tropic effect in depth by infusing MSCs in an experimental model of colitis. Here we
observed a significant survival benefit in colitis-induced animals that had been treated with
MSCs and identified an increase in natural suppressor cells within associated lymph nodes.
Finally, in Chapter 10 we have demonstrated that MSCs express self protein antigens, a
phenomenon similar to other resident lymphoid tissue cells that have been previously shown to
induce tolerance in T cells in vivo.
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CHAPTER VIII
TROPIC EFFECTS OF STROMAL CELL TRANSPLANTATION IN MULTI-ORGAN
AUTOIMMUNITY
8.1. INTRODUCTION
Autoimmune disease is the result of a failure of the immune system to regulate self-
reactive lymphocytes. There are more than 80 different types of autoimmune disorders with a
variety of genetic/environmental triggers and symptomatology. These disorders affect millions
worldwide and represent a staggering burden in quality of life and healthcare costs. Current
clinical approaches to these diseases often involve non-specific immunosuppressive/modulatory
treatments, such as corticosteroids, which do not correct the etiology of the disorder and leave a
significant population refractory to therapy.
Cell-based tolerogenic therapy has gained momentum in recent years with the
identification of endogenous suppressor cells capable of inhibiting lymphocyte effector
functions28 3. Mesenchymal stem cells (MSCs), the precursor to stromal cells in the bone marrow,
have been reported to have immunosuppressive effects in vitro and in vivo. The majority of
these studies have shown that MSCs can inhibit the activation of CD3+, CD4+ T cell
proliferation and secretion of interleukin (IL)-2 and interferon (IFN)-y induced by mixed
lymphocyte reactions 87 ',284-28 6 , mitogens285,287 and receptor engagement"""123. These in vitro
studies have revealed that soluble factors secreted by MSCs may be the primary mode of
immunomodulation,8528 6 however cell contact-dependent mechanisms of suppression may also
coexist9 2,288. Regardless, the efficacy of MSC transplantation in severe acute graft-versus-host
disease (GVHD) in clinical trials demonstrates the potency of these cells as immunosuppressive
agents 13 ,84
In light of these findings, MSCs may be a viable cellular therapeutic for autoimmune
disease because of their tolerogenic properties. Recent reports have stated pre-clinical efficacy
of MSC transplantation in rheumatoid arthritis 289, experimental autoimmune
encephalomyelitis2 90,291 , and type I diabetes292, suggesting that MSCs maybe useful in a multi-
system autoimmune disorder, however the efficacy of such treatment has not been fully
explored. To this end, the goal of the present study was to determine if MSCs can suppress
autoimmune pathology in multiple tissues during active disease in Foxp3sf mice. These animals
have a spontaneous mutation in Foxp3, a forkhead-winged helix box transcription factor
specifically expressed in CD4+ CD25+ Foxp3+ regulatory T cells (Tregs), an endogenous
suppressor cell of peripheral self-reactive T lymphocytes in vivo2 93-2 95. Therefore, these
animals have a failure in one mode of peripheral tolerance, because of a deficiency in the Treg
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pool, and do not regulate self-reactive lymphocytes leading to an associated multi-organ
autoimmune disease. Self-reactive T cells can be found in many target organs of Foxp3sf
animals, such as skin, endocrine glands and the gastrointestinal (GI) tract. We screened
multiple targets of autoimmune attack after MSC transplantation and compared the specificity of
any effects to Tre transplants as a stringent control. Based on this comparative analysis, we
discovered a new MSC-specific site of therapy, the GI tract. Furthermore, we tracked infused
MSCs and observed no engraftment in the end organ, but rather gut-associated and ancillary
lymph nodes with notable differences in morphology between the two lymph node sites. Finally,
we observed systemic signs of immunosuppression after MSC treatment.
8.2. MATERIALS AND METHODS
8.2.1. Mice
C57BI/6 mice between 4 to 6 weeks of age were purchased from Charles River Laboratory.
Foxp3sf mice were purchased from Jackson Laboratory. Animals were maintained in a light-
controlled room (12-h light-dark cycle) at an ambient temperature of 25VC with chow diet and
water ad libitum. The animals were cared for in accordance with the guidelines set forth by the
Committee on Laboratory Resources, National Institutes of Health. All experimental procedures
performed were approved by Subcommittee on Research Animal Care and Laboratory Animal
Resources of Massachusetts General Hospital. Foxp3sf mice were housed and used in a
pathogen-free facility at Shriners Hospitals for Children in accordance with all applicable
guidelines.
8.2.2. Antibody and Reagents
The following antibodies used for flow cytometry were purchased from Pharmingen: CD4-APC,
CD44-FITC, CD25-PE, CD8-FITC, CD106-FITC, Flk-1-PE, CD90-FITC, and Sca-1-FITC.
Biotinylated antibodies to CD4 and CD25 were purchased from eBiosciences. Streptavidin
microbeads, CD45 and CD1 1 b microbeads along with magnetic columns were purchased from
Milenyi Biotec. For immunocytochemistry, anti-mouse a-SMA was purchased from Santa Cruz
Biotechnology. MSC expansion medium consisted of alpha-MEM without deoxyribonucleosides
and ribonucleosides (Gibco), 10% lot selected FBS (Atlanta Biologicals), 100 U/ml penicillin
(Sigma), and 100 gg/ml streptomycin (Sigma).
8.2.3. Isolation and Culture of Bone Marrow-Derived MSCs
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Bone marrow was harvested from wild-type mice after euthanization. Tibias and femurs were
dissected and the marrow space was flushed with MSC expansion medium using a 23 gauge
needle. Bone marrow plugs were collected on ice, dissociated by repeated passage through an
18 gauge needle and passed through a 70 gm filter to remove bony spicules and debris.
Approximately 50x10 6 bone marrow cells were plated on a 100 mm 2 tissue culture dish and
cultured for 3 days to allow for differential adhesion of stromal cells. Non-adherent cells were
aspirated on day 3 and the adherent population was cultured in MSC expansion medium for a
subsequent 4-10 days to achieve the maximal number of colony forming unit-fibroblast prior to
initial passage. Cells were passaged using 0.1% trypsin/0.1 % EDTA, and subcultured at a
density of 5x103 cells/cm2 . Prior to transplantation, stromal cells were then depleted of CD1 1b
and CD45 cells using magnetic activated cell sorting (MACS) per vendor's instructions.
Enhanced green fluorescent protein (eGFP)-MSCs were kindly donated by the Center for Gene
Therapy at Tulane University and grown in MSC expansion medium. All cultures were used
between passages 2-5.
8.2.4. Isolation and Analysis of Cells from Lymph Nodes and Thymii
Lymphoid organs were dissected from experimental mice and dissociated into cellular
components by mechanical disruption of the tissue into a saline solution. The cell suspensions
were centrifuged at 1500 rpm for 10 min. and were exposed to ACK lysis buffer for 1-2 minutes
to remove contaminating erythrocytes. ACK lysis buffer consisted of 8.024 mg NH4CI, 1.0 mg
KHCO3, 3.722 mg Na2EDTA.2H 20 in a 1 liter solution of deionized H20 adjusted to a pH of 7.4.
The solution was neutralized with serum containing medium and pelleted. Cells were
resuspended in a blocking solution containing 0.5% BSA and antibodies to the Fc receptor
CD16/32. This cellular preparation was incubated with specific primary antibody combinations
for 30 minutes at 4 degrees C. After incubations, the cells were pelleted and resuspended in
buffer and analyzed using a flow cytometer (FACSCalibur, Becton Dickinson). For the isolation
of CD4+ CD25+ splenocytes, we used MACS protocols per vendor's instructions to enrich
splenocytes of regulatory T cells.
8.2.5. Enzyme-Linked Immunosorbant Assays (ELISAs)
Peripheral blood was collected from animals by cardiac puncture and centrifuged at 1500 rpm
for 15 minutes to collect serum. Serum was analyzed for IFN-yand interleukin IL-10 by ELISA.
Mouse IFN-y capture antibody (BD Bioscences) diluted at 2 gg/ml in carbonate buffer (pH 9.0)
was physisorbed on 96 well plates at 40 C overnight. Plates were washed with PBS with 0.1%
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Triton X-100 (Sigma) and blocked with borate-buffered saline (pH 8.0)/2% bovine serum
albumin (Sigma) at room temperature for 2 hours. Standards of mouse recombinant IFN-y (R&D
Systems) and samples were loaded and incubated at 40 C overnight. Plates were washed and
incubated with biotin anti-IFN-y (1 l.g/ml; BD Biosciences) at room temperature for 45 minutes.
Plates were washed and incubated with horseradish peroxidase conjugated to avidin (1:1000 in
BBS/2% BSA; BD Bioscences) for 45 minutes. Plates were washed and incubated with citrate
buffer supplemented with ABTS (Sigma) and 30% hydrogen peroxide, colorized and read at 415
nm on a microplate reader. ELISA for mouse IL-10 (BD OptiEIA IL-10 kit) was performed per
vendor's instructions. Each animal's serum was tested in triplicate and data is representative of
4 animals per group for each cytokine analyzed.
8.2.6. Histology
Tissue from the distal ileum, pancreas and liver was harvested from animal groups, one week
after treatments. Tissue was fixed in 10% buffered formalin, embedded in paraffin, sectioned to
6-gm thickness, and stained with hematoxylin and eosin. Images are representative of 6
animals per group for the distal ileum and 4 animals for each other tissue.
8.2.7. Immunohistochemistry
Tissues of interest were harvested and placed in a solution of 4% paraformaldehyde and 10%
sucrose for 3 hours. Samples were then transferred to a 30% sucrose solution and left
overnight to allow for full penetration of the cryoprotectant. Tissues were then embedded in
OCT, frozen, and sectioned. Eight-micron thick sections of fixed tissue were washed 3 times in
PBS for 15 minutes and blocked with a buffer containing 5% donkey serum and 0.1% Triton X-
100 for 30 minutes at room temperature. Slides were washed again with blocking buffer and
then incubated with a primary anti-eGFP antibody (Molecular Probes, clone 3EH) at a 1:250
dilution overnight at 4 degrees. After washing with PBS, a secondary donkey anti-rabbit
antibody conjugated to Cy3 at a 1:500 dilution in blocking buffer for 30 minutes at room
temperature was used for detection. Note that detection of eGFP using this method of indirect
immunofluorescence with the stated secondary antibody results in a red signal rather than a
green signal, which was better for visualization purposes. The sections were then washed 3
times with blocking buffer and PBS and developed using 3,3'-diaminobenzidine. All histology
images were captured on a Nikon Eclipse E800 upright microscope.
8.2.8. Digital Cell Cluster Quantification
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Quantification of cell clusters in stained sections was performed on 5 random 40x images per
section where at least one cluster was found in that section. Ten sections were made for each
tissue from each animal and 3 animals were used in cell trafficking studies. Clusters were
visually distinct and defined as a local aggregate of at least 10 eGFP+ cells.
8.2.9. Statistical Analysis
For flow cytometry data, median values ± standard deviations are reported. For cytokine
analysis, results were analyzed using an unpaired Student's t-test given an unskewed data set
and assuming a normal distribution. Significance values of P<0.05 were considered statistically
significant. Results are given as a mean ± standard error of the mean.
8.3. RESULTS
8.3.1. Purification and Characterization of Marrow Stromal Subpopulation
The anchorage-dependent population of bone marrow cells, also known as stromal cells,
consists of a relatively heterogenous mixture of cells (Figure 8.1A). Evidence exists that a
subpopulation of this heterogeneous mixture, which displays phenotypic similarities to MSCs, is
responsible for the immunosuppressive effect of the marrow stroma. For the current study, we
purified this subpopulation by immunodepleting adherent bone marrow cells of CD 1 b+ and
CD45+ cells using MACS. The CD1 1 b+ CD45+ cell fraction resembled macrophage-like cells
(Figure 8.1B), while the negative fraction had a more fibroblastoid morphology (Figure 8.1C).
These fibroblastoid cells were found to be positive for a-smooth muscle actin expression by
immunocytochemistry (Figure 8.1D). The immunophenotype of the CD1 1 b- CD45- fraction was
CD106+, Flk-1+, Sca-1+ and CD90- as determined by cytofluorimetry (Figure 8.1E-H). The
phenotype of these cells is identical to C57BI/6 MSCs296,297 and will be referred to as MSCs
herein for the sake of convenience.
8.3.2. MSCs Suppress Histopathological Changes of Target Organs in Foxp3sf Mice
We evaluated the immunosuppressive efficacy of different cell-based transplantation strategies
in Foxp3sf mice, which have widespread autoimmunity due to inefficient peripheral tolerance.
Formulations using MSCs were compared with Tregs - the suppressor cells that are deficient in
Foxp3sf mice because of the genetic mutation. At 4 weeks of age, Foxp3sf mice were infused
with 3x10 5 cells MSCs intraperitoneally (i.p.) and were sacrificed 1 week post-infusion. For
comparison, we used age- and sex-matched mice of the following groups: (a) wild-type C57BI1/6,
(b) Foxp3sf treated with vehicle, and (c) Foxp3sf mice treated with MACS-selected CD4+ CD25+
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Figure 8.1. Morphology and Immunophenotype of Infused Subpopulation of Marrow
Stroma. Phase contrast images of adherent bone marrow cells (A) prior to immunodepletion.
Cells were negatively immunodepleted against CD11b and CD45 using MACS. Fractions of
CD1 1b+, CD45+ cells (B) and CD1 1 b-, CD45- cells (C) are shown. (D) Immunocytochemistry of
CD1 1 b-, CD45- adherent bone marrow cell fractions showing positive reactivity to a-SMA. Flow
cytometry analysis of adherent bone marrow cells after immunodepletion of CD1 1 b+ and
CD45+ cells. Histogram analysis of CD106 (E), CD90 (F), Flk-1 (G) and Sca-1 (H). Solid
distributions represent cells stained with antibodies compared to unstained cells.
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T lymphocytes (3 x 10s5 cells) - a Treg phenotype, and hence the most stringent control. Self-
reactive T cells can be found in many target organs of Foxp3sf animals, such as skin, endocrine
glands and the GI tract. We harvested the distal ileum, pancreas and liver, as representative
tissue targets of autoimmunity and examined histopathology. The most dramatic histological
change was found in the distal ileum. Foxp3sf animals treated with MSCs regenerated crypt
structures similar to wild-type while untreated and Tregs-treated animals failed to do so (Figure
8.2A-D). We observed this GI finding in 4 of 6 animals tested, whereas no vehicle treated mice
and only one Treg-treated mouse showed any signs of regrowth.
8.3.3. Reduction of Cellularity and Activated T Cells in Mesenteric Lymph Nodes of
Foxp3' f Mice after MSC Infusion
We then analyzed lymphoid tissue associated with the intestine for changes in disease.
Mesenteric lymph nodes (MLNs) are typically enlarged when there is adjacent inflammation of
intestinal tissue. We harvested MLNs and measured total cellularity at 7 days post-infusion of
cell transplants. Representative gross histology for MLNs within each group is shown in Figure
8.3A. Draining MLNs remained hypercellular in Foxp3sf mice when treated with vehicle (73.5 ±
8.1 x 106 cells) were compared to wild-type (17.8 ± 2.8 x 106 cells), whereas cellularity was
reduced by MSC (48.1 ± 7.3 x 106 cells) or Tregs treatment (63.2 ± 5.3 x 106 cells) when
compared to mutant mice (Figure 8.3B). Lymph node cells were isolated, gated for CD4
expression, and analyzed for the cell surface activation marker, CD44 using flow cytometry.
Compared to wild-type mice (18.8% ± 3.8), the majority of CD4+ lymph node cells were
activated in mutant mice (83.4% ± 4.0; Figure 8.3C). The CD44h population was reduced in
both MSC and Treg treatments (57.9% ± 8.1 versus 69.2 ± 7.0, respectively). Overall, treatment
with MSCs was qualitatively more remarkable in effect than with Tregs with respect to
suppressing local inflammation in the MLN.
8.3.4. MSCs do not Engraft in Intestine, but Rather Ancillary and Gut-Associated Lymph
Nodes
After a tissue- and cell-specific effect of MSC treatment was observed, we attempted to
delineate whether this therapy was due to MSC-mediated regeneration of gut tissue versus an
alteration of the immunological attack at the intestine. We infused 3x105 eGFP-labeled MSCs
i.p. and harvested the distal ileum at 7 days post-treatment. We found no appreciable eGFP+
cells in the intestinal tissue at the 7-day time point (Figure 8.4A). On the contrary, eGFP+ cells
were detected in the MLN at a significant proportion of the graft relative to intestinal tissue
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Figure 8.2. Histological Changes in Ileal Tissue of Foxp3st Mice after MSC Transplant.
Cross sections of distal ileum comparing wild-type (A) to Foxp3sf mice treated with i.p. infusions
of saline (B), Tregs (C), or MSCs (D). Inset images present higher magnification of boxed regions
in original micrographs. Scale bars equal 250 lim (4x magnification). Data representative of 3
independent trials with a total of N=6 per group.
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Figure 8.3. MSC Treatment Reduces MLN Cellularity and Activated T Cell Number.
Lymph nodes were harvested 7 days post-cell infusion of MSCs or Tregs and compared to
untreated and wild-type nodes. (A) Gross histology of lymph nodes from mice. (B) After tissue
harvesting, cellularity was determined using a Coulter Counter. (C) Lymph node cells were
analyzed for CD4 and CD44 expression using flow cytometry. Data represent mean ± s.e.m. of
N=5 per group.
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(Figure 8.4B). Clusters of eGFP+ cells were found in a network with each cell having a distinct
fibroblastoid morphology (Figure 8.4B inset). To determine if this engraftment was specific to
MLNs in this model of autoimmune disease, we harvested inguinal lymph nodes as an ancillary
site. Transplanted cells were also found in inguinal nodes (Figure 8.3C). Semi-quantitative
image analysis of lymph node engraftment, as assessed by the number of clusters counted,
showed no differences between the two sites (Figure 8.4D). However, the majority of the cells
found within inguinal lymph nodes were not fibroblastoid in morphology and did not form a
network.
8.3.5. Systemic Evidence of Immunosuppression in Foxp3"f Mice after MSC Treatment
Since we had observed engraftment of MSCs in lymph nodes in two anatomically remote sites,
we hypothesized that the cell transplant may have had systemic immunological effects. Two
circumstantial measures of systemic immunsuppression are: (1) an increase in the percentage
of newly formed CD4+CD8+ thymocytes; and (2) a change in the serum cytokine profile. After
cell treatment we observed no difference in total thymocyte number (data not shown), but found
that the number of CD4+CD8+ thymocytes of animals treated with MSCs (74.0% + 5.6) were
increased relative to wild-type (69.2% ± 5.5), untreated (63.0% ± 7.6), and Tregs treated (69.2%
+ 3.1) animals (Figure 8.5A). In addition, serum IFN-y. (Figure 8.5B), an indicator of cell-
mediated immune responses and IL-10 (Figure 8.5C), a potent immunosuppressive cytokine,
were shifted in favor of a global downregulation of the immune system after MSC treatment.
8.4. DISCUSSION
The bone marrow stroma has been identified as a unique site of regenerative and
immunosuppressive cells. Many studies have reported inhibition of T lymphocyte functions
when cocultured with MSCs by cell contact-dependent and independent mechanisms. However,
the use of MSCs as a cellular therapeutic for autoimmune diseases has not been fully explored.
We chose to stringently test the efficacy of MSCs as a treatment for autoimmune disease by
transplanting these cells in Foxp3sf mice, which lack one mode of peripheral tolerance due to a
genetic mutation in the transcription factor Foxp3 that leads to a deficiency in regulatory T cells.
Since it has been reported that MSCs can induce the proliferation of CD4+ CD25+ T
lymphocytes in vitro888'9,298, albeit without rigorous analysis of Foxp3 protein expression, the use
of Foxp3sf mice as a testbed should not be confounded by such an indirect pathway of
therapeutic benefit. As a corollary to our study, we attempted to use our animal model deficient
in the Tregs pool to test this hypothesis in vivo. In wild-type mice, 5% of splenocytes were
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Figure 8.4. Evaluation of eGFP+ MSC Engraftment in Foxp3sf Mice. Tissues were
harvested at 7 days post-treatment. Representative immunofluorescent images of the (A) distal
ileum, (B) MLN, and (C) inguinal lymph node. eGFP is detected in red and DAPI is used as a
nuclear counter-stain. (D) Semi-quantitative analysis of the number of eGFP+ cell clusters in
MLNs and inguinal nodes.
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Figure 8.6. Cotransplantation of MSCs and Tregs Increases Splenic Engrafted Tregs.
Splenocytes were harvested after 7 days of cell treatment and Foxp3+ cells were analyzed by
flow cytometry. Wild-type C57B1/6 mice have an endogenous Tregs compartment that is 5% of
the spleen (A). Knockout mice have no Foxp3 expression, which is not altered by Foxp3-
mMSCs (B). I.p. infusion of 3x10 5 cells Tregs resulted in 6% of splenocytes showing a positive
reactivity for Foxp3. A 1:10 cell ratio of MSCs to Tregs led to an expansion of Foxp3+
splenocytes.
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reactive to Foxp3 demonstrating a compartment of peripheral splenocytes is devoted to
maintaining tolerance (Figure 8.6A). Foxp3sf mice treated with MSCs showed no Foxp3
expression in the spleen (Figure 8.6B), consistent with the genetic defect in these animals and
the finding that MSCs do not express Foxp3. Infusion of 3x105 Tregs into mutant animals showed
a detectable signal in the splenic Tregs pool (Figure 8.6C). In contrast, infusion of 2.5x105 Tregs
and an adjuvant dose of MSCs (2.5 x 104 cells) resulted in an approximate doubling of the Tregs
pool (Figure 8.6D). This is the first preliminary evidence showing that MSCs can expand the
Tregs pool in vivo using an animal model deficient in Tregs although we caution rigorous
interpretation of the results given the small number of animals used in the groups (N=2). More
importantly, the current study does not rule out a MSC-Treg interaction in vivo that can amplify
the immunosuppressive efficacy of MSC transplantation by secondary effects of boosting
endogenous Treg-mediated peripheral tolerance. Our preliminary results suggest this may be
a real phenomenon in vivo and we will further explore this phenomenon in Chapter 9.
We infused MSC transplants in a multi-organ autoimmunity model and screened various
tissue targets of autoimmune attack. Since Foxp3 sf mice are essentially moribund 4-6 weeks
after birth because of the magnitude and nature of their autoimmunity, this study looked at
short-term benefits of cell transplantation during active disease. We provide the first evidence
that MSCs can specifically ameliorate autoimmune enteropathy. We have shown that MSCs
infused into these autoimmune mice led to striking improvements in the distal ileum. The
regrowth of villous structures was observed 7 days after MSC treatment, whereas Tregs treated
animals still had visible disease. There are different potential explanations for ileal regrowth
based on experimental evidence. Previous studies have shown that bone marrow-derived
mesenchymal cells can give rise to newly-formed myofibroblasts and vasculature in a
physiological response to chemically-induced colitis in mice and humans2 ',300. Furthermore,
we and others have shown that MSCs can promote regeneration by paracrine stimulation of
endogenous self-replicating tissue cells 120 and stem cell populations142. Taken together, our
result could have been due to cell homing to the distal ileum and: (a) a direct regenerative
response of MSCs, (b) paracrine signals to promote intestinal stem cell expansion and
differentiation, or (c) inhibition of immunological attack on the tissue and allowance for natural
regeneration of villi. We did not observe any infused eGFP-MSCs in the distal ileum ruling out
direct or local, paracrine interactions between MSCs and intestinal cells. The natural
replenishment of cells in the GI tract during normal tissue turnover is primarily due to an
endogenous stem cell population located in the crypt, which in the mouse can occur in 2-3
days301-303. Thus, it is likely that the regeneration of villi was not due to MSC differentiation or
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Figure 8.6. Cotransplantation of MSCs and Tregs Increases Splenic Engrafted Tre,.
Splenocytes were harvested after 7 days of cell treatment and Foxp3+ cells were analyzed by
flow cytometry. Wild-type C57BI/6 mice have an endogenous Tregs compartment that is 5% of
the spleen (A). Knockout mice have no Foxp3 expression, which is not altered by Foxp3-
mMSCs (B). I.p. infusion of 3x105 cells Tregs resulted in 6% of splenocytes showing a positive
reactivity for Foxp3. A 1:10 cell ratio of MSCs to Tregs led to an expansion of Foxp3+
splenocytes.
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paracrine actions, but rather an inhibition of the immune response to the tissue and repopulation
of parenchymal cells by crypt stem cells.
To support the concept that MSCs may have modulated the immune reaction at the GI
tissue target, we analyzed gut-associated lymph nodes. We observed a decrease in MLN
cellularity and activated CD4+ lymph node cells, which support this hypothesis. Inhibition of T
cell activation by MSCs may be the result of selective apoptosis of activated T cells, prevention
of further T cell activation by direct or indirect (eg. licensing tolerance-inducing antigen
presenting cells1 1o) mechanisms or dedifferentiation of activated T cells, although more
mechanistic studies are warranted. These results are consistent with the benefit seen with
MSCs in severe GVHD, a condition which is thought to matriculate from the Peyer's patches of
intestinal tissue3 4.
We identified MSCs organized in clusters in engrafted tissues, specifically lymph nodes.
Others have also described clusters of engrafted human fetal MSCs that had homed to the bone
marrow after in utero treatment of children with osteogenesis imperfecta3 05, although it was not
determined if this a clonal population derived from a single engrafted cell or a local distribution
of transplanted cells based on circulatory patterns intrinsic to the tissue of study. Interestingly,
there were no relative differences in the number of clusters in MLNs when compared to an
anatomically distinct lymph node bed in the inguinal space. Instead, MSCs were
morphologically different within the MLN tree displaying spiculated projections and formed a
fibroblastoid network. The relevance of this morphological difference is unclear, although we
speculate that the engrafted cells seemed more differentiated and integrated into the stroma of
the MLN and this may be relevant to MSC functions necessary for therapeutic gains. In the
treatment of experimental encephalomyelitis, MSCs were also localized in secondary lymphoid
organs including the spleen and lymph nodes290, the latter finding of which was reproduced and
extended to other lymph nodes in this study. Prior work has shown trafficking of peritoneal
infused lymphocytes to MLNs and pancreatic lymph nodes3°6 suggesting these may be likely
sites of tolerance induction after MSC transplantation assuming similar homing mechanisms
exist in MSCs. Ultimately, these data suggest certain "tropic" aspects of MSC transplantation
efficacy that may hinge upon endogenous properties of the host, namely: (a) a tissue-
associated lymphoid bed for engraftment and immunomodulation, and (b) a host-autonomous
system of regeneration to restore tissue function and homeostasis.
Moreover, we observed an increase in the number of CD4+ CD8+ thymocytes and
changes in the serum cytokine profile after MSC infusion. T cells are born in the thymus and
studies have shown that the mesenchyme is integral in the proper education of T cells307. In
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addition, other investigators have shown that infused MSCs can migrate and functionally engraft
at lower numbers in the thymus83. Our study only examined engraftment in lymph node tissue,
so a more comprehensive view of MSC engraftment in this, and other, autoimmunity models
may elucidate the role of transplanted cells on thymic cell output and function. In Chapter 2, we
have shown that human MSCs secrete immunomodulatory molecules that can provide a
significant survival benefit to rats undergoing acute liver failure121 and also shift the serum
cytokine profile 120 independent of cell contact mechanisms. We infer the change in the cytokine
profile in the study may be a paracrine effect of engrafted or lysed infused cells that resulted in
global serological differences, although there are obvious pathological and pharmacological
differences between the former study and the current one to consider. More importantly, these
studies may indicate a systemic immunosuppressive effect after MSC transplantation. It may be
argued that successful treatment of autoimmunity may require a systemic-scale approach and
this study validates MSC therapy within such a context, however general concerns of
immunocompromise should be considered. Other reports have observed a loss of
immunosurveillance of cancer growth9 '"17 and pathogens after MSC infusion305 , which is a
major concern with MSC immunomodulation. Comparative studies between MSCs and other
immunosuppressive treatments for autoimmune diseases are needed to determine the relative
differences in risk of cell-based versus molecular therapeutic strategies.
In conclusion, we report the first use of MSCs in a multi-organ model of autoimmunity,
including a MSC-specific amelioration of autoimmune enteropathy. These results will hopefully
empower future investigations in the use of MSCs for the treatment of IBD as well as other
autoimmune disorders. In the next chapter, we further delve into the effects of MSC transplant
in a more defined model of IBD.
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CHAPTER IX
MESENCHYMAL STEM CELL GRAFTS
PREVENT AND AMELIORATE EXPERIMENTAL COLITIS
9.1. INTRODUCTION
Inflammatory bowel disease (IBD) is a group of chronic, relapsing, and remitting intestinal
inflammatory condition, which is classified into two major forms, ulcerative colitis (UC) and
Crohn's disease (CD). Pathological hallmarks of disease distinguish UC from CD281. UC
typically involves the colorectal tissue only, with restricted inflammation in mucosal lesions. On
the other hand, CD has pan-gastrointestinal involvement and is characterized by transmural
inflammation and granulomas. Growing evidence has demonstrated that changes in epithelial
barrier function, as well as impairments in innate and adaptive immunity increase susceptibility
to the disease282. IBD has a prevalence of 1.2 million people in the US alone representing a
significant burden to healthcare costs and patient morbidity/mortality 280 . Current medical
standards of care do not specifically target self-reactive lymphocytes and therefore have
deleterious side effects281 .
There is evidence of an endogenous role of non-hematopoietic cells derived from the
bone marrow in intestinal injury. Intestinal subepithelial myofibroblasts (ISEMFs) are found in
the lamina propria of the intestine juxtaposed to epithelial cells, and are thought to intimately
interact with the parenchymal and stem cell populations of the tissue. They are fenestrated in
tight apposition to the intestinal crypts and their projections pass through the lamina propria of
the gut to merge with the vasculature, contacting perivascular cells and the endothelium via
adherens and gap junctions. ISEMFs appear in the human embryo at the 21st week of gestation,
and it has been suggested that their origin might be from the neural crest308. Interestingly,
recent reports have observed an initial expansion of mesenchymal progenitor cells within the
neuroepithelial germ layer of the neural crest23 and that bone marrow-derived cells give rise to
ISEMFs in natural, healthy intestinal tissue in both the mouse and human308 . Intestinal
myofibroblasts are believed to form the stroma that maintains the intestinal epithelial stem cell
self-renewal and turnover as well as regulate epithelial cell proliferation via
mesenchymal/epithelial cell interactions3 9. In a healthy gut, intestinal myofibroblasts exist as
transiently differentiated, quiescent cells. However, in inflamed tissue they become activated
and mitotic and upregulate soluble and insoluble mediators of inflammation69 '31 0' 311
There are few reports documenting the natural role of non-hematopoietic cells from the
bone marrow in IBD. In one study, these cells have been observed to migrate from the marrow
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and contribute to the regenerative response to chemically-induced colitis in vivo300, namely the
generation of ISEMFs. In order to study this phenomenon, myeloabletive deletion of the bone
marrow followed by sex-mismatched bone marrow transplant led to the detection of Y+, non-
hematopoietic cells that gave rise to ISEMFs in high proportions during human and mouse
disease300. Yet, it is unclear if non-hematopoetic cells that have homed to the injured intestine
from the bone marrow or that naturally exist in associated lymph nodes modulate the
inflammatory reaction at the intestinal tissue level thereby providing endogenous repair
programs to take place.
A progenitor to many adult mesenchymal-derived cells has been postulated to exist and
maintain residence within the bone marrow throughout adulthood312. These cells have been
referred to as multipotent marrow stromal cells or mesenchymal stem cells (MSCs). In addition
to their regenerative capacity, MSCs have been shown to have potent immunomodulatory
abilities87,284-286 and have been experimentally and clinically tested in immunological
diseases13,84, including autoimmune pathologies289292. We tested the efficacy of MSCs in a
multi-organ autoimmunity model caused by a deficient in regulatory T cells, which have a failure
in one mode of peripheral tolerance, and found histological improvements in intestinal tissue
(Chapter 8). In addition, we found engraftment of MSCs in gut-associated lymph nodes and
inhibition of activated T cells within this tissue space. In this chapter, we further explore the
utility of MSC transplants in a more specific model of chemically-induced colitis. We observe
physical evidence of colitis prevention and amelioration and that MSC grafts lead to increased
numbers of regulatory T cells within intestinal lymph nodes.
9.2. MATERIALS AND METHODS
9.2.1. Mice
C57B1/6 mice between 4 to 6 weeks of age were purchased from Charles River Laboratory.
Animals were maintained in a light-controlled room (12-h light-dark cycle) at an ambient
temperature of 25C with chow diet and water ad libitum. The animals were cared for in
accordance with the guidelines set forth by the Committee on Laboratory Resources, National
Institutes of Health. All experimental procedures performed were approved by Subcommittee
on Research Animal Care and Laboratory Animal Resources of Massachusetts General
Hospital.
9.2.2. Cell Culture
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Syngenic MSCs were kindly donated by the Center for Gene Therapy at Tulane University.
MSC expansion medium consisted of alpha-MEM without deoxyribonucleosides and
ribonucleosides (Gibco), 10% lot selected FBS (Atlanta Biologicals), 100 U/ml penicillin (Sigma),
and 100 tg/ml streptomycin (Sigma). NIH 3T3-J2 fibroblasts were a kind gift from Dr. Howard
Green and cultured according to donor's protocol.
9.2.3. Mesenchymal Stem Cell Conditioned Medium (MSC-CM)
For the generation of MSC-CM, cells were allowed to grow to 70-80% confluence, washed
thoroughly and cultured in 15 ml serum free Dulbecco's Modified Eagle's Medium supplemented
with 0.05% bovine serum albumin. Conditioned medium was collected 24 hours later and
concentrated 25-fold using ultrafiltration units (Millipore, Bedford, MA) with a 3kD cutoff. The
conditioned medium from an equivalent of 1x10 6 cells was concentrated to 100 WI for
intravenous use in mice.
9.2.4. Colitis Induction and Cell Transplantation
C5781/6 mice (male, 6-8 weeks) were weighed, fasted for 24 hours, and re-weighed to
document baseline data. Mice were then anesthesized using a 300 uL i.p. injection of 2.5%
Avertin (40x stock: 1g/mL of tribomoethyl alcohol solubilized in tertiary amyl alcohol; Sigma).
Prior to IBD induction, MSCs or MSC conditioned medium were infused by tail vein injection or
i.p. at different cell doses. Fibroblast infusion and saline infusions will serve as controls. To
induce colitis, mice were administered 100 uL of a haptenating agent, trinitrobenzosulfonic acid
(TNBS), at a 1:1 ratio of 5 mg/mL of TNBS to 100% ethanol (used to disrupt the epithelial
barrier) per rectum. The mixture was slowly administered into the lumen of the colon via a 22g
catheter (Becton Dickinson) fitted onto a 1-mL syringe with the animals under Avertin
anesthesia, and mice were then kept in a vertical position for 30 seconds. Control mice
received 50% ethanol in phosphate-buffered saline (PBS) using the same technique as
previously described. After induction, mice were observed for weight changes and mortality on
a daily basis. In therapeutic trials, cells were infused two days after TNBS induction and similar
physical parameters were measured.
9.2.5. Test for Fecal Occult Blood
Fresh feces from animals was procured three days after TNBS induction and tested for fecal
occult blood per vendor's instructions (Hemoccult Sensa, Beckman Coulter). The tests were
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read by an independent observer and given a semi-quantitative score of 0-5 as shown by the
color indicators provided by the manufacturer.
9.2.6. Isolation and Analysis of Lymph Node Cells
Lymph nodes were dissected from experimental mice and dissociated into cellular components
by mechanical disruption of the tissue into a saline solution. The cell suspensions were
centrifuged at 1500 rpm for 10 minutes and were exposed to ACK lysis buffer for 1-2 minutes to
remove contaminating erythrocytes. The solution was neutralized with serum containing
medium and pelleted. Cells were resuspended in a blocking solution containing 0.5% BSA and
antibodies to the Fc receptor CD16/32. This cellular preparation was incubated with anti-Foxp3-
FITC (eBiosciences) and analyzed using flow cytometry.
9.2.7. Gross and Microscopic Histology
Lymph nodes and intestinal tissue from animal groups were harvested one week after
treatments. Lymph nodes and the colon, dissected from the ileocecal junction to the sigmoid
rectum, were prepared for gross histological imaging using a digital camera and subsequently
prepared for microscopic evaluation. Intestinal tissue was fixed in 10% buffered formalin,
embedded in paraffin, sectioned to 6-lam thickness, and stained with hematoylin and eosin.
9.3. RESULTS
9.3.1. MSC Transplant, and not MSC-CM, Inhibits Physical Evidence of TNBS-lnduced
Colitis
We have previously demonstrated that: (a) human MSC secreted factors can reverse
hepatotoxin-induced fulminant hepatic failure and (b) mouse MSC transplants can inhibit
autoimmune enteropathy without a need for regulatory T cells. In this study, we sought to test
the efficacy of these treatments (ie. MSC molecules vs. MSC transplant) in a more classical
model of colitis. One such model that leads to a TH1 immune response resembling CD can be
induced by administering TNBS solubilized in ethanol (disrupts epithelial barrier) directly into the
colon. TNBS is a hapten that binds to endogenous proteins and forms neo-antigens which are
the target for autoimmune attack. In a prevention trial, animals were randomized and treated
with saline (internal control), or unit doses of NIH-3T3 fibroblasts (cell control) or mMSCs.
Animals then were anesthesized and administered a 1:1 chemical mixture per rectum consisting
of either ethanol:saline (sham control) or ethanol:TNBS.
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Intravenous treatment with 1U of MSC medicine improved all physical evidence of colitis
after MSC transplantation. A significant survival benefit was observed, with 94% of animals
surviving after TNBS induction when treated with MSCs, compared to 47% and 33% when
treated with vehicle or a fibroblast control, respectively (Figure 9.1A). Approximately 63% of
mice survived after infusion of 0.25U of MSCs, which was not statistically significant but
suggested survival was a function of MSC dose. No significant improvement in survival was
seen when MSCs were infused intraperiotoneally (Figure 9.1B) compared to controls. In
addition, we measured animal weight and fecal occult blood as indicators of disease. A
maximal 22% reduction in body weight loss was observed post-fast in animals treated with
vehicle or 1U of fibroblasts i.v. with a final 14% loss at the study endpoint (Figure 9.1C). MSC-
treated animals had a maximal 13% loss of body weight post-fast with a 1% gain in body weight
at the study endpoint. Similarly, stool guiac tests performed on day 3 post-induction showed
nearly complete absence of occult blood in feces of MSC treated mice when compared to
vehicle treatment (Figure 9.1D). Finally, MSC-CM infused prior to induction of disease did not
provide an equivalent survival benefit to mice suggesting that secreted factors alone are not
responsible for the therapeutic efficacy of an MSC transplant in colitis (Figure 9.1 E).
9.3.2. Prevention of Histopathological Changes in Target Organs by MSCs
At the study endpoint, we examined histopathological changes in the colon and associated
lymph nodes of the surviving animals. Vehicle treated animals had macroscopically enlarged
lymph nodes and thickened colonic walls (Figure 9.2A), which is likely due to edematous fluid,
with major lesions and ulcerations found in distal half of the colon. On the other hand, mice
transplanted with MSCs showed no gross signs of disease and were qualitatively similar to mice
that had minor inflammation caused by the local ethanol infusion (Figure 9.2B-C). Mesenteric
lymph node cellularity and colonic weight/length ratio were quantified and listed in Table 9.1.
Colonic tissue was microscopically examined using conventional H&E methods. Mice treated
with MSCs had few, if any, inflammatory infiltrates, crypt abscesses, goblet cell thickening, and
loss of tissue architecture when compared to other treated groups (Figure 9.2D-F). Pathological
scoring of the tissue quantitatively confirmed the significant differences in histology (Table 9.2).
9.3.3. MSC Transplantation Leads to Higher Numbers of Foxp3+ Cells in Mesenteric
Lymph Nodes
Based on our prior observation in Chapter 8 of regulatory T cell (Treg) expansion after co-
transplant of Tregs and MSCs in Treg-deficient mice, we enumerated the Treg cell number in colitis-
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Table 9.1. Quantitative Histological Analysis of Colitis-Induced Mice
Treatment Arm Mesenteric Lymph Node Cellularity Colonic Weight/Length Ratio
(x106 cells/node) (mg/cm)
Ethanol 32.59 ± 1.53 35.69 ± 4.72
TNBS 63.07 ± 1.53 83.82 ± 10.66
MSC-CM 53.82 ± 2.83 67.24 + 7.21
Fibroblast (iv, 1 U) 65.93 ± 10.92 77.55 ± 11.93
MSC (iv, 1 U) 37.84 + 6.67 42.10 ± 3.86
Note: 1U = 1x10 6 cells
induced animals at the study endpoint. Indeed, we saw a preservation of Treg frequency in the
lymph nodes of MSC-treated mice consistent with our hypothesis that MSCs may "amplify" their
immunosuppression by indirectly expanding endogenous suppressor T cells
(Figure 9.3A). When infused with 1U of MSCs, 2.6% of lymph node cells from TNBS-induced
mice were Foxp3+ compared to 0.6% and 0.9% in saline and mock cell treated animals,
respectively. Moreover, infusion of MSC-CM slightly increased Foxp3+ cells to 1.2% but this
was not statistically significant. We further quantified the absolute number of Tre, given that
there were quantifiable differences in lymph node cellularity (Figure 9.3B). Treatment with
MSCs had an approximately 2.5 fold absolute number of Foxp3+ cells (9.8 ± 1.7 x 106 cells)
when compared to saline treated animals (3.7 ± 0.5 x 106 cells).
9.3.4. Amelioration of Colitis by MSC Graft After Disease Onset
After identifying an optimal cell dose and analyzing the histopathological response to MSC
transplantation in a preventative setting, we tested MSCs therapy after disease onset, which is a
more clinically relevant case. We chose to infuse cells two days after TNBS induction, based on
our prevention trial which showed that vehicle treated animals began to die at this time point.
Intravenous infusion of 1U of MSCs led to 80% of animals surviving, which was still significant
compared to controls (Figure 9.4A). In addition, the body weights of MSC treated animals
showed only 9% loss in body weight at the study endpoint compared to a 14% loss in control
treatments (Figure 9.4B).
Table 9.2. Pathological Analysis of Microscopic Colon Sections
Treatment Arm Average Pathology Score (N=4 per group, max 18)
Ethanol 0
TNBS 9
MSC (iv, 1 U) 0.8
Fibroblast (iv, 1 U) 6
MSC-CM 2
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Figure 9.1. Prevention of TNBS-Induced Colitis by MSC Transplantation. Kaplan-Meier
analysis of cell-based transplantation strategies with intravenous (A) or intraperitoneal cell
delivery (B). Percentage of original body weight loss of mice over time (C). Semi-quantitative
fecal occult blood testing of experimental groups (D). Kaplan-Meier analysis of MSC-CM
prevention trial in colitis (E).
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9.4. DISCUSSION
In Chapter 8, we demonstrated a site-specific benefit in the intestine after MSC transplantation
in a multi-organ autoimmunity model. In this study, we further elaborated on these results using
a chemically-induced model of colitis. MSC transplantation was found to increase survival prior
to and after the onset of disease. Interestingly, only intravenous treatment led to a significant
survival benefit which is contrary to our intraperitoneal treatment of Foxp3sf mice in the previous
chapter. Since no distinct survival benefit was observed in Foxp3sf mice compared to other
treatments, the histological differences of the study were not a hard endpoint but rather a useful
measure of potential tropism of MSC grafts. Indeed, other reports using antigen-based
tolerance strategies also confirmed that the route of drug administration was crucial to the
therapeutic outcome. Specifically, intravenous infusion of antigen-coupled cells to induce
deletional or anergic tolerance was the only delivery method that could impact disease, whereas
intraperitoneal delivery did not show significant benefits and subcutaneous implantation actually
aggrevated the disease313 . This issue of delivery may be generalized to other tolerance
inductive methods and should be considered in future endeavors in the field.
Our previous studies in Chapters 2-5 demonstrated that MSCs can secrete bioactive
molecules that can modulate the inflammatory reaction to liver injury. We did not see any
benefit to mice treated with MSC-CM prior to colitis induction suggesting that secreted
molecules alone did not infer any therapeutic value in this model of colitis. However, we cannot
rule out a paracrine effect of MSC therapy because of issues such as the species source of
MSC-CM, time of delivery, and the challenge of studying paracrine effects in situ.
MSCs have been shown to generate suppressor cells of both the CD4+ and CD8+
lineages in vitro88,89,298, however few reports exist of this phenomenon in vivo. We had
previously shown preliminary evidence in Chapter 8 that cotransplantation of MSCs and Tregs at
a 1:10 cell ratio leads to an increase in the number of engrafted Tregs in the spleen. In this study,
we provide definitive proof that infusion of MSCs can maintain levels of Tregs during disease.
The maintenance of Treg number could be due to: (a) an increase production of cells from nal've
T cells; (b) decreased elimination of Tregs; (c) increased proliferation of existing Tregs; and/or (d)
alterations in trafficking of Tre~s to the local area. Indeed, many of the secreted factors such as
prostaglandin E289 and nitric oxide314,3 15 that MSCs produce and that have been shown to be
involved in T cell suppression also act as mitogens for regulatory T cell conversion of peripheral
nalve T cells 316,317. In addition, a study had shown that MSCs do not only inhibit the proliferation
of T cells, but promote the survival of T cells in a quiescent state under apoptotic conditions318.
Although the details of the mechanism were poorly understood, it is likely that a similar
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protection of T cell death may also affect regulatory T cells. Moreover, peripheral Tregs have a
high turnover rate and a somewhat terminally differentiatied phenotype suggesting that they
may be the remnants of previously activated T cells319 . It is possible that MSCs may enhance
this differentiation process before or after T cells have already undergone activation by an
inflammatory stimuli.
In conclusion, we definitively show that MSC transplantation can be an effective means
to prevent and treat colitis in mice. This treatment correlated with a higher local regulatory T cell
number in gut-associated lymph nodes indicating that the immunosuppressive signature of MSC
transplantation may be amplified through the maintence of endogenous suppressor cells in vivo.
In the final chapter, we discover that MSCs belong to a larger class family of cells that naturally
have unique antigen presentation abilities known to induce T cell tolerance to self antigens in
other lymphoid organs.
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CHAPTER X
PERIPHERAL TISSUE ANTIGEN PRESENTATION BY MARROW STROMAL CELLS
10.1. INTRODUCTION
One of the central tenets of immunology states that the immune system must respond
appropriately to antigens. The immune system requires a number of checks and balances to
respond to antigens appropriately during health and disease. For protein antigens, a T cell
response is required and this necessitates a need for T cells to discriminate between self and
non-self protein antigens to thereby limit self-reactivity and autoimmune disease. This issue of
tolerance first occurs during the development of T cells in a process known as negative
selection and this tolerance education is further reinforced in the periphery.
There are resident cell populations in lymphoid organs whose function is to educate T
cells to self-antigens. These cell populations rely on a unique ability to promiscuously express
self peptide antigens synthesized within the cell itself. In other words, these cells endogenously
make peripheral tissue antigens (pTAs), which were typically thought to be "tissue-specific", in
order to induce tolerize T cells to self proteins. The first cell population shown to express pTAs
was identified in the thymus. Medullary thymic epithelial cells (mTECs) have been shown to
directly present pTAs to maturing T lymphocytes in the thymus as part of the negative selection
of thymocytes320-323. Alternatively, mTECs can serve as a local reservoir for pTAs that are
transferred to DCs and cross-presented to thymocytes32 1' ,324,325. This process of pTA expression
is regulated by the "master" transcription factor, AIRE. Current knowledge of AIRE is fairly
limited; there are few studies that have characterized the transcription factor network dynamics
and upstream signaling pathways that interact with, and regulate, AIRE. The presentation of
self peptides centrally by AIRE+ cells was recently found to be involved in the generation of
suppressor T cells, also known as regulatory T cells326. Regulatory T cells express Foxp3, a
transcription factor essential for their development and function, and promote peripheral
tolerance of self-reactive lymphocytes that have evaded thymic selection293. This observation
suggests that a pTA expressing cell can amplify regulatory T cells as an additional mode to
prevent self-reactivity.
This process of pTA presentation was thought to be restricted to the thymus until it was
recently discovered that this phenomenon also takes place in the periphery. In this study, the
group demonstrated that non-hematopoietic (CD45-) lymph node stromal cells (LNSCs) also
express pTAs and induce tolerance to intestinal antigen-specific lymphocytes in vivo 2 7 . This
finding adds to the repertoire of tolerance mechanisms that exist in the periphery to regulate
self-reactive lymphocytes that have evaded deletion within the thymus. Although these cells
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would be ideal for tolerance inductive strategies, there are several bioprocess issues that may
hinder their use as a therapeutic. Isolating cells from the thymus or lymph node is an invasive
procedure not routinely performed in clinical settings and the ex vivo culture and expansion of
these cells to clinical scales remains a significant challenge. Most importantly, current methods
to culture mTECs in vitro have observed a loss of antigen display that suggests these cells have
dedifferentiated and may not function appropriately when used after culture.
We hypothesized that an explanation for the immunomodulatory function of MSCs may
lie in their ability to promote tolerance in T cells by antigen presentation mechanisms similar to
mTECs and LNSCs. In this chapter we discover that mouse and human MSCs, indeed, can
express pTAs at the mRNA and protein level.
10.2. MATERIALS AND METHODS
10.2.1. Mice
C57B1/6 mice between 4 to 6 weeks of age were purchased from Charles River Laboratory.
The animals were cared for in accordance with the guidelines set forth by the Committee on
Laboratory Resources, National Institutes of Health. All experimental procedures performed
were approved by Subcommittee on Research Animal Care and Laboratory Animal Resources
of Massachusetts General Hospital. Animals were maintained in a light-controlled room (12-h
light-dark cycle) at an ambient temperature of 25C with chow diet and water ad libitum.
10.2.2. Antibody and Reagents
The following antibodies were used for flow cytometry and immunochemistry: UEA-1-FITC
(Vector Laboratories), biotinylated Ulex europas agglutinin (UEA)-1, biotinylated CD45
(eBiosciences), PD-L1 (Pharmingen), and H-2Db (Pharmingen). Streptavidin microbeads, CD45
and CD1 1 b microbeads along with magnetic columns were purchased from Milenyi Biotec. For
immunocytochemistry, anti-mouse AFP was purchased from Santa Cruz Biotechnology.
10.2.3. Isolation and Culture of Bone Marrow-Derived MSCs
Bone marrow was harvested from wild-type and iFABP-tOVA mice after euthanization. Tibias
and femurs were dissected and the marrow space was flushed with MSC expansion medium
using a 23 gauge needle. Bone marrow plugs were collected on ice, dissociated by repeated
passage through an 18 gauge needle and passed through a 70 um filter to remove bony
spicules and debris. Approximately 50x106 bone marrow cells were plated on a 100 mm 2 tissue
culture dish and cultured for 3 days to allow for differential adhesion of stromal cells. Non-
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adherent cells were aspirated on day 3 and the adherent population was cultured in MSC
expansion medium for a subsequent 4-10 days to achieve the maximal number of colony
forming unit- fibroblast prior to initial passage. Cells were passaged using 0.1% trypsin/0.1 %
EDTA, and subcultured at a density of 5x103 cells/cm2 . All cultures were used between
passages 2-8. Prior to use, stromal cells were then depleted of CD 1 b and CD45 cells using
magnetic activated cell sorting (MACS) per vendor's instructions. Long term cultured MSCs
were kindly donated by the Center for Gene Therapy at Tulane University and grown in MSC
expansion medium. MSC expansion medium consisted of alpha-MEM without
deoxyribonucleosides and ribonucleosides (Gibco), 10% lot selected FBS (Atlanta Biologicals),
100 U/ml penicillin (Sigma), and 100 gpg/ml streptomycin (Sigma).
10.2.4. Total RNA Isolation and Endpoint/Quantitative RT-PCR
RNA was extracted from 0.1-1.0 x 106 MSCs using the Nucleospin RNA purification kit (BD
Biosciences, Palo Alto, CA) per the manufacturer's instructions. Approximately 500-1000 ng of
total mRNA was reverse transcribed to cDNA using the Two-Step RT-PCR Kit (Qiagen,
Valencia, CA) per manufacturer's instructions and amplified in a Perkin Etus Thermal Cycler
480 or a Stratagene Light Cycler. Cycling conditions for PCR were: 1) 50 oC for 30 minutes; 2)
95 OC for 15 minutes ; 3) 40 cycles at 94 OC for 30 seconds, 55 OC for 30 seconds, and 72 OC for
1 minute; and 4) a final extension step at 72 oC for 10 minutes. Primers used for amplification
are listed in Table 10.1. For quantitative analysis, we used a ACt method with stated controls
with results stated as relative differences between experimental groups. For endpoint analysis,
amplified cDNA was ran on a 1.2% agarose gel and visualized using a gel imager.
10.2.5. Histology and Immunohistochemistry
The tibia was harvested from wild type animals and fixed, decalcified as previously described42,
embedded in paraffin, sectioned to 6-lgm thickness, and stained with hematoxylin and eosin.
Other paraffin-embedded sections incubated at 60 degrees for 1 hour on a slide warmer and
deparaffinized and hydrated through graded levels of xylene clearing followed by ethanol
washes. Antigen retrieval was performed by microwaving slides in a sodium citrate buffer (pH
6) for 10 minutes. The endogenous peroxidase was quenched using a 3% H202/methanol
solution for 10 minutes. The slides were then washed 3 times in PBS for 15 minutes and
blocked with a buffer containing 5% donkey serum and 0.1% Triton X-100 for 30 minutes at
room temperature. Slides were washed again with blocking buffer and then incubated with
biotinylated UEA-1 (Vector Laboratories) at a 1:200 dilution overnight at 4 degrees. After
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washing with PBS, an immunoperoxidase procedure was performed according to vendor's
protocols (Vectashield). The sections were then washed 3 times with PBS and counter-stained
with methyl green. All histology images were captured on a Nikon Eclipse E800 upright
microscope.
Table 10.1. Oligonucleotide Sequences to Study Peripheral Tissue Antigen Expression
Mouse Human
Primer Sequence Primer Sequence
OVA F: GCTGCAGATCAAGCCAGAGAGC RetS-Ag F: CGCAGGGACCTGTACTTCTC
R: ATTGATTTCTGCATGTGCTGC R: TCAGGAGAAAGGGGTACGTG
RetS-Ag F: TGACTACCTACCCTGTTCAG Gad67 F: AGCACCGCCATAAACTCAAC
R: TTCACTGGATGTGAGCTCTC R: ATCTGGTTGCATCCTTGGAG
iFABP F: ACGGCACGTGGAAAGTAGAC iFABP F: AAAGAATCAAGCGCTTTTCG
R: AGAAACCTCTCGGACAGCAA R: TCCATTGTCTGTCCGTTTGA
II-FABP F: GGACAGGACTTCACCTGGTC il-FABP F: TAATCGAAAAGGCCCACAAC
R: CAAGCCAGCCTCTTGCTTAC R: ATGTTGCTTTCCTTGCCAAC
CK-8 F: ATGCTGGAGACCAAATGGAG CK-8 F: GACATGGACAGCATCATTGC
R: CCTCATACTGGGCACGAACT R: GGCTCTGCAGCTCCTCATAC
A33 F: CCGAAGTCAGACGGAAAGAG AFP F: AGCTTGGTGGTGGATGAAAC
R: TGCTGGAGGTGCAGATGTAG R: TCTTGCTTCATCGTTTGCAG
INS-1 F: TGTTGGTGCACTTCCTACCC INS-1 F: GGGAACGAGGCTTCTTCTAC
R:TAGAGGGAGCAAATGCTGGT R: CACAATGCCACGCTTCTG
Gad67 F: TGCAACCTCCTCGAACGCGG A33 F: CTTCGCAGGGAAAGAGTGTC
R: CCAGGATCTGCTCCAGAGAC R: GACTGCTCAGCATTGTTGGA
AFP F: CTCAGCGAGGAGAAATGGTC 13-actin F: CTCAGCGAGGAGAAATGGTC
R: CTCAGCGAGGAGAAATGGTC R: CTCAGCGAGGAGAAATGGTC
Aire F: TGGTCCCTGAGGACAAGTTC Aire F: GAACGGGATTCAGACCATGT
R: TGAATTCCGTTTCCAAGAGG R: AACCTGGATGCACTTCTTGG
GAPDH F: ATGACATCAAGAAGGTGGTG MOG F: TCACCTGCTTCTTCCGAGAT
R: CATACCAGGAAATGAGCTTG R: GAGGAGAACCAGCACTCCAG
10.2.6. Statistical Analysis
For flow cytometry data, median values ± standard deviations are reported. Results were
analyzed using an unpaired Student's t-test given an unskewed data set and assuming a normal
distribution. Significance values of P<0.05 were considered statistically significant. Results are
given as a mean ± standard error of the mean.
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10.3. RESULTS
10.3.1. MSCs Express mRNA and Protein for a Variety of Endogenous and Transgenic
pTAs after Long-Term Culture Expansion. We hypothesized that MSCs may present pTAs in
a similar fashion to other non-hematopoietic cells of lymphoid origin. To determine if mMSCs
can present promiscuous antigens, we first analyzed mRNA expression for a panel of pTAs.
After 7 days of in vitro culture, gene expression profiling reveled that adherent bone marrow
stromal cells expressed all pTAs surveyed mirroring the expression of thymic tissue (Figure
10.1A). In addition, when we fractionated the stromal population based on CD45 expression,
we found that pTA transcription was restricted to the CD45- population, which is consistent with
a MSC phenotype. This expression pattern also included the transcription factor AIRE, which is
known to be essential for promiscuous gene expression in mTECs. We then determined protein
expression of one pTA, alph-fetoprotein (AFP), by immunocytochemistry. Figure 10.1B shows
that all CD45- cells were reactive to AFP indicating that the message was transcribed into a
properly folded protein. More importantly, pTA expression was found in human cells and is
retained in long-term culture (Figure 10.1C). Based on our prior work in intestinal autoimmune
disease described in Chapters 7-8, we then quantified the amount of AIRE and intestinal pTAs
using quantitative RT-PCR. In all analyzed genes, mouse MSCs expressed approximately 2-
7% of the mRNA transcripts for AIRE and pTAs compared to mTECs (Figure 10.1 D).
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Figure 10.1. Mouse and Human MSCs Express Endogenous pTAs. Mouse stroma was
isolated from wild-type mice, grown in culture for 7 days and separated by CD45 expression
using MACS. (A) Endpoint RT-PCR analysis of pTA gene expression comparing whole bone
marrow stroma, CD45+, and CD45- marrow stromal. Thymic tissue used as a positive control.
Data is representative of 3 separate tests of mouse pTA expression using this pTA panel. (B)
Immunofluorescence of AFP expression in CD45- cells. (C) Human pTA expression in MSCs
after cryopreservation. (D) Quantitative RT-PCR analysis of AIRE and intestinal pTAs
comparing UEA-1+ and UEA-1- thymic cells, CD45+ and CD45- fresh bone marrow cells, and
long-term mouse MSCs after cryopreservation.
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10.3.2. Clusters of UEA-1+ marrow cells Express mRNA for pTAs.
Reactivity to UEA-1 has been shown to specifically label mTECs and LNSCs demonstrating a
correlation with this lectin to pTA expression. Prior reports state the presence of CD45+ cells
with UEA-1 expression in the bone marrow that suggested an endothelial cell or megakaryocyte
precursor. We found CD45- UEA-1+ cells from a freshly prepared bone marrow aspirate
(Figure 10.2A). In addition, we found that UEA-1+ cells specifically expressed pTAs (Figure
10.2B). After long-term culture of MSCs, UEA-1 activity was lost (Figure 10.2C). We sought to
visualize UEA-1+ cells in the bone marrow space. Using an immunoperoxidase method, we
saw UEA-1+ cells in perivascular spaces in clusters (Figure 10.3A,D). In addition, these cells
were found in close proximity to megakaryocytes. Expression of CD45 was lacking in cells
around megakaryocytes relative to other CD45+ cells (Figure 10.3C-F). Due to the high
autofluorescence of the bone marrow cavity and the limited amplification of biotinylated
molecules, we failed to identify co-immunostaining for CD45 and UEA-1.
10.3.3. Upregulation of Antigen Presentation and Inhibitory Co-Stimulation Molecules
After Cytokine Stimulation.
In addition, we examined the ability of MSCs to upregulate antigen presentation and inhibitory
co-stimulation molecules after cytokine stimulation. After 24 hours of incubation with interferon
(IFN)-y, a TH1 cytokine secreted by many cell types in response to inflammation, mMSCs
showed prominent upregulation of programmed death-ligand 1 (PD-L1) and MHC class II
(Figure 10.4). These data suggest that mMSCs may actively respond to inflammation by
expressing inhibitory surface proteins such as PD-L1, which is known to anergize T cells32 9,330
as well as communicating with CD4+ T cells via class II presentation.
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Figure 10.2. UEA-1+ Bone Marrow Cells Express pTAs. (A) Bone marrow aspirates were
analyzed by flow cytometry for CD45 expression and UEA-1 reactivity. (B) UEA-1 reactivity in
cultured MSCs. (C) MACS-separated UEA-1+ bone marrow cells express pTAs.
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Figure 10.3. Immunohistochemistry of CD45-UEA-1 Localization in the Bone Marrow.
Low and high power magnification of immunoperoxidase staining for UEA-1 (A,D), H&E stained
(B,E), and CD45 (C,F) in wild-type mice. Two different fields of view are shown.
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10.4. Upregulation of Antigen Presentation Molecules after IFN-y Stimulation. Purified
MSCs were cultured in the presence of 20 ng/ml of IFN-y for 24 hours and assessed for (A) PD-
L1 and (B) MHC class II expression. Isotype control is a rat anti-lgG monoclonal antibody.
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10.4. DISCUSSION
The ability of MSCs to present exogenous antigens to T cells has been previously
studied by a number of investiagators123,288' 331. Furthermore, MSCs have been found to inhibit
the proliferation, cytotoxicity and number of lymphokine-producing antigen-specific T cells123.
These results were independent of MSC secreted factors and the function of other antigen
presenting cells or regulatory T cells. In these reports, the effect of IFN-y was observed to
upregulate antigen presentation machinery and capability of MSCs to stimulate antigen-specific
T cells. IFN-y stimulation led to the upregulation of PD-L1 and MHC class II. The expression of
pTAs was found to be maintained in long-term culture as opposed to mTECs, which rapidly
undergo apoptosis upon AIRE expression. We hypothesize that the relatively high level of
mRNA of mTECs observed by qRT-PCR analysis may lead to a significant stress on the mTECs
ultimately causing programmed cell death or autophagy. Moreover, MSCs may be endowed
with robust mRNA and protein synthesis machinery that may allow them to tolerate moderate
stresses well.
Recent studies have shed light on how tolerance is induced both centrally and
peripherally. In both locations, there exist specialized antigen presenting cells that are essential
for preventing autoimmunity. Within the localized compartment of the thymus T cells are first
exposed to self protein antigens by the direct or indirect presentation of pTAs by mTECs3 20-325.
Self-reactive T cells that have escaped central deletion can be further tolerized in the periphery
by LNSCs327,332,333. Our data shows that marrow-derived stromal cells naturally express these
antigens in a similar fashion to mTECs and LNSCs and implicates the bone marrow as a
potentially new site of pTA expression. The bone marrow is well known as a primary lymphoid
organ that provides unique microenvironments that support lymphogenesis 334335. But recent
studies have shown that the marrow can also be considered as a secondary lymphoid organ
which houses naYve, circulating B cells53, long-lived plasma cells336' 337 , and mature CD4+, CD8+,
and memory T cells 3381341. These lymphocytes participate in distinct immune responses in situ.
Bone marrow-resident B cells were shown to partake in T cell-independent humoral immune
responses to blood-borne microbes by differentiating into antibody-secreting plasma cells 3.
Resident T cells are thought to be primed to blood-borne pathogens as well as initiate full-blown
memory responses from the bone marrow niche338341 . It is likely that in such a cellular milieu, a
tolerance mechanism is required to inhibit self-reactivity. MSCs may be a part of such a
mechanism in situ to directly or indirectly tolerize developing and/or mature lymphocytes to self
antigens within the bone marrow. Furthermore, these lymphocytes are compartmentalized in
perivascular spaces exactly where we had located UEA-1+ cells that are presumably MSCs.
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These spatial results are consistent with transplantation experiments with MSCs where we and
others showed that transferred mouse (see Chapter 8) and human MSCs1 62 form clusters within
engrafted tissues, the latter report focusing on the bone marrow. The close proximity with
megakaryocytes may be relevant to physiological processes such MSC maintenance via
megakaryocyte-mediated signals (e.g. TGF-P3) or an MSC-specific effect on thrombopoiesis.
The expression of pTAs by MSCs may be causally related to the efficacy of these cells
in various types of autoimmune disease289 2 92 . We put forth an integrated theory of the
therapeutic mechanism of action of MSC transplantation based on pTA expression in Figure
10.5. Here, we depict our hypothesis of AIRE-dependent translation and presentation of pTAs.
The first pathway involves direct contact between MSCs and lymphocytes, whereby the
presentation of self-peptides along with negative costimulation leads to to T cell anergy. In the
second pathway, MSCs license DCs by serving as a reservoir of self antigens that are then
phagocytosed by the dendritic cells to indirectly tolerize lymphocytes. The third pathway,
involves the direct generation of tolerizing DCs and/or the generation of regulatory T cells in situ.
Ultimately, these pathways may all exist in concert to amplify the local immunosuppressive
effects of the initial engrafted cell mass.
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Figure 10.5. Theory of Therapeutic Action Based on pTA Expression. In the thymus,
mTECs can directly present pTAs to thymocytes or passively transfer antigens to thymic DCs
after cell death. In the periphery, LNSCs have been shown to induce tolerance to antigen-
specific CD8+ T cells. Here, we depict our hypothesis of AIRE-dependent translation and
presentation of pTAs. This mechanism is hypothesized to lead to immunosuppression by either:
(a) anergizing self-reactive T cells, (b) transfer antigens to DCs to anergize T cells, or (c)
indirect generation of tolerizing DCs and the generation of regulatory T cells in situ. pTA,
peripheral tissue antigen; mTEC, medullary thymic epithelial cell; DC, dendritic cell; LNSC,
lymph node stromal cell.
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SECTION V
CONCLUSIONS AND FUTURE WORK
SUMMARY
Developing new immunotherapies that affect multiple disease pathways is of growing
importance for patient care. In this work, we demonstrate the efficacy of three different
therapeutic strategies that harness the endogenous function of a human cell type - a
mesenchymal stem cell (MSC). Furthermore, the work sheds light into new mechanisms
involved in MSC therapy that can be recast to better our understanding of the natural role of
these cells during health and disease in vivo.
We first developed a molecular therapeutic based on the natural secreted molecules
from MSCs. We tested the efficacy of MSC molecules (referred to as MSC-CM) in a rat model
of acute liver failure and demonstrated a significant survival benefit with marked improvement in
histological and serological parameters of disease. This survival benefit was a function of the
cell mass from which MSC-CM was derived and showed a therapeutic range. We also
illustrated that MSC-CM alters the fate of peripheral blood leukocytes and adoptively transferred
leukocytes during acute liver failure treatment.
To elucidate if MSC-CM has multiple cellular targets, we analyzed the function of
resident liver cells in response to said molecules in vitro and in vivo. Delivery of MSC-CM to
acutely injured rats led to a quantifiable increase in hepatocellular proliferation and an inhibition
of apoptotic indices in vivo. We performed in vitro assays to further verify that the changes in
hepatocellular proliferation and death was a direct function of MSC-CM. Furthermore, we
showed that MSCs can modulate activated hepatic stellate cells in a dynamic fashion in vitro,
suggesting that these molecules may also be effective in the treatment of liver fibrosis and
cirrhosis.
Rational and shotgun approaches were taken to describe the individual species of MSC-
CM and determine which constituents imparted therapeutic efficacy in liver failure. Size-based
chromatography revealed a unique peak of >50kDa molecules secreted by MSCs when
compared to fibroblasts. Although, this molecular weight fraction did not provide a survival
benefit there were qualitative indications that this fraction may be partially active. Proteomic
analysis using a high-density antibody array detected 69 of the 174 proteins assayed, the
majority of which were classified as chemokines and growth factors. When MSC-CM was
fractionated over a heparin-binding column, which would bind many growth factors and nearly
all chemokines, this bound fraction was found to contain the majority of active components.
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Finally, we developed and employed a new radiotracer assay for cell-derived proteins, which
showed that MSC-CM has a non-specific distribution pattern and thus ruled out any "tropic"
nature of these molecules.
We next created cell-based extracorporeal devices to consolidate the secretory and
metabolic function of MSCs in a single platform. Treatment with a MSC-EB resulted in a short-
term survival benefit and decrease in plasma biomarkers of liver injury. Furthermore, we show
by proteomic methods that MSCs stimulated with liver failure serum dramatically alter their
secretome compared to stimulation with healthy serum. These data imply that MSCs within the
extracorporeal device are dynamically reacting to serum components and changing their
secretory pattern accordingly.
A composite cellular device was made that incorporated primary hepatocytes and MSCs.
In vitro studies demonstrated that MSCs can stabilize hepatocellular function in a dose-
dependent manner. Moreover, it was definitively shown that MSCs do not differentiate into
hepatocyte-like cells which ruled out the possibility that MSCs were performing hepatocellular
functions in these systems. Extracorporeal support with a MSC+Hep-LAD led to a long-term
survival benefit that was significantly different from Fibroblast+Hep-LAD - a coculture method
known to optimize hepatocellular function only. These results demonstrate the importance of
choosing the correct stromal cells in the context of disease treatments. More importantly, a
combination of hepatic and immunological support of acute liver failure subjects may result in
the greatest therapeutic efficacy and should be considered in next generation treatment
protocols. Moreover, these studies potentially illustrate a platform to study stem cell function
and the bone marrow microenvironment ex vivo.
In our final treatment modality, we used MSC transplants as a cellular therapy for
autoimmune disease. We screened MSC grafts in vivo using a mouse model deficient in
regulatory T cells and thereby afflicted with multi-organ autoimmunity due to ineffective
peripheral tolerance. We observed a tropic effect in the intestine and associated lymph nodes.
Furthermore, we showed in this mouse model that coinfusion of MSCs in an "adjuvant" manner
could increase the number of transferred regulatory T cells suggesting that MSCs can indirectly
increase suppressor T cell number. We used a more classical model of colitis to stringently test
the effects of MSC transplantation. In a chemically-induced model of disease, MSC infusion led
to a significant survival benefit in both a preventative and therapeutic setting. Physical and
histopathological signs of disease were generally absent due to MSCs. In addition, we
demonstrate that the endogenous population of suppressor cells within the associated
mesenteric lymphatics was increased. These data indicate that MSCs may amplify their
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immunosuppressive effect by increasing local regulatory T cells. Finally, we discover that MSCs
are, in fact, peripheral tissue antigen presenting cells and have similar gene and protein
expression patterns to cells within other lymphoid organs which are known to tolerize T cells to
self antigens. This finding may be the single reason why MSCs are immunoevasive and
immediately gives insight into new hypotheses of MSC function in therapeutic and natural
settings.
FUTURE DIRECTIONS
The promise of MSC immunotherapy is only now beginning to be realized clinically. Phase III
clinical trials in GVHD and Crohn's disease initiated by industry are signs of a revolution in
cellular therapy. This work creates a number of new avenues for both basic science research
and also development into potential clinical products. Each therapeutic modality is discussed
with an emphasis on fundamental and practical issues at hand.
Molecular Therapeutic
The present description of MSC-CM - although the most comprehensive to date - remains
incomplete. Advanced proteomic methods using mass spectrometry are required, however
such methods may not uncover other therapeutic species such as rare molecules, lipids, or
matrix glycoproteins. These analyses become critical to the understanding of MSC-CM, the
targets of these biomolecules, and potential side-effects. Furthermore, the opportunity to modify
the conditioning regimen to tailor the MSC-derived cocktail exists. For example, pre-
conditioning MSCs in hypoxic conditions may favor the secretome to produce anti-apoptotic
molecules that can protect ischemic tissue. MSC-CM can also be formulated differently
depending on the indication. The creation of standard operating protocols for industrial scale
purification and storage of MSC-derived molecules is of utmost importance for manufacturing
purposes. This will likely involve high-end proteomic analysis of MSC-derived molecules to
identify batch-to-batch variations, shelf-life time, and other critical product specifications.
Cell-Based Biomedical Devices
Since MSCs are adherent cells and have minimal metabolic demands, these issues should
readily allow for their incorporation into existing biomedical devices. Seeding MSCs in FDA-
approved hollow-fiber bioreactors and determining their viability and function within these
devices would streamline future testing of MSC-based bioreactors without the concern of
regulatory issues of new device design. In addition, the potential to innoculate cells into plasma
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exchange devices could broaden the use of MSCs to other conditions such as disseminated
intravascular coagulation where recirculation of plasma through a closed circuit that can be
fortified with MSC molecules is indicated. Initiating therapeutic testing of these treatments in
larger animal models will be necessary to prove safety and efficacy before human trials.
Cell Transplantation for Autoimmune Disease
A detailed view of the trafficking of MSCs in colitic mice will be critical to the understanding of
cell fate and function. The verification of a causal relationship between pTA expression in
MSCs and therapeutic efficacy in autoimmune disease will provide insight into the future
development of MSC transplantation. Acquiring bone marrow from animals that overexpress or
are deficient in pTA expression would allow for testing of this hypothesis. AIRE-deficient
animals have been previously shown to have a loss in pTA expression, although it is unknown if
pTA expression in MSCs is AIRE-dependent. The pathway of pTA expression can essentially
become a target for MSC drug development and optimization as well as being monitored and
manipulated naturally in vivo. Fundamentally, many new approaches can be designed to
determine the role of MSCs within the context of the immune cell niche.
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